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The tryptophan synthase β-subunit (TrpB) naturally catalyzes a pyridoxal phosphate 
cofactor-mediated β-substitution reaction between indole and serine to form L-tryptophan. 
Almost half a century ago, it was realized that TrpB could accept nucleophiles other than 
indole to synthesize noncanonical amino acids (ncAAs), which are highly useful small-
molecule building blocks that are found in many bioactive molecules. Since then, TrpB has 
been applied to synthesize a wide range of ncAAs. This thesis details the engineering of TrpB 
for synthesis of new and useful ncAAs and the application of TrpB as a model to study the 
principles that govern intra-protein interactions. Chapter I chronicles the history of 
tryptophan synthase, provides useful information about the enzyme’s catalytic cycle, and 
describes how TrpB has been used to synthesize ncAAs in works preceding this thesis. 
Chapter II describes the evolution, application, and characterization of TrpB for the synthesis 
of a blue, fluorescent noncanonical amino acid β-(1-azulenyl)-L-alanine (AzAla). Chapter III 
details the engineering and mechanistic characterization of TrpB to asymmetrically catalyze 
C–C bond formation with an entirely new class of nucleophile: ketones. Chapter IV describes 
the in vivo continuous evolution of TrpB which resulted in sequence-diverse TrpB orthologs 
that have been adapted to function at lower temperatures and display a range of substrate-
selectivity profiles. Chapter V describes the development of a deep mutational scanning 
experiment of combinatorial site-saturation mutagenesis (SSM) libraries for generating a 
large dataset that maps enzyme sequence to function for the purpose of studying epistasis 
with machine learning. Overall, the work presented in this thesis expands the repertoire of 
ncAAs that can be synthesized by TrpB and demonstrates unique applications of TrpB as a 
model enzyme for continuous in vivo directed evolution and for generating a dataset that will 
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C h a p t e r  I  
TRYPTOPHAN SYNTHASE: BIOCATALYST EXTRAORDINAIRE 
Material from this chapter appears in “Watkins-Dulaney, E. J., Straathof, S., Arnold, F. 







Tryptophan synthase (TrpS) has emerged as a paragon of noncanonical amino acid (ncAA) 
synthesis and is an ideal biocatalyst for synthetic and biological applications. TrpS catalyzes 
an irreversible, C–C bond forming reaction between indole and serine (Ser) to make L-
tryptophan (Trp); native TrpS complexes possess fairly broad specificity for indole analogs, 
but are difficult to engineer to extend substrate scope or to confer other useful properties due 
to allosteric constraints and their heterodimeric structure. Directed evolution freed the 
catalytically relevant TrpS β-subunit (TrpB) from allosteric regulation by its TrpA partner 
and has enabled dramatic expansion of the enzyme’s substrate scope. This chapter examines 
the long and storied career of TrpS from the perspective of its application in ncAA synthesis 





Noncanonical amino acids (ncAAs) enable researchers to interact with and modify life at the 
molecular level, and are a vital tool for many modern biological studies. Defined as amino 
acids that are not genetically encoded, ncAAs bear chemical motifs not found in the 20 
canonical amino acids and can alter the characteristics of molecules that incorporate them. 
Though often referred to as unnatural amino acids, many ncAAs do occur naturally as post-
translationally modified peptide residues or as intermediates in biosynthesis of secondary 
metabolites.1 Nature thus demonstrates that ncAAs can serve as handles to manipulate 
biochemical properties. Furthermore, substituting canonical amino acids with ncAAs imbues 
molecules with different functionalities while minimally perturbing structure.2 As such, 
ncAAs are seeing growing applications in research, where they are useful as biophysical 
probes,2,3 are introduced into polypeptides to create improved or entirely new functions,4,5 
and are incorporated into bioactive small molecules and peptide therapeutics.6–8  
A barrier to realizing the potential of ncAAs is that they are challenging to synthesize owing 
to laborious protection and deprotection sequences necessary to prevent epimerization of the 
chiral center or undesired reactivity with the amine and carboxylate groups.9 Simpler, more 
effective, and more direct routes to ncAAs are necessary to better harness their potential 
applications. A promising approach for ncAA synthesis is to use enzymes, which can 
perform transformations with exquisite precision in the presence of multiple reactive centers 
without the need for protecting groups. With carefully tuned active sites, enzymes can 
overcome regio- and stereoselectivity challenges by directing substrates and reactive 
intermediates during a catalytic cycle.  
Another major advantage of enzymes is that they can be combined in one-pot biocatalytic 
cascades to access value-added products from simple and inexpensive starting materials.10 
However, enzymes from biosynthetic pathways to naturally occurring ncAAs may not be 
practical to engineer or scale up if, for example, they catalyze reversible reactions, express 
poorly in recombinant hosts, are allosterically regulated, or have limited substrate scopes.11 




to ncAA synthesis, and examples of new, engineered ncAA synthases and enzyme cascades 
are emerging.11 
Tryptophan synthase (TrpS) is a premier example of an enzyme that can be used for scalable 
ncAA synthesis. TrpS possesses covetable qualities for an ncAA synthase: it forms a C–C 
bond between readily available starting materials to make L-tryptophan (Trp) and closely 
related derivatives in a single enzymatic step.12 TrpS exists as a heterodimeric complex 
comprised of two α- and β-subunits (TrpA and TrpB, respectively) that work together to 
transform indole glycerol phosphate (IGP) and L-serine (Ser) into Trp (Scheme 1-1). The 
TrpA subunit is responsible for the cleavage of IGP into indole and glyceraldehyde and does 
not directly participate in the C–C bond forming step. In fact, TrpA can be bypassed entirely 
by providing indole analogs to the enzyme complex, where they are transformed by the TrpB 
subunit into Trp analogs. Although TrpS can be used to synthesize a variety of Trp-based 
ncAAs, directed evolution of the catalytically relevant TrpB subunit to create a stand-alone 
enzyme dramatically simplified engineering efforts and allowed for a systematic expansion 
of accessible ncAA products.13 
This chapter provides an overview of how TrpS and its laboratory-evolved TrpB progeny 
have been used to produce ncAAs. We also give examples of how this enzyme has been 
incorporated in biocatalytic cascades to access D-amino acids and tryptamine products.  
1.2 Properties of tryptophan synthase (TrpS)  
Tryptophan synthase is a pyridoxal 5’-phosphate (PLP)-dependent enzyme that has captured 
the interest of enzymologists and bioengineers for over half a century. The study of TrpS 
dates back to when the burgeoning field of molecular biology had barely taken its first steps. 
Discovered in the 1940s, TrpS has served as a model enzyme for a wide range of 
investigations, from proving gene-protein collinearity14 to studying the evolution and nature 
of allostery,15 conceptualizing and understanding vectorial catalysis and substrate 




TrpS is found in all domains of life as an αββα heterodimeric complex that catalyzes the 
formation of Trp from IGP and Ser (Scheme 1-1). The α-subunit (TrpA) and β-subunit 
(TrpB) experience mutual allosteric activation, the evolutionary history and nature of which 
are still an active area of research.17,18 The two subunits interact with one another through 
rigid-body motion of the TrpB communication (COMM) domain and a monovalent cation 
(MVC) binding site within TrpB. When IGP binds TrpA, it initiates a conformational change 
activating TrpB to promote formation of the (PLP)-bound amino-acrylate derived from Ser. 
The TrpB subunit then reciprocally stimulates TrpA to induce retro-aldol cleavage of IGP, 
releasing indole.19 Once released, indole diffuses along a 25-Å long tunnel to the β-subunit 
where it can immediately participate in a PLP-mediated β-addition reaction, releasing water 
and Trp. 
 
Scheme 1-1. Native transformation catalyzed by TrpS. TrpA (left, pink) performs a 
retro-aldol cleavage on indole glycerol phosphate (IGP) releasing indole and 
glyceraldehyde phosphate. Indole diffuses to the TrpB subunit (right, green) which 
catalyzes a PLP-mediated β-substitution reaction between indole and l-serine (Ser), 
releasing water and l-tryptophan (Trp). (PDB:5E0K) 
The TrpB PLP cofactor absorbs in the UV-vis region, and each reactive intermediate 
possesses a characteristic spectral trace, allowing observation of the catalytic cycle via UV-
vis spectroscopy. In the TrpB resting state, PLP is covalently bound to the ε-nitrogen of a 




Schiff-base linkage referred to as the internal aldimine, E(Ain) (λmax= 412 nm).20 In the 
first stage of the catalytic cycle (Scheme 1-2), Ser enters the active site and replaces the 
lysine via transimination to form an external aldimine intermediate, E(Aex1) (λmax = 428 
nm). This step is concomitant with a rigid-body conformational change in the TrpB COMM 
domain, with the enzyme adopting a ‘partially closed’ state.  
PLP-dependent enzyme specificity is largely dependent on alignment of the bond to be 
broken with the π molecular orbital system of PLP.21–23 TrpB promotes Cα deprotonation by 
using a hydrogen bonding network formed with the Ser carboxylate that locks the C–H bond 
periplanar to the PLP π system.23 The free K82 residue deprotonates the Cα of Ser, ablating 
the chiral center and forming a carbanion that is delocalized by the PLP cofactor to form a 
quinonoid intermediate, E(Q1) (λmax= 470 nm).24 Subsequent elimination of the hydroxyl 
group forms the electrophilic amino-acrylate species, E(A-A) (λmax= 350 nm), which is 
poised for attack by the indole nucleophile. During this step, the COMM domain assumes a 
‘fully closed’ conformation that is stabilized by TrpA.17,25 If no indole is present, a kinetically 
competing transimination reaction with the active site lysine can occur, releasing 
dehydroalanine that hydrolyzes to form ammonia and pyruvate (β-elimination pathway).26 If 
indole is present, it arrives in the active site of TrpB and is positioned by the catalytic 
glutamate (E104, PfTrpB numbering) for nucleophilic attack. The catalytic glutamate is 
important for controlling the regioselectivity of the reaction; mutagenesis reveals its crucial 
role to effect C–C bond formation at C3 over a C–N bond at N1.27  
The beginning of the second stage of the TrpB catalytic cycle is marked by irreversible 
nucleophilic attack by indole on the E(A-A) to form a second quinonoid intermediate, E(Q2) 
(λmax = ~476 nm). The (S)-indolenene species is quickly deprotonated, restoring 
aromaticity, to reach a third and final quinonoid intermediate, E(Q3) (λmax = 476 nm).28 Cα 
is then re-protonated by K82 stereospecifically to form the Trp-bound external aldimine, 
E(Aex2) (λmax = 420 nm), re-establishing the chiral center and completing Trp 
formation.29,30 Trp release from the enzyme via transimination by K82 returns PLP to the 





Scheme 1-2. Catalytic cycle of TrpB.  
1.3 Synthesis of noncanonical Trp derivatives 
Tryptophan derivatives (Scheme 1-3) are a subclass of ncAAs that have been used 
extensively as probes for chemical biology. Trp itself is a major source of UV absorption and 
fluorescence in proteins, and its spectral properties, which are highly influenced by the 
surrounding environment, have been leveraged to study protein dynamics, folding, and 
ligand binding.31 Substitutions on the indole moiety, such as in 4-cyanoTrp and 5-
hydroxyTrp, as well as Trp isosteres like azaTrps (1, 2, 3, 4) can enhance or alter these 
spectroscopic properties to exhibit higher quantum yields or shift excitation/emission 
spectra.32–34 Decorations and substitutions on the indole side chain bestow many other useful 
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thienyl functional groups are used for phasing crystallographic structures,36 and halides can 
allow for site-specific modification through palladium-catalyzed coupling reactions with 
alkenes and alkynes.37 Like many other ncAAs, Trp derivatives are biosynthetic precursors 
to compounds that exhibit diverse pharmacological activities, including anticancer, 
antibiotic, immunosuppressant, and phytotoxic properties.38,39 
 
Scheme 1-3. TrpS- and TrpB-catalyzed synthesis of Trp analogs. (a) TrpB-catalyzed 
synthesis of Trp analogs (b) TrpB-catalyzed synthesis of β-branched Trp analogs. (c) 
TrpS/TrpB substrate profile: modified indoles that any TrpS or TrpB variants have been 
demonstrated to accept. Position represents carbon where substitution, R, occurs on indole 
moiety. The profile is not to be interpreted as a TrpS/TrpB selectivity profile, and gaps in 
activity may be due to lack of testing (not all indole derivatives are readily available). (d) 
Other tryptophan isosteres: TrpS and TrpB catalyze the synthesis of a number of Trp 
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Shortly after the discovery of TrpS, researchers began using substituted methylindoles (2-, 
4-, 5-, 6-, 7-CH3-indole) to gain insights into the enzyme’s mechanism and pathway 
regulation.29,40,41 The synthetic utility of TrpS, however, was first realized in 1974 when 
Wilcox synthesized a series of Trp derivatives (5-F-, 6-F-, 5-OH-, 5-MeO-, 6-MeO-, 2-CH3- , 
5-CH3-, 7-CH3-Trp; 1, 4) from Ser and indole analogs using TrpS from Escherichia coli 
(EcTrpS).42 During the following decades, various wild-type TrpS homologs were shown to 
have activity on a number of other decorated indoles and indole isosteres: Saito et al. 
demonstrated the synthesis of azido-substituted Trps (4-, 5-, 6-, 7-N3-Trp) using a TrpS from 
Neurospora crassa;43 the Phillips group applied TrpS from Salmonella typhimurium for the 
synthesis of chloroTrps (4-, 5-, 6-, 7-Cl-Trp),44 sulfur, selenium, and oxygen-containing Trp 
isosteres (5, 6, 7, 8, 9),45–47 as well as azaTrps (1, 2, 3, 4);48 Goss and colleagues prepared an 
exceptionally diverse set of substituted Trp analogs including methyl- (2-, 4-, 5-, 6-, 7-CH3-
Trp),49 amino- (4-, 6-, 7-NH2-Trp),50 halo- (4-, 5-, 6-, 7-F; 4-, 5-, 6-, 7-Cl; 5-, 6-, 7-Br; 7-I-
Trp),49–52 and nitroTrp (7-NO2-Trp)52 using TrpS from E. coli and Salmonella enterica. TrpS 
has also been found to catalyze a C–N bond forming reaction with indoline to form 
dihydroisotryptophan (10).27,53,54 
Despite this ability to produce desirable compounds, TrpS still has limitations that restrict 
practical and widespread use. Even under optimized conditions, ncAA yields with TrpS 
catalysts are typically under 50%.49,52 Insolubility of indole compounds in water also limits 
the substrate concentrations. Although this was partially remedied by addition of co-solvents, 
the TrpS homologs used lacked solvent tolerance, limiting the effectiveness of this solution.44 
Furthermore, extensive engineering of the TrpB subunit for improved activity or expanded 
substrate scope was impeded by the need for the TrpA subunit, which does not directly 
participate in the coupling of indole and Ser, but nonetheless increases metabolic load on 
host cells. Unfortunately, without co-expression and allosteric activation from their 





1.3.1 Engineering stand-alone TrpB for indole-derived nucleophiles  
Enzyme homologs are valuable assets that often display divergent activities with non-natural 
substrates. Javier Murciano-Calles and co-workers investigated homologs of PfTrpB for 
activity on 5-substituted indoles.57 They recombined activating mutations discovered by 
Buller et al. into the TrpB derived from the hyperthermophilic bacterium Thermotoga 
maritima (TmTrpB, 64% sequence identity to PfTrpB) and found a variant with broadly 
improved activity toward 5-substituted indoles (5-CH3-, 5-OCH3-, 5-Cl-, 5-Br-, 5-NO2-, 5-
CHO-, 5-CN-, 5-B(OH)2-Trp) compared to previous catalysts. 
With a set of stand-alone TrpB enzymes that were straightforward to express and engineer 
in hand, David Romney and his team aimed to broaden the platform’s substrate scope to 
include challenging indoles on which TrpS had previously shown poor activity.56,57 The 
resultant panel of evolved TrpB enzymes accepted indoles bearing different substitution 
patterns and functional moieties such as halogen (4-F-; 6-, 7-Cl-; 4-, 6-, 7-Br-; 5-, 7-I-; 5,6-
Cl2-, 5-Br-7-F-, 5-Cl-7-I-Trp), nitro (4-, 5-, 6-, 7-NO2-Trp ), cyano (4-, 5-, 6-, 7-CN-Trp), 
carboxamide (5-CONH2-Trp), boronate (5-, 6-B(OH)2-Trp), and trifluoromethyl groups (5-
CF3-Trp) with most isolated yields ranging from 70–99%.13 Christina Boville and colleagues 
continued engineering one of Romney’s variants, TmTrpB2F3, to improve activity for 4-
cyanoTrp, a useful blue fluorescent ncAA with high quantum yield and lifetime.58 This 
transformation demonstrated a marked improvement over the best synthetic route, which was 
a palladium-catalyzed cyanation reaction that achieved a maximal yield of 10%.32 Cells from 
one liter of E. coli shake-flask culture expressing the final variant, TmTrpB9D8*, could 
synthesize 4-cyanoTrp on a larger scale (800 mg, 49% yield). Notably, laboratory-evolved 
TmTrpB9D8* was discovered to function better at lower temperatures (such as 37 °C), 




1.3.2 β-Branched Trps  
Beta-branched amino acids are found in many useful bioactive natural products and 
pharmaceuticals; however the presence of two adjacent chiral centers makes them 
particularly challenging to synthesize.59,60 Buller’s team engineered their stand-alone TrpB 
to accept L-threonine (Thr) as the electrophile to produce β-methylTrp (Scheme 1-3b).61 
Unlike in earlier works, where modified electrophiles ultimately produced the same amino-
acrylate as Ser,62,63 the use of Thr generated an entirely new β-substituted amino-acrylate-
like species (amino-crotonate) that diastereoselectively formed a second chiral center upon 
C–C bond formation. This is remarkable: Thr is a universal and abundant metabolite that 
TrpS naturally discriminates against. Buller discovered that native TrpS actually binds Thr 
efficiently, but binding results in decreased affinity for indole and disrupts the allosteric 
signaling that regulates the catalytic cycle. These effects translate to a >82,000 fold-
preference for Ser over Thr in the native enzyme complex when both substrates are present.64 
However, in the absence of Ser competition, PfTrpS—and more importantly PfTrpBWT—
showed trace activity with indole and Thr, providing the foothold necessary to apply directed 
evolution. Starting from an evolutionary intermediate from their previous campaign that had 
better activity with Thr than the wild-type enzyme, PfTrpB4D11, two rounds of evolution 
accumulating three new mutations resulted in PfTrpB2B9, which exhibited a >6,000-fold 
boost in activity for β-methylTrp formation relative to wild-type PfTrpB.61 
Shortly after this work appeared, the Micklefield group published an engineered StTrpS 
bearing one mutation, L166V, that could also catalyze the formation of β-branched Trps (β-
methyl- ; β-methyl-2-, 4-, 6-, 7-CH3-; β-methyl-4-, 7-F-; β-methyl-7-Cl-; β-methyl-7-OMe-
Trp) from Thr and indole analogs.65 Similar to PfTrpS, the enzyme struggled with 5-
substituted indoles. Instead of applying further evolution to increase the substrate scope, the 
authors took a different approach, using StTrpSL166V to synthesize β-methylTrp (11), which 
they then derivatized chemoenzymatically. The flavin-dependent Trp-5-halogenase PyrH 
was used with MgCl2 or NaBr to create halogenated 5-substituted Trps (5-Br-, 5-Cl-Trp) 
which could undergo a palladium-catalyzed cross coupling reaction with phenylboronic acid 





Scheme 1-4. One-pot C5-arylation of β-methylTrp (11). Flavin-dependent Trp-
halogenase PyrH brominates C5, which then participates in a palladium-catalyzed Suzuki 
cross-coupling to install the aryl group (12).65 
Christina Boville and her team engineered stand-alone PfTrpB2B9 to accept β-branched Ser 
analogs with longer alkyl chains such as β-ethyl- and β-propylSer.66 Bulkier alkyl chains at 
the β-position were thought to hinder nucleophilic attack, allowing the competing β-
elimination to unproductively consume the electrophile. Initial activity with PfTrpB2B9 on β-
ethylSer and indole was too low for high-throughput screening, so the authors mutated an 
active-site residue presumed to clash sterically with the alkyl β-substitution. Investigating 
the very same residue mutated by Micklefield et al.,65 Boville and colleagues discovered that 
both valine (Val) and alanine (Ala) improved activity. While Ala was slightly less beneficial 
than Val, the authors rationalized that Ala may provide more room in the active site for 
electrophiles with longer β-alkyl substituents. This boosted activity enough to enable 
Boville’s team to use a high-throughput UV-based screen with libraries generated by random 
mutagenesis for three more rounds of evolution. The final variant, PfTrpB7E6, was assayed 
against combinations of electrophiles (Thr, β-ethyl-, β-propylSer) and nucleophiles (indole; 
2-, 4-, 5-, 6-, 7-CH3-; 4-, 5-F-; 5-Cl-; 7-aza-indole) to determine its substrate scope and 
generality. Although PfTrpB7E6 was only evolved on β-ethylSer, the mutations substantially 
improved activity for Thr and β-propylSer as well. Notably, PfTrpB7E6 required only one 
equivalent of Thr to achieve a 3.5-fold greater yield for β-methylTrp than the parent 
PfTrpB2B9 did with ten equivalents of Thr. X-ray crystallography, measurement of the 
deamination rates, and UV-spectrophotometric evidence supported the hypothesis that 
evolution stabilized the closed conformation of the enzyme and generated a more persistent 












1.4 Engineering stand-alone TrpB for non-indole-derived nucleophiles 
TrpB proved its mettle as a noncanonical Trp synthase, but it remained to be seen whether 
the enzyme could become a more generalized ncAA synthase. The observation of activity 
with thiol- and nitrogen-based nucleophiles provided precedent for the possibility that TrpB 
can accept molecules that are not explicitly indole-like to create C–N,27,54,56,67,68 C–S,69 and 
C–Se69 bonds (Figure 1-1). In principle, any sufficiently activated nucleophile that fits in the 
active site could react with the amino-acrylate. Carbon-based nucleophiles would be 
attractive synthons for TrpB, allowing for enzymatic C–C bond formation to make a broad 
panel of ncAAs. One major challenge, however, is that strong carbon-based nucleophiles, 
which are normally accessed via deprotonation of weakly-acidic C–H bonds, are highly 
disfavored in water because of their high basicity (pKa > 7). Nevertheless, enzymes are 
known to exert profound effects on substrates to lower activation barriers, making the 
endeavor at least worth investigating. To our surprise and satisfaction, we discovered that 
TrpB can react with a number of carbon nucleophiles to form novel ncAAs.  
 
Figure 1-1. Products of non-carbon and non-indole nucleophiles produced by TrpS 
and TrpB.  27,54,56,67–69 
Nitroalkanes readily tautomerize to form a nucleophilic carbon alpha to the nitro group and 
have been used in the past as substrates for C–C bond formation reactions with electrophile-
activating enzymes.70–72 They have also been shown to react with chemically formed amino-
acrylates to synthesize a wide range of amino acids, albeit under harsh conditions and with 
no enantioselectivity.73–76 This led David Romney to hypothesize that nitroalkanes could act 
as nucleophiles in the TrpB β-elimination reaction.77 This was indeed the case, and many of 
the pre-existing TrpB variants they tested displayed at least some activity 
with (nitromethyl)benzene (Scheme 1-5, a) and the more sterically 





























(nitromethyl)benzene was found to decompose, leading the authors to reduce the reaction 
temperature to 50 °C. The variant with the best activity on both substrates was subjected to 
several rounds of site-saturation mutagenesis (SSM) targeting the active site to ultimately 
produce two specialized variants that both exhibited a maximum of 2,700 turnovers with 
their respective substrates. Because nucleophilicity is dependent on pH, the authors 
investigated the effect of pH and discovered that higher pH (pH 9.0) did not necessarily 
improve the initial reaction rate, but did result in higher total turnovers and consequently 
higher yield. The authors probed the substrate scopes of the two enzymes with a panel of 
nitrocyclohexane and (nitromethyl)benzene derivatives (Scheme 1-5, boxed). 
Unfortunately, the carbon alpha to the nitro group is still readily deprotonated after product 
formation, resulting in stereoablation of the products with newly formed chiral centers. 
Nevertheless, the authors suggested that the platform could be engineered for α-nitro-
substituted substrates to synthesize ncAAs with multiple chiral centers. 
 
Scheme 1-5. Reaction scheme and product scope (boxed) of engineered TrpB with 
nitroalkanes as nucleophiles for ncAA synthesis.  Nitroalkanes readily tautomerize in 
water to form a nucleophilic carbon species that reacts with the amino-acrylate 
intermediate in TrpB to form a new C–C bond. Model substrates a and b (dashed box) were 
used for directed evolution of TrpB.77  
Biologically active compounds are replete with all-carbon quaternary centers whose regio- 
and stereoselective formation is a challenge for both organic synthesis and biocatalysis. In a 
recent study, Markus Dick and Nicholas Sarai engineered TrpB for selective quaternary bond 
formation with 3-substituted oxindoles.78 3,3-Disubstituted oxindoles are a common motif in 
natural and synthetic bioactive compounds. Similarly to the tautomerization of nitroalkanes 















































tautomers, the latter of which is nucleophilic. In contrast to the nitroalkanes, whose 
tautomerization in water could be readily observed by NMR, the equivalent tautomer could 
not be observed for oxindoles, which suggested that there could be a significant activation 
barrier for TrpB to overcome in order for nucleophilic attack to occur. 3-Methyloxindole (17) 
was initially tested due to its abundance in synthetic and natural compounds. However, the 
methyl group appeared to sterically hinder nucleophilic attack from C3, and the initial TrpB 
variants that were tested primarily formed the N-alkylation product (Scheme 1-6, 18). A few 
variants, however, also formed the desired C3-alkylation product, providing a foothold for 
directed evolution. To prevent N-alkylation, Dick and Sarai chose to use 1,3-
dimethyloxindole (1-CH3-17) as the model substrate to begin evolution. Impressively, a 
single generation was enough to switch the chemoselectivity almost entirely from N- to C3-
alkylation, allowing the authors to continue with their original substrate, 3-methyloxindole, 
for the remainder of the evolution. After three more rounds of mutagenesis and screening, 
they obtained variant PfTrpBquat that exhibited >99% chemoselectivity for C3-alkylation and 
a 52% yield (122 mg) from 1 mmol of 3-methyloxindole using only 100 mL of E. coli cell 
culture. They determined that the enzyme was S,S-stereoselective with 3-methyloxindole, 
though stereoselectivity decreased with bulkier substitutions at C3. The enzyme could also 
tolerate ketone and lactone structures, demonstrating its ability to create quaternary centers 
with a diverse suite of carbonyl-containing nucleophiles bearing a tertiary carbon (Scheme 





Scheme 1-6. Reaction scheme and product scope (boxed) of oxindoles as nucleophiles 
for TrpB-catalyzed ncAA synthesis. Initially, TrpB variants catalyzed primarily N-
alkylation of 17 to form 18. With directed evolution, the regio- and chemoselectivity were 
switched to favor the desired C–C product (19, green dashed box). The final evolved 
variant accepted oxindoles with aryl (20, 21), N-methyl (22), and C3 substitutions (23, 24, 
25, black box). It also catalyzed the formation of lactone (26) and cyclic ketone (27 & 28) 
products (pink dashed box), which suggests that evolution could be applied to expand the 
scope of ncAA synthesis to encompass other nucleophiles.78  
The ability of TrpB to accept non-indole substrates such as nitroalkanes and oxindoles 
inspired other members of our lab to explore more molecules with known nucleophilic 
character such as the cyclic aromatic hydrocarbon azulene (Scheme 7, 29). Until this point, 
carbon nucleophiles accepted by TrpS and TrpB possessed heteroatoms that could stabilize 
the accumulation of charge during nucleophilic attack. Although azulene has no heteroatoms, 
it experiences a permanent dipole readily apparent in its resonance structure, which is a 
cycloheptatrienyl cation (tropylium) fused to a cyclopentadienyl anion (Cp–). We 
hypothesized that the electron accumulation of the Cp– stabilized by the tropylium system 
could promote nucleophilic attack by azulene on the amino-acrylate to form the ncAA β-(1-
azulenyl)-L-alanine (Scheme 1-7, AzAla, 30).79 AzAla is a blue Trp isostere whose 
fluorescent properties have been leveraged for spectroscopic studies,80–82 but whose use was 
limited due to its difficult, time-sensitive, multi-step synthesis.83 The discovery, and 
















































































Scheme 1-7. TrpB-catalyzed synthesis of β-(1-azulenyl)-l-alanine (AzAla)  (30) from 
azulene (29) and serine.79 
1.5 Biocatalytic cascades 
Designing and optimizing enzymatic cascades can be a laborious process, and to date many 
do not best their synthetic rivals. Nonetheless, their continued development is paramount for 
realizing the potential of biocatalysis as a sustainable route to many of the world’s chemicals. 
The ever-expanding catalog of engineered biocatalysts and advances in metabolic 
engineering have transformed the once pipe dream of whole-cell biocatalytic cascades into 
an attainable reality. In this realm, stereo- and regioselective enzymes that can be engineered 
easily and expressed heterologously reign supreme. It is thus not surprising that TrpS and 
TrpB—which are simple to use and boast large scopes of biologically relevant products—
have already been used in a number of cascades. Some of the in vivo implementations have 
required only the host’s native TrpS, which speaks to the latent potential of this remarkable 
complex. Others have made use of the simplicity provided by the stand-alone TrpB platform. 
In the following section, we highlight notable applications of TrpS and TrpB in biocatalytic 
cascades and discuss their biotechnological relevance. 
1.5.1 D-Amino acids  
Although L-amino acids comprise an overwhelming majority of amino acids in natural and 
synthetic compounds, their mirror counterparts are still found in many bioactive molecules 
and are important targets for enantiopure synthesis. D-Amino acids face similar synthetic 
challenges to L-amino acids but lack their diverse abundance of synthases, making direct 
biocatalytic access difficult. Unfortunately, TrpS’ strict retention of stereoselectivity for 
making the L-amino acid hinders its ability to be repurposed as a D-amino acid synthase. 
Nevertheless, because TrpS still represents a simple way to make Trp derivatives, numerous 












Parmeggiani and colleagues coupled TrpS from S. enterica (SeTrpS) with an L-amino acid 
deaminase (LAAD) followed by an engineered D-alanine aminotransferase (DAAT) to 
synthesize d-Trp derivatives in a one-pot, two-step transformation (Scheme 1-8).84 LAAD 
and DAAT were found to possess promiscuous activity for L-Ser, putting Ser in direct 
competition with L-Trp for stereoinversion and lowering the overall enantiomeric excess (ee) 
of the product. To circumvent this, the cascade was converted into a one-pot telescopic 
system whereby the stereoinversion biocatalysts were introduced after the TrpS-mediated 
synthesis was complete. This proved to be an effective strategy to synthesize numerous D-
Trp derivatives at gram scale with high yields and high ee. 
 
Scheme 1-8. Biocatalytic cascade for synthesis of D-Trp derivatives. In the first 
reaction, a substituted indole is transformed into its respective Trp derivative by TrpS. In 
the second reaction, an L-amino acid deaminase (LAAD) deaminates the Trp to form an 
imine intermediate, which then spontaneously hydrolyzes to the α-keto acid. A D-alanine 
aminotransferase (DAAT) transaminates the α-keto acid with D-Asp, forming oxaloacetate 
and the D-Trp. Adapted with permission from ref. [85]. Copyright: 2019, ACS Catalysis. 
In their preparation of β-branched Trps using TrpS, the Micklefield group used an l-amino 

















































epimer of β-methylTrp (Scheme 1-9, (2R,3S)-β-methylTrp, 32).65 Ammonia borane 
nonspecifically reduces the imine product formed by the LAAO to form both the L- and D-
amino acids; LAAO re-oxidizes the L-isomer to the imine while the D-isomer accumulates. 
The synthesis was performed in two steps in separate pots and resulted in an overall yield of 
66%. While the authors only demonstrated this proof of concept with β-methylTrp (31), the 
LAAO they used exhibits a broad substrate scope, and it is likely that the method could be 
used to make other derivatized D-β-branched Trps.85 
 
Scheme 1-9. One-pot chemoenzymatic approach for the stereoinversion of β-
methylTrp (31) to form D-β-methylTrp (32).65 
1.5.2 Tryptamine products 
In addition to its essential role as a proteinogenic amino acid, Trp is a precursor to numerous 
primary and secondary metabolites across all domains of life.86 Tryptamines are one such 
class of Trp-derived molecules that possess a wide range of bioactive properties. Reflecting 
their importance, significant efforts to develop synthetic approaches for tryptamines have 
resulted in several effective methodologies.87–90 However, there is still room for biocatalysis 
to improve upon the cost, sustainability, and level of oversight needed for their synthesis. 
Recently, there has been interest in the study of psychoactive natural products like psilocybin 
as treatments for psychological and neurological afflictions. Psilocybin is a hallucinogenic 
tryptamine that is an effective treatment option for patients with anxiety,91 substance 
addiction,92,93 and depression,94,95 and it is possible that the molecule will be approved as a 


















inconsistent amounts by the mushroom Psilocybe cubensis, making commercial extraction 
impractical.96 
Recent elucidation of the natural biosynthetic pathway by the Hoffmeister group revealed 
that TrpS lies upstream of only four enzymes, PsiH, PsiD, PsiK, and PsiM (which provide 
monooxygenase, decarboxylase, kinase, and methytransferase activities, respectively) to 
reach psilocybin (Scheme 1-10, black arrows).97 The relative simplicity of the pathway 
coupled with the product’s newfound pharmacological relevance encouraged them to 
investigate whether the cascade could be expressed in a model host organism to provide a 
scalable biosynthetic route. Indeed, the proteins expressed in E. coli allowed Fricke et al. to 
validate the putative activities of each enzyme and demonstrate an in vitro biosynthetic 
cascade of psilocybin.98 In characterizing the enzymes, they discovered, perhaps 
unsurprisingly, that P. cubensis TrpB (PcTrpB) could accept 4-hydroxyindole to produce 4-
hydroxyTrp. Fortuitously, PsiD could accept 4-hydroxyTrp, which obviated the need for 
PsiH and further simplified the in vitro synthesis to a four-enzyme cascade that starts from 
4-hydroxyindole (Scheme 1-10, dashed arrows).  
 
Scheme 1-10. Enzymatic synthesis of psilocybin. Black arrows represent the natural 
pathway and the pathway implemented by Milne et al. in S. cerevisiae.99 Dashed arrows 
represent the synthetic pathway that exploits promiscuity of TrpS to synthesize 4-












































Since then, there have been several instantiations of the cascade in different hosts. The 
first in vivo attempt ported the four enzymes downstream of TrpS into Aspergillus nidulans, 
accomplishing a modest 110 mg/L titer and more importantly establishing precedence for 
further in vivo applications.101 Adams et al. transferred the cascade without PsiH into E. coli, 
instead exploiting the promiscuity of EcTrpS to synthesize 4-hyroxyTrp from 4-
hydroxyindole that was provided exogenously.100 Attempts at EcTrpS overexpression did 
not improve titer, with native levels of expression sufficient for the pathway’s flux. Scale up 
led to 1.16 g/L of psilocybin after 72 hours, a ten-fold enhancement over the previous 
method. Most recently, Milne et al. transferred the entire pathway into Saccharomyces 
cerevisiae for the de novo biosynthetic production of psilocybin.99 They chose to use the 
natural functionality of TrpS to engineer a biosynthetic route to psilocybin rather than exploit 
the enzyme’s promiscuity for relatively costly 4-hydroxyindole. A fed-batch fermentation 
process yielded 627 mg/L of psilocybin and 580 mg/L of psilocin, the dephosphorylated 
bioactive form of psilocybin, after 200 hours. However, their metabolically engineered 
pathway takes about three-fold longer to reach approximately the same titer as the in vivo 
pathway starting from 4-hydroxyindole put forth by Adams et al.100 
Psilocybin is one of the most well-known examples of a tryptamine, perhaps second only to 
the neurotransmitter serotonin. However, tryptamines are an abundant motif among alkaloid 
natural products, and substitutions around the aromatic indole ring have profound effects on 
their bioactive properties. In Nature, substitutions are installed after Trp biosynthesis by 
specific enzymes, not unlike the natural psilocybin pathway. Harnessing these enzymes for 
biocatalysis to produce tryptamine derivatives, however, presents the arduous task of 
identifying and expressing separate tailoring enzymes for different Trp modifications.102 
The modular and convergent nature of TrpB to combine substituted indoles with Ser offers 
a simpler and more general method to access Trp analogs. Buller and colleagues 
hypothesized that coupling a stand-alone TrpB with a promiscuous Trp decarboxylase would 
create a simple and streamlined route to diverse tryptamines.103 No Trp decarboxylases that 




microbe Ruminococcus gnavus (RgnTDC), whose active site appeared to be large enough 
to accommodate substituted indoles. RgnTDC possessed relatively high promiscuous activity 
suitable for immediate biocatalytic application with TrpB. Because the two enzymes operate 
at dramatically different optimal temperatures (75 vs. 37 °C), PfTrpB2B9 was combined with 
RgnTDC in a one-pot, two-step reaction to produce a range of tryptamine derivatives with 
isolated yields ranging from 12–99% (Scheme 1-11). The ability to access a large number 
of products by combining TrpB and RgnTDC is a testament to the versatility and power that 
generalist enzymes bring to biocatalysis. 
  
Scheme 1-11. One-pot, two-step synthesis of tryptamine derivatives with TrpB and 
and Ruminococcus gnavus Trp decarboxylase (RgnTDC). Top: reaction scheme, 
bottom boxed: product scope. 
1.6 Summary and outlook 
TrpS is a remarkable enzyme and ideal ncAA synthase. Its long history as a model enzyme 
led to substantial knowledge about its allosteric regulation and catalytic mechanism that 
granted enzyme engineers the ability to re-imagine its function. In this chapter, we have 
covered major applications of TrpS, from humble beginnings preparing simple Trp analogs 
to becoming a powerful platform of TrpB enzymes that produce entirely new-to-nature 
ncAAs, as well as its use in biocatalytic cascades to make new Trp-derived products. The 




























































rapid expansion and exploration of the synthase’s substrate scope. Recent success in 
evolving TrpB to catalyze C–C bonds with new, non-indole nucleophiles bodes well for the 
platform’s further expansion into ncAA space. We envision that the discovery of highly 
stable and evolvable TrpB variants that function well at moderate temperatures will promote 
future applications in cascades, replacing multi-step syntheses that currently must 
accommodate different temperature optima. Mesophilic TrpB variants may also be used for 
in vivo synthesis to improve intracellular delivery of the ncAA (indole passes through cellular 
membranes more readily than a charged amino acid), reducing the amount of product that 
must be supplied exogenously, which could improve incorporation rates and reduce costs. In 
vivo synthesis and incorporation of ncAAs into proteins or secondary metabolites might also 
be used for robust biocontainment.100,104,105 
Although many substituted indoles are commercially available, one of the roadblocks for 
biocatalytic synthesis of Trp derivatives by TrpS and TrpB is the high price and limited 
availability of these substrates. This issue is highlighted by Milne et al., who used PsiH to 
install a hydroxyl group on Trp rather than provide expensive 4-hydroxyindole to TrpS 
directly.99 However, as we reach beyond the domain of naturally occurring chemical motifs, 
it is more difficult to find enzymes like PsiH that can make desired Trp modifications. In this 
non-natural space the TrpB platform truly shines for ncAA synthesis; it is simpler to engineer 
TrpB to accept new derivatives than it is to discover and engineer whole new enzymes that 
modify Trp. Therefore, advances in indole analog synthesis will continue to make TrpB a 
desirable route to Trp analogs. We expect that further applications of TrpS and TrpB are on 
the horizon and demonstrations like those from Parmeggiani et al.84 and McDonald et al.103 
will inspire others to use this biocatalyst extraordinaire.  
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We report a simple, one-step enzymatic synthesis of the blue fluorescent noncanonical amino 
acid β-(1-azulenyl)-L-alanine (AzAla). Using an engineered tryptophan synthase β-subunit 
(TrpB), stereochemically pure AzAla can be synthesized at scale starting from commercially 
available azulene and L-serine. Mutation of a universally conserved catalytic glutamate in 
the active site to glycine has only a modest effect on native activity with indole but abolishes 
activity on azulene, suggesting that this glutamate activates azulene for nucleophilic attack 




2.1 Introduction  
Proteins and peptides can be imbued with new chemical and physical properties via the 
inclusion of noncanonical amino acids (ncAAs). These molecules resemble the natural 
building blocks of proteins, but contain distinct structures and functional groups. When 
incorporated into proteins, ncAAs can serve as handles for chemical reactions or as 
spectroscopic probes to examine protein function, including reactivity, localization, and 
interaction with other biomolecules.1–3 Unfortunately, applications of many potentially 
useful ncAAs are limited owing to their high cost and lack of availability. The paucity of 
available ncAAs also hinders engineering of aminoacyl tRNA synthetases (aaRS) necessary 
for site-specific, in vivo ncAA incorporation into proteins.  
The ncAA β-(1-azulenyl)-l-alanine (AzAla, Scheme 2-1) is a tryptophan (Trp) isostere with 
unique fluorescent properties that make it a useful spectroscopic probe for investigating 
protein dynamics and protein-protein interactions. It can be incorporated into proteins in 
place of Trp without significantly disturbing tertiary structure or function.4–8 In contrast to 
Trp, its spectroscopic properties are insensitive to the environment, making it ideal in 
contexts where local conditions and quenchers (e.g., methionine, histidine) could complicate 
analysis of fluorescent signals.4 Its qualities have been leveraged for Förster resonance 
energy transfer (FRET) experiments to elucidate protein-protein interactions as well as 
vibrational energy transfer (VET) studies to probe anisotropic energy flow within 
proteins.9,10 Recently, a method for synthesis of AzAla via Negishi cross-coupling was 
described (Scheme 2-1a).11 Although proceeding with good yields on gram scale, the multi-
step process is highly time-sensitive and uses precious metal catalysts and organic solvents. 
A simpler route to AzAla would expand its applications in biochemical studies. 
Researchers have begun to look to enzymes as complementary or alternative approaches for 
the synthesis of enantiomerically pure ncAAs.12 Enzymes can perform enantio- and 
regioselective chemistry in the presence of reactive moieties such as primary amines, 
obviating the need for expensive and intricate chiral catalysts, chiral separations, and 




tryptophan synthase β-subunit (TrpB) as a stand-alone biocatalytic platform for the 
synthesis of diverse tryptophan analogues (Scheme 2-1b).13,14 Here we report a simple, 
efficient route for synthesis of AzAla from stable, commercially available starting materials 
using an engineered TrpB (Scheme 2-1c). 
 
Scheme 2-1. Synthesis of AzAla and Native TrpB activity. (a) Current synthetic route to 
Boc-protected AzAla. (b) TrpB natively catalyzes the condensation of indole and serine to 
form tryptophan. (c) Single-step biocatalytic synthesis of AzAla from azulene and serine 
described in this work.  
TrpB is a Type-II pyridoxal phosphate (PLP)-dependent enzyme that natively performs a 
conjugate addition reaction between indole and L-serine (Ser) to make Trp. During the 
catalytic cycle, Ser binds the PLP cofactor, and subsequent β-elimination and release of water 
forms an electrophilic amino-acrylate species (Scheme 2-2a). A highly conserved active-site 
glutamate stabilizes the accumulation of positive charge on the pyrrole ring of indole and 
helps facilitate the nucleophilic attack on the amino-acrylate to form a new C–C bond that 
produces Trp. The similarity of AzAla to Trp prompted us to investigate whether TrpB could 
accept azulene as a nucleophile in the place of indole. Unlike indole, azulene lacks 
heteroatoms that can help stabilize the accumulation of charge during nucleophilic attack. 
Despite this, azulene has a permanent dipole exemplified by its resonance structure of a 
cycloheptatrienyl cation (tropylium) fused to a cyclopentadienyl anion (Cp–). We 
hypothesized that, analogous to indole, the buildup of electron density on the Cp– could 
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system could stabilize the resulting positive charge (Scheme 2-2b). Aromatic ions are 
common moieties in synthetic chemistry15 and as enzyme inhibitors,16 but there are few 
reports of enzymes that can interact productively with aromatic ions in their catalytic cycles. 
We were therefore unsure if the active site of TrpB could accommodate or activate such a 
substrate, or if the reactivity of azulene would be sufficient for nucleophilic attack. 
 
Scheme 2-2. Parallels between indole and azulene in the TrpB reaction.  
2.2 Results  
We first examined the conversion of azulene and Ser to AzAla using a small panel of 
previously engineered TrpB variants from the thermophilic organisms Pyrococcus furiosus 
(PfTrpB) and Thermotoga maritima (TmTrpB). The variants were selected to provide an 
efficient sampling of the engineered TrpB evolutionary lineage beginning from wild-type 
TrpS and ending with stand-alone TrpB variants evolved for activity with different indole 
and serine analogues. Nearly every enzyme we tested demonstrated significant activity for 








































this reaction, the exception being variants in which the highly conserved glutamate 
mentioned above was mutated to glycine. 
The significant effect of the E104(105)G mutation suggested that this conserved catalytic 
residue may be playing an important role in the non-native azulene reaction. We explored 
this possibility by examining two engineered variants with and without the E104(105)G 
mutation: Pf5G8, which exhibits optimal activity at 75 °C,13 and Tm9D8*, which exhibits 
optimal activity at lower temperatures such as 37 °C.17 Challenging the enzymes with indole 
demonstrated that this mutation only modestly decreases the rate of Trp formation (Figure 
2-1), with an additional slight decrease in the chemoselectivity of the reaction that leads to 
formation of trace amounts of isoTrp (a product of the N-alkylation of indole, shown in 
Figure S2 and described previously13). In contrast, the E104(105)G mutation exerts a 
profound effect on AzAla production, practically abolishing all activity with azulene. 
Product was only detected in low amounts when the reaction was performed with high 
catalyst loadings overnight (0.1 mol %, 16 h; Appendix A, Figure A-2). We speculate that 
the glutamate residue stabilizes the tropylium cation to facilitate nucleophilic attack from 





Figure 2-1. Effect of E104(105)G mutation on Trp and AzAla production. Mutation of 
a conserved glutamate residue affects the rate of AzAla production more significantly than 
that of native Trp production. Bars represent the average of two to three replicates, with 
replicates being shown as individual points. Reaction conditions can be found in Table A-
1 n.d. = not detected by LC-MS.  
Next, we wished to develop a biocatalytic method for the production of AzAla at scale. 
Although Pf5G8 catalyzed the reaction roughly 4.5-fold faster at its optimum temperature of 
75 °C than Tm9D8* at 37 °C, azulene readily sublimes at high temperatures, making its 
containment at 75 °C difficult. We thus opted to use directed evolution to improve the activity 
of Tm9D8* at 37 °C to create a stand-alone biocatalyst for the production of AzAla in vivo 
and in vitro. 
A single round of random mutagenesis and screening identified two variants containing the 
mutations F184S and W286R. These mutations were combined to yield the final variant 
TmAzul, which had a three-fold improved rate of AzAla formation compared to Tm9D8* 
(14.0 turnovers per minute; Appendix A, Table A-1). As we have not been successful in 




of Tm9D8* to try to understand the locations of each mutation and their possible effects 
(Figure 2-2). The W286R mutation sits on a flexible loop, where its role in catalysis is 
difficult to infer. F184S sits directly in the active site and is one of only a handful of residues 
whose side chains are in close proximity to the azulene substrate. This residue may interact 
directly with the substrate during catalysis or adjust the active site to be more accommodating 
for AzAla synthesis.  
 
Figure 2-2. Homology model of Tm9D8* with azulene in the active site. Azulene (deep 
blue) is shown in a putative productive binding mode within a model of Tm9D8* with the 
amino-acrylate intermediate (cyan) formed in the active site (see Appendix A, Section A.4 
for model construction). Active-site residues in the native TmTrpB enzyme (green) and the 
mutations found in this study (red, mutation in parentheses) are shown as sticks. 
Because the Escherichia coli expression cultures were heat treated at 75 °C for three hours 
prior to screening, TmAzul retains high thermostability, and highly pure enzyme can be 
obtained simply by heating the E. coli expression host at 75 °C for >1 h, pelleting the 
denatured E. coli proteins by centrifugation, and collecting the enzyme-bearing supernatant. 
To demonstrate scalability of this method, we synthesized AzAla on a gram scale using heat-
treated lysate from a 1-L culture expressing the evolved TmAzul variant. We found that 














presumably by keeping azulene from forming insoluble crystals in the reaction mixture 
due to the sparing solubility of azulene in aqueous buffer. We thus used 20% DMSO 
cosolvent, and the reaction progress was monitored by taking small aliquots of the reaction 
mixture and combining with an equal volume of ethyl acetate to observe the relative ratio of 
azulene to AzAla in the organic and aqueous layers, respectively. After 48 hours, the product 
was purified by removing any remaining azulene by extraction with ethyl acetate, removing 
the aqueous solvent in vacuo, and precipitating AzAla from the remaining DMSO cosolvent 
by the addition of excess ethyl acetate. The crude precipitate was collected by filtration and 
then further purified by reverse-phased column chromatography to afford 965 mg of pure 
AzAla (57% isolated yield). Crude azulene can be recovered from ethyl acetate by gently 
evaporating off the solvent under a constant stream of nitrogen and reused. The enantiopurity 
of the isolated AzAla product is >99% ee.  
In conclusion, we have described a new-to-nature reaction catalyzed by tryptophan synthase 
and identified a conserved residue that is critical for this non-native reaction. Based on 
comparisons to the native reaction, we suggest that E104(105) stabilizes the aromatic ions in 
azulene to facilitate nucleophilic attack from Cp–. To improve access to this useful ncAA, 
we have engineered a highly active enzyme catalyst that synthesizes enantiomerically pure 
AzAla from commercially available starting materials in a single step. Given that an 
engineered synthetase/tRNA pair has been reported for this ncAA, TmAzul also closes the 
gap for in vivo synthesis and incorporation of AzAla.10  
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SUPPLEMENTARY INFORMATION FOR CHAPTER II 
A.1 Figures and tables 
 
Figure A-1. Isotryptophan formation catalyzed by TrpB E104(105)G mutants. Traces 
shown as total ion count filtered by [M+H]+ for Trp (m/z = 205). (a) A trace amount of 
isoTrp is formed by Pf5G8 E104G alongside Trp. (b) Tm9D8* E105G also produces 
isoTrp as the minor product. Reactions prepared according to Section A.3.7, with 
conditions given in Table S1. 
 
Figure A-2. Trace AzAla production by Tm9D8* E105G. After 16 hours at 37 °C with 
0.1 mol % catalyst loading, only a small amount of AzAla (peak at 0.653 min) is formed 
by Tm9D8* E105G. The reaction was prepared according to Section A.3.7, but the reaction 
mixture was not diluted after centrifugation to increase the concentration of product in the 
sample. Trace AzAla yield is also seen for Pf5G8 E104G at 75 °C, but the sublimation of 
























Table A-1. Rate comparisons among native and engineered TrpB enzymes[a]  
 initial turnover frequency (min-1)  
 to Trp to AzAla 
catalyst E104(105) G104(105) E104(105) G104(105) 
TmTrpS[b] 174  1 — 12.0  0.4 — 
Pf5G8[b] 12.5  0.3 6.8  0.6 21.4  1.4 n.d. 
Tm9D8*[c] 19.0  0.1 0.68  0.1[d] 4.6  0.6 n.d. 
TmAzul[c] — — 14.0  0.4 — 
[a]Reactions performed according to Section 3.7 with 0.02 mol % catalyst loading and 
allowed to react for 15 minutes (Trp production) or 1 hour (AzAla production). [b]Reactions 
run at 75 °C. [c]Reactions run at 37 °C. [d]Reaction time and catalyst loading increased to 2 
hours and 0.1 mol % catalyst loading to improve quantification. n.d. = not detected by LC-
MS. 
 
A.2 Experimental procedures 
A.2.1 General experimental methods 
Chemicals and reagents were purchased from commercial sources and used without further 
purification. Proton and carbon NMR were recorded on a Bruker 400 MHz (100 MHz) 
spectrometer equipped with a cryogenic probe. Proton chemical shifts are reported in ppm 
(δ) relative to tetramethylsilane and calibrated using the residual solvent resonance (D2O, δ 
4.79 ppm). Data are reported as follows: chemical shift (multiplicity [singlet (s), doublet (d), 
doublet of doublets (dd), doublet of doublet of doublets (ddd), triplet (t), triplet of doublets 
(td), multiplet (m)], coupling constants [Hz], integration).  
All cultures were grown in Terrific Broth supplemented with 100 μg/mL carbenicillin 
(TBcarb). Cultures were shaken in the New Brunswick Innova 4000 shaker (shaking diameter 
19 mm), with the exception of 96-well plates, which were shaken in the Multitron INFORS 
HT shaker (shaking diameter 50 mm). Lysis buffer was composed of 50 mM potassium 




Lysis was performed in 75 °C water bath (Fisherbrand™ Isotemp™ Digital-Control Water 
Baths: Model 220) for >1 h. Reactions were performed in 50 mM KPi, pH 8.0, unless 
otherwise stated. High-resolution mass spectrometry (HRMS) was conducted on an Agilent 
6200 TOF using electrospray ionization (ESI) to ionize the sample. Liquid 
chromatography/mass spectrometry (LCMS) was performed on an Agilent 1290 UPLC-
LCMS equipped with a C-18 silica column (1.8 µm, 2.1 × 50 mm) using CH3CN/H2O (0.1% 
acetic acid by volume): 5% to 95% CH3CN over 2 min; 1 mL/min. 
A.2.2 Cloning, expression, and purification of TrpB variants 
The genes encoding TmTrpAWT (Uniprot P50908), TmTrpBWT (Uniprot G4FDT2), Pf5G8, 
Pf5G8 E104G, Tm9D8*, and Tm9D8* E105G were previously cloned into pET22b(+) with 
a C-terminal 6x His tag. Protein expression of the variants was carried out in Escherichia 
coli BL21(DE3) E. cloni Express® cells (Lucigen) by inoculating 5 mL TBcarb with a single 
colony and incubating this pre-culture overnight at 37 °C and 230 rpm. For expression, 2.5 
mL culture were used to inoculate 500 mL Tbcarb in a 2-L flask and incubated at 37 °C and 
130 rpm for 2.5 hours to reach OD600 0.6–0.8. Cultures were chilled on ice for 20–30 minutes, 
and protein expression was induced with a final concentration of 1 mM isopropyl β-D-
thiogalactopyranoside (IPTG). Expression proceeded at 20 °C and 130 rpm for 
approximately 24 h. Cells were harvested by centrifugation at 10,000g for 20 minutes at 4 
°C and the supernatant was decanted. The pellet was stored at −20 °C until further use. 
For protein purification, cells were thawed and were resuspended in 4 mL lysis buffer/g 
pellet. Cells were heat-treated at 75 °C for >1 h. The supernatant was collected from clarified 
lysate following centrifugation for 20 min at 14,000g and 4 °C. Purification was performed 
with a 1-mL Ni-NTA gravity flow column at room temperature. Buffer A: 20 mM imidazole, 
25 mM KPi buffer, Buffer B: 500 mM imidazole, 25 mM KPi buffer. The column was 
equilibrated with 10 column volumes (CV) Buffer A. Subsequently, heat-treated lysate was 
loaded onto column and washed with 10 CV Buffer A. Next, 10 CV 1:1 Buffer A: Buffer B 




Buffer B. Proteins were dialyzed into 50 mM KPi buffer, flash frozen in liquid nitrogen, 
and stored at −80 °C.  
To obtain the purified TmTrpS complex, TmTrpAWT was co-purified with TmTrpBWT. Heat-
treated lysate of both TmTrpAWT and TmTrpBWT were mixed together in a roughly 5:1 ratio 
(concentrations determined relative band intensities from SDS-PAGE analysis) and 
purification was followed as described above. 
A.2.3 Construction of random mutagenesis libraries 
Random mutagenesis libraries were generated with the Tm9D8* gene as template by the 
addition of 200–400 μM MnCl2 to a Taq (New England Biolabs) PCR reaction as previously 
reported.1 PCR fragments were treated with DpnI for 1 h at 37 °C, purified by gel extraction, 
and then inserted into a pET22b(+) vector via Gibson assembly.2 The Gibson assembly 
product was purified and concentrated using Zymo DNA Clean and Concentrate–5 kit 
(Catalog #: D4004). BL21(DE3). E. cloni Express® cells were transformed with the Gibson 
assembly product. Libraries generated with 200, 300, and 400 μM MnCl2 were tested (one 
96-well plate, each) to determine which library gave the optimal balance of high diversity 
and low rate of inactivation. The chosen library was then tested further (see below).  
A.2.4 Library expression and screening 
Individual colonies were grown in 300 μL TBcarb in deep-well 96-well polypropylene plates 
and grown overnight at 37 °C, 250 rpm, 80% humidity. The following day, 20 μL overnight 
culture were used to inoculate 630 μL TBcarb cultures in deep-well 96-well plates and grown 
at 37 °C, 250 rpm. After 2.5 h, cultures were chilled on ice for 20–30 minutes and protein 
expression was induced upon addition of 50 μL IPTG (final conc. 1 mM) diluted in TBcarb. 
Cultures were shaken at 20 °C, 250 rpm for 20–24 h, after which they were subjected to 
centrifugation at 4,000g for 10 min. The cell pellets could be frozen at −20 °C until further 
use or used immediately.  
Pellets were lysed in 300 μL lysis buffer and heat-treated lysate clarified by centrifugation at 




0AF) charged with 10 μL azulene dissolved in DMSO (final conc. 0.625 mM), 30 μL heat-
treated lysate was transferred using Microlab NIMBUS96 liquid handler (Hamilton), 
followed by addition of 70 μL serine (final conc. 10 mM), and 90 μL 50 mM KPi buffer with 
a 12-channel pipet. Reactions were sealed with Microseal ‘B’ PCR plate sealing film 
(BioRad, catalog #: MSB1001) and incubated in a 37 °C water bath. Reaction progress was 
monitored by measuring absorption at 340 nm over the course of 24 h, in which more active 
variants retained AzAla in solution while the wells of inactive variants lost azulene due to 
absorption into the plastic assay plate and/or due to sublimation from solution. This can be 
seen below (Figure A-3), in a case where Tm9D8* is not given Ser, resulting in no activity, 
as opposed to the case where the addition of Ser allows for AzAla formation and retention 
of signal at 340 nm:  
 
Figure A-3. Graphs of UV absorbance (A.U.) vs. wavelength for AzAla screen. 
Reactions (200 μL) were run in UV-transparent plates for 17 hours, incubated at 37 ºC. 
Lysate (30 μL) and 0.625 mM azulene were added to each well. No-serine control received 
50 mM Kpi instead of 10 mM serine in 50 mM Kpi. Averaged data from two replicates of 
plate. Initially, samples have similar absorbance, but over time serine (-) control wells lose 
absorbance while serine (+) wells maintain signal. 
A.2.5 Recombination of mutations 
Site-directed mutagenesis was performed to combine mutations identified through screening 




F184S and W286R mutations. Using Tm9D8* W286R as template, the F184S mutation 
was introduced. Two PCRs were performed using Phusion polymerase (New England 
Biolabs), each fragment originating from the F184S site and ending in the center of the 
ampicillin resistance gene. The PCR fragments were treated with DpnI for 1 h at 37 °C, 
purified by gel extraction, and then combined via Gibson assembly.2 The Gibson assembly 
product was purified using Zymo DNA Clean and Concentrate–5 kit (Catalog #: D4004). 
BL21(DE3) E. cloni Express® cells were transformed with the Gibson assembly product. 
Table A-2. Gibson assembly primers 
Fragment Size (Kb) Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
1 4.8 CCTGCAGACCACCTATTACGTGTCCGGCTCTGTGGTTGGTCCGCATCCATATCCG 
CTGCCATAACCATGAGTGATAACACTGCGGCCAAC
TTACTTCTGACAACGATCG  
2 1.7 CCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGC 
GCGTGACTGGATTACCAACCTGCAGACCACCTATT
ACGTG 
A.2.6 Small-scale analytical reactions 
All analytical reactions were performed in 2-mL glass HPLC vials (Agilent) charged with 
10 μL azulene or indole (final conc. 10 mM) dissolved in DMSO (5% v/v), followed by 
addition of serine (final conc. 10 mM) and purified enzyme diluted in 50 mM KPi buffer to 
a final volume of 200 μL. Reactions were incubated at 75 °C or 37 °C for 24 h. The reaction 
was then diluted with 800 μL of 1:1 CH3CN/1 M aq. HCl and subjected to centrifugation at 
20,000g. For indole, this reaction mixture was analyzed directly by UHPLC-MS at 277 nm, 
representing the isosbestic point between indole and tryptophan and allowing quantification 
of yield by comparing the substrate and product peak areas.3 For azulene, the reaction 
mixture was further diluted by adding 10 µL of this mixture into 190 µL of 1:1 CH3CN/1 M 
aq. HCl and analyzed by UHPLC-MS. The yield was estimated comparing the integration of 
the product peak at 254 nm to a calibration curve (Section A.3.8). 
A.2.7 Calibration for measuring HPLC yield of AzAla 
Solutions of azulene and an authentic AzAla standard were made in 1:1 CH3CN/1 M aq. HCl 
(total conc. 1 mM) and mixed in different ratios (9:1, 3:1, 1:1, 1:3, 1:9) in duplicate and 
analyzed by HPLC. The ratios of substrate to product peaks at 254 nm were correlated to the 





Figure A-4. AzAla calibration curve.  
A.2.8 Large-scale preparation of AzAla 
Two 500 mL cultures of BL21(DE3) cells expressing TmAzul were grown according to 
expression conditions described in Section 3.2. The expression cultures were centrifuged for 
20 min and 14,000g. The pellets (14 g) were resuspended in 50 mL lysis buffer (100 μM 
PLP, 50 mM KPi buffer) and lysed at 75 °C for >1 h. Heat-treated lysate was centrifuged 20 
min, 14,000g, and the lysate decanted into a fresh container.  
To a 500-mL Erlenmeyer flask azulene (7.8 mmol, 1.0 g) and serine (8.6 mmol, 0.90 g), 30 
mL DMSO (20% v/v), 70 mL 50 mM KPi buffer, and 50-mL heat-treated lysate were added. 
The reaction was covered in aluminum foil, placed in 37 °C incubator, and shaken at 180 
rpm. After 48 h, the reaction was washed with ethyl acetate to remove any remaining azulene, 
allowing crude starting material to be recovered from ethyl acetate by gently evaporating off 
the solvent under a constant stream of nitrogen. The aqueous layer was concentrated in vacuo 
and resulting in a dense paste comprised of DMSO, AzAla, and buffer salts. Ethyl acetate 
was added to remove DMSO and precipitate the amino acid product. The blue solid was 
filtered and washed with ethyl acetate. At this stage, AzAla is relatively pure by NMR and 
can be used for further applications. For highly pure AzAla, the blue solid was solubilized in 




silica as the stationary phase, CH3CN (0.1% acetic acid) as the strong solvent, and H2O 
(0.1% acetic acid) as the weak solvent. AzAla should not spend long durations of time in 
strongly acidic conditions (such as 1 M HCl) as the product can decompose over time. The 
purified product fractions were combined and concentrated in vacuo to afford pure AzAla 
(blue solid, 0.965 g, 57% yield). 
A.3 Variant sequences 
Variants identified through screening were DNA sequenced using Sanger Sequencing 
(Laragen) to determine their identities. The DNA sequences of all TrpB genes tested in this 
project are included here. All variants were cloned into a pET22b(+) vector as described 
above. T7 and T7-terminator primers were used to sequence all variants.  
Table A-3. TrpB sequencing primers 
Primer Direction Sequence 
T7 Forward (5’ to 3’) taatacgactcactataggg 

















































































































A.4 Structural modeling  
A crystal structure of a homologous TrpS complex (Salmonella typhimurium, StTrpS) has 
been reported with the amino-acrylate in the β-subunit stabilized in the active site by 
benzimidazole, a competitive inhibitor (PDB: 4HPX).4 This TrpB structure served as the 
template for construction of a homology model of Tm9D8* (57% sequence identity) using 
the SWISS-MODEL program.5 The alignment of Tm9D8* homology model and the StTrpB 
structure allowed benzimidazole and the amino-acrylate to be placed within the Tm9D8* 
structure in PyMOL, and the five-membered ring of azulene was aligned directly to the five-
membered ring of benzimidazole to simulate a productive binding pose. 
A.5 Characterization of AzAla 
The enzymatic AzAla product was characterized by NMR, HRMS, and chiral derivatization. 
The spectra were taken in a mixture of D2O/5% DCl to increase solubility, resulting in 
deuterium exchange of one of the protons on the five-membered rings. 1H NMR (400 MHz, 
D2O) δ 7.85 (dd, J = 10.9, 9.6 Hz, 2H), 7.29 (s, 1H), 7.16 (t, J = 9.9 Hz, 1H), 6.72 (dt, J = 
11.7, 9.8 Hz, 2H), 3.89 (dd, J = 7.1, 5.8 Hz, 1H), 3.23 (dd, J = 15.3, 5.9 Hz, 1H), 3.15 (dd, J 




137.48, 136.66, 133.71, 123.74, 123.09, 120.83, 54.63, 27.64. HRMS (m/z) for [M+H]+ 
C13H14NO2 requires 216.1019, observed 216.1019. 
Enantiopurity was determined by derivatization with enantiopure and racemic FDNP-
alanamide. In a 2-mL vial, AzAla (0.5 μmol) was dissolved in 1 M aq. NaHCO3 (100 μL), 
to which 10 µL of a 33-mM FDNP-alanamide solution in acetone (0.33 µmol) was added. 
The vial was shaken for 2 h at 230 rpm, 37 °C. The reaction was allowed to cool to room 
temperature, then diluted with 1:1 CH3CN/1 M aq. HCl (600 μL). The solution was analyzed 
via LC-MS (40% to 95% CH3CN, monitored by using total ion count filtered for the expected 
mass of 468). Absolute stereochemistry for AzAla was inferred by analogy to L-tryptophan 
and determined to have >99% enantiomeric excess.  
 






A.6 NMR spectra 
 
Figure A-6. 1H NMR of pure AzAla. *Acidic conditions in deuterated solvents result in 
the exchange of one of the Cp– protons (6.9 ppm) for deuterium. 
 





Figure A-8. 1H NMR of crude AzAla.  *Acidic conditions in deuterated solvents result in 
the exchange of one of the Cp– protons (6.9 ppm) for deuterium. 
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Turi S., Arnold F. H., Buller A. R. Asymmetric Alkylation of Ketones Catalyzed by 
Engineered TrpB. Manuscript in progress. 
E.J.W.D. participated in the conception, design, execution of the research, and preparation 
of the manuscript. N.P.D. participated in the design and analysis of mechanistic experiments 
and preparation of the manuscript. S.S. participated in the execution of round 4 of evolution 






The β-subunit of tryptophan synthase (TrpB) catalyzes a PLP-mediated β-substitution 
reaction between indole and serine to form L-Trp. A succession of TrpB protein engineering 
campaigns to expand the enzyme’s nucleophile substrate range has enabled the biocatalytic 
production of diverse noncanonical amino acids (ncAAs). Here, we show that ketone-derived 
enolates can serve as nucleophiles in the TrpB reaction to achieve the asymmetric alkylation 
of ketones, an outstanding challenge in synthetic chemistry. We engineered TrpB by directed 
evolution to catalyze the asymmetric alkylation of propiophenone and 2-fluoroacetophenone 
with a high degree of selectivity. In reactions with propiophenone, preference for the opposite 
product diastereomer emerges over the course of evolution, demonstrating that full control 
over the stereochemistry at the new chiral center can be achieved. The addition of this new 
reaction to the TrpB platform is a crucial first step toward the development of efficient 




3.1 Introduction  
The formation of carbon–carbon (C–C) bonds in a controllable and selective manner is 
central to the construction of the diverse organic scaffolds upon which biological systems 
depend. While the fundamental challenges of C–C bond formation are constant, the ensuant 
solutions put forth by Nature and the synthetic chemist are distinct yet complementary. 
Nature has met these challenges with a relatively modest set of C–C bond-forming enzymes 
that operate under mild conditions and exhibit astonishing control over chemo-, regio-, and 
stereo-selectivities.1,2 By contrast, chemists have accumulated an arsenal of creative 
methods, many of which boast impressively large scopes of useful substrates. To overcome 
deficiencies in selectivity, however, chemists often employ precious-metal catalysts and 
complex ligands, and rely on addition and removal of protecting groups, which can quickly 
result in inefficient, multistep syntheses. Furthermore, most of these reactions are not 
compatible with aqueous solutions, and instead require harsh conditions and environmentally 
hostile solvents. New catalytic methods for C–C bond formation that draw from the vast 
array of nucleophilic substrates in the synthetic literature while leveraging the renowned 
selectivity of enzymes would be highly useful. 
The tryptophan synthase β-subunit (TrpB) is a pyridoxal phosphate (PLP)-dependent, C–C 
bond-forming enzyme that catalyzes the last stage in tryptophan biosynthesis. Natively, TrpB 
is bound to, and allosterically activated by, the tryptophan synthase α-subunit (TrpA), which 
cleaves indole-3-glycerol phosphate into indole and glyceraldehyde-3-phosphate.3 Indole 
diffuses along a 25 Å tunnel from TrpA to TrpB, where the PLP cofactor mediates C–C bond 
formation between C3 of free indole (in preference to N1) and an electrophilic serine-derived 
amino-acrylate species (E(A-A), Figure 3-1A). A recent engineering study demonstrated 
that activity lost by removal of TrpA could be recovered by directed evolution, leaving the 
stand-alone TrpB subunit as a simpler, more readily programmable platform for the synthesis 
of noncanonical amino acids (ncAAs).4 
The electrophilic amino-acrylate intermediate of the native TrpS complex can react with 




aniline, benzenethiol, and benzeneselenol to form new C–N,4–9 C–S,10 and C–Se bonds,10 
respectively (Figure 3-1B). By engineering the stand-alone TrpB (vide supra), Buller, 
Arnold, and coworkers systematically broadened the scope of ncAAs that are accessible 
using various nucleophiles, including an assortment of substituted indoles,4,8,11,12 azulene,13 
nitroalkanes,14 and oxindoles15 (Figure 3-1B). Impressively, the TrpB variant engineered to 
utilize 3-substituted oxindoles facilitates the formation of quaternary C–C bonds in 
preference to C–N bond formation in a powerful demonstration of how enzyme selectivity 
can be leveraged for the construction of C–C bonds that are otherwise challenging to make.15 
In this study, we investigated the capacity of ketone-derived enolates to serve as nucleophiles 
in TrpB-catalyzed reactions (Figure 3-1C). While these compounds are one of the most well-
researched carbon-based nucleophiles in the synthetic literature, there are still no general 
methods for their direct asymmetric α-alkylation.16 Enzymatic reactions with enolates are 
relatively rare, and to our knowledge there are no examples engineering enzymes to accept 
enolates if they are not already the native substrate. Nevertheless, we hypothesized TrpB 
might be able to accomplish this feat, and that realizing this chemistry may inspire others to 
investigate further chemoenzymatic reactions with enolates. At the outset, we considered 
four main obstacles to achieving selective alkylation of ketones: (1) ketone tautomerization 
can result in multiple enolate stereo- and regioisomers, the latter stemming from 
asymmetrical ketones with multiple deprotonation sites; (2) the facial approach of the enolate 
to the electrophile dictates the Cα stereochemistry and therefore must be precisely controlled 
to achieve stereoselectivity; (3) the substituted ketone product may also tautomerize and 
racemize the newly set chiral center; (4) enols are thermodynamically disfavored in aqueous 
conditions, so the population of reactive nucleophile available in solution would be very 
small. We reasoned that if TrpB could accept enolates as nucleophiles, the selectivity 





Figure 3-1. Overview of past and present work. (a) The C–C bond-forming step in TrpB-
catalyzed reactions: nucleophilic addition of C3 of indole to the amino acrylate (E(A-A)). 
(b) Nucleophiles previously shown to be used by TrpS/TrpB. (c) Enolate nucleophiles, 
supplied to the reaction as their ketone tautomer, can be used by TrpB to form linear ncAAs 
that undergo spontaneous cyclization.  
3.2 Results and discussion  
We began by screening a panel of purified TrpB enzymes from previous evolution projects 
for activity with serine and propiophenone. We selected propiophenone because it absorbs 
light in the ultraviolet (UV) region, bears a bulky phenyl substituent that resembles other 
non-indole nucleophiles that react with TrpB, and has been highlighted as a ketone for which 
no direct asymmetric alkylation methods have been reported.16 A 
Thermotoga maritima TrpB (TmTrpB) variant previously engineered to synthesize 4-
cyanotryptophan11—Tm9D8*—displayed trace activity with propiophenone (30 TTN, 






































































To improve this novel enzymatic reactivity, we initiated a directed evolution campaign 
using a combination of site-saturation and random mutagenesis and screened the mutant 
libraries for increases in product formation, remaining agnostic as to whether beneficial 
mutations resulted from enhanced enzymatic activity or expression. We screened lysate 
reactions at 37 °C during the first round of engineering, as this temperature elicited the 
highest activity of the Tm9D8* variant in previous reactions with 4-cyanotryptophan.11 
Optimizing the reaction conditions, we found product formation with the propiophenone 
substrate  reached a maximum at 55 °C, and this temperature was used for subsequent rounds 
of directed evolution. Three rounds consecutively accrued the mutations F184H (TmE1, 26 
TTN), I174T (TmE2, 28 TTN), and F41Y (TmE3, 39 TTN; Figure 3-2A). 
Constrained to product detection by HPLC-MS, limited analytic screening capacity quickly 
became an obstacle to discovering improved variants. Thus, we explored screening by 
Multiple Injections in a Single Run (MISER), a flow-injection analysis method in which each 
sample in a 96-well plate is injected sequentially, passed through a short guard column, and 
analyzed by the mass spectrometer.17 This strategy dramatically improved screening 
throughput, decreasing the time per 96-well plate from 5 hours to 35 minutes. With MISER, 
we screened a larger error-prone PCR (epPCR) random mutagenesis library and found an 
improved variant bearing four additional mutations: K39I, E40G, P54Q, and I195T (TmE4, 
53 TTN; Figure 3-2A). During this round of engineering, however, the poor signal-to-noise 
ratio of the MISER screen resulted in a number of false positives that impeded the overall 
workflow. Therefore, we decided to examine the substrate scope of TmE4 with the prospect 
of uncovering a new substrate that could be detected by MISER more reliably. To our delight, 
TmE4 exhibited much higher activity with 2-fluoroacetophenone (90 TTN, Figure 3-2B), 
which is consistent with the expected activating effect of the fluorine on the Cα–H bond. 
For the remainder of the evolution, we screened for activity with serine and 2-
fluoroacetophenone using the MISER analysis method. In the next two rounds of 
engineering, several variants that yielded improvements were identified (TmE5, TmE6.3, 




mutations now observed throughout the lineage, we generated a recombination library 
using staggered extension process (StEP) PCR,18 which allowed each residue of interest to 
either retain its mutation or revert back to wild type. Of the 600 colonies screened, the best 
variant displayed a further 2-fold increase in activity over the best round 6 variant, TmE6.3, 
by recombining mutations I166V and S228G (TmE7, 700 TTN; Figure 3-2B). 
Because enolates are structurally and electronically dissimilar to the reactive indole enamine-
like species, we investigated the roles of active-site residues E105 and H184 by introducing 
alanine mutations at each site and measuring changes in activity for both indole and 2F-
acetopheneone. E105 facilitates nucleophilic attack on the amino acrylate by stabilizing the 
accumulation of positive charge on the pyrrole ring of indole (Figure 3-1A); the E105G 
mutation in TmTrpB was shown to be deleterious to activity with indole and several 
analogs.13 Previous studies have shown that mutations to H184, which is spatially adjacent 
to E105, also strongly affect activity,11,14 although the specific role of histidine is less clear. 
The E105A mutation reduced the indole activity of TmE7 unsurprisingly by 93%, but only 
decreased the 2-fluoroacetophenone activity by 30% (Figure 3-2C). While the H184A 
mutation had no effect on indole activity, we were pleasantly surprised to find that it 
improved 2-fluoroacetophenone activity 3.8-fold. TrpB TmE7 with the H184A mutation 






Figure 3-2 Directed evolution of enolate activity. (a) Activity of variants in the TrpB 
evolutionary lineage with propiophenone (PP) and serine. Bars represent the average of 
two or three replicates shown as individual points. Colors refer to the substrate used for 
screening. The diastereoselectivity, shown as individual points, for the cyclized imine 
product was measured for each variant. (b) Activity of variants in the TrpB evolutionary 
lineage with 2-fluoroacetophenone (2F) and serine. Bars represent the average of two or 
three replicates shown as individual points. Colors refer to the substrate used for screening. 
The diastereoselectivity, shown as individual points, for the cyclized imine product was 
measured for each variant. (c) Activities of alanine mutants with indole and 2-
fluoroacetophenone, relative to TmE7. (d) Michaelis-Menten kinetics of Tm9D8* (teal) 
and TmE8 (dark blue). Dotted lines represent the 𝐾 . Reaction conditions for Figure 2 
can be found in Appendix B, Section B.2.8 and B.2.9  
Using the best variant for each respective substrate, we isolated the products from enzymatic 
reactions for NMR characterization, as reported syntheses for making the authentic standards 
were absent from the literature. The enzymatic products of the reactions with propiophenone 
and 2-fluoroacetophenone were each identified to be a mixture of two imine isomers. 
Reapplication of the propiophenone-derived imine product mixture as an authentic standard 
showed that directed evolution had a strong influence on the diastereomeric outcome (Figure 
3-2A). Although we had not screened specifically for diastereoselectivity, the preference for 




diastereomeric ratio, d.r., Figure 3-2A), demonstrating that stereochemistry at the newly 
formed chiral center can be tuned with this platform. In reactions with 2-fluoroacetophenone, 
the enzymes exhibited an even higher degree of selectivity, with the final variant, TmE8, 
boasting a d.r. of 95:5 (Figure 3-2B). However, we observed an erosion in selectivity at 
prolonged reaction times (Appendix B, Figure B-2), suggesting the newly formed chiral 
center racemizes through tautomerization in solution, as discussed above. In principle, 
subsequent reduction of the product would fix the stereochemistry, and indeed we observed 
the expected shifts in product mass by HPLC-MS upon treatment with sodium 
cyanoborohydride (Appendix B, Figure B-3), but the resulting mixture of diastereomers 
rendered rigorous product characterization problematic. Leveraging the selectivity of a 
suitable reductase in an enzymatic cascade may be the best solution to this problem (vide 
infra). 
To gain insight into the mechanism of this new transformation, we first explored the kinetics 
of product formation in reactions with 2-fluoroacetophenone catalyzed by Tm9D8* and 
TmE8 (Figure 3-2D). TmE8 exhibited a 56-fold increase in apparent turnover number 
(𝑘 ) compared to Tm9D8* (9.0 min-1 and 0.16 min-1, respectively), which is likely the 
principal factor contributing to the 20-fold increase in TTN observed across the evolutionary 
lineage. The change in the apparent KM 𝐾 )  was modest (57 mM and 44 mM for Tm9D8* 
and TmE8, respectively). The dramatic improvement in 𝑘  without a significant change in 
the strikingly high 𝐾  values prompted us to investigate whether the enzyme was binding 
the ketone and facilitating its tautomerization in the active site or simply reacting with the 
small population of the enol tautomer present in solution (Figure 3-3A). 
We measured the rate of deuterium exchange into 2-fluoroacetophenone from deuterated 
buffer in the absence of enzyme (Figure 3-3B). Under these conditions, the rate of 
uncatalyzed tautomerization is an order of magnitude faster than the enzymatic reaction 
(Figure 3-3C). We measured the rate of protium exchange into 2,2-d2-2-fluoroacetophenone 
in unlabeled buffer, from which we calculated a kinetic isotope effect (KIE) of 5.7 for 




background rate of enolization is calculated by measuring the formation of isotopically 
labeled ketone resulting from two tautomerization events and is a conservative 
approximation of the in-solution tautomerization rate, as a single-step conversion to the enol 
would be marginally faster. To learn more about tautomerization in the enzyme active site, 
we extracted the initial velocity (V0) of product formation from the progress curves of TmE8 
with the unlabeled 2-fluoroacetophenone substrate and 2,2-d2-2-fluoroacetophenone and 
determined a KIE of 5.8 (Figure 3-3C). The remarkable similarity of these two KIEs 
suggests that the KIE measured in the enzymatic reaction may also originate from in-solution 
tautomerization of the ketone. We therefore considered a second scenario wherein TmE8 
binds the enol tautomer directly (Figure 3-3A, Enol-binding pathway). Based on known 
equilibrium constants of acetophenone tautomerization,19,20 we estimate that the 2-
fluoroacetophenone-derived enol tautomer is present at low µM concentrations for these 
experiments. Under these conditions, approximately a single turnover of enzyme (present at 
10 μM) would deplete the starting material entirely, obliging the system to then wait for 
tautomerization to deliver more substrate. In such a scenario, the KIE observed in the 
enzymatic reaction would then exactly match the KIE for the uncatalyzed exchange, which 
was observed. 
A key distinguishing feature of the ketone-binding vs enol-binding models is the kinetic 
order of the reaction in catalyst. For the ketone-binding model, initial velocities should be 
directly proportional to catalyst concentration. However, for the enol-binding model, the 
reaction is fundamentally limited by the speed of the uncatalyzed tautomerization, which 
would manifest as non-linearity between catalyst concentration and initial velocity. To 
examine this hypothesis, we extracted V0 values from progress curves with increasing 
concentrations of TmE8 (10 µM–150 µM, Figure 3-3D). We observed a clear break in the 
linearity between [TmE8] and V0, with the rate of the enzyme-catalyzed reaction 
asymptotically approaching the 2-fluoroacetophenone exchange rate (Figure 3-3E). We 
therefore conclude that TmE8 does not bind the ketone substrate and catalyze 





Figure 3-3. Mechanistic characterization of enolate activity. (a) Possible pathways to 
enolate formation. (b) Exchange curves of 2-fluoroacetophenone and 2,2-d2-2-
fluoroacetophenone in deuterated buffer and unlabeled buffer, respectively (c) TmE8 (10 
µM) progress curves with 2-fluoroacetophenone and 2,2-d2-2-fluoroacetophenone at 50 
mM substrate loading.  (d) TmE8 progress curves at varying [enzyme] with 50 mM 2-
fluoroacetophenone. (e) Initial velocty of product formation extracted from the progress 
curves in D represented as a function of [TmE8]. Details of nonlinear regression analyses 
can be found in Appendix B, Section B.2.8 and B.2.10.  
The enol-binding mechanism provides clarity to other observations that arose during our 
studies. The parent enzyme, Tm9D8*, is over 50-fold slower than the final variant and has a 
much lower KIE of 3.9 (Appendix B, Figure B-4), which we hypothesize is due to the larger 
steady-state concentration of enol tautomer in solution resulting from slower consumption 




be impacted by changes in both kcat and KM under the conditions we used to screen for 
improvements during directed evolution. However, we observed virtually no change in 𝐾 , 
despite the significant structural differences between indole and acetophenones. Instead, the 
enol-binding mechanism suggests the KM for the true substrate is in the low μM regime, thus 
providing no selective pressure for this parameter to change. In order to achieve such a low 
KM, we speculate that the TrpB active site must have exquisite complementarity for the 
substrate. 
To understand the effect of Cα substitutions, we evaluated the substrate scope of the 
engineered variants and measured the rates of deuterium exchange into those substrates that 
are compatible with aqueous solutions (Table 3-1 and Appendix B, Section B.2.10). 
Comparing observed rate constants (kexg), propiophenone tautomerizes an order of 
magnitude slower than acetophenone (5.86 x 10-4 min-1 vs. 4.14 x 10-3 min-1, respectively). 
However, Tm9D8* exhibited a higher level of activity with propiophenone than 
acetophenone, suggesting that small changes in substitutions at the Cα position are 
distinguished by the enzyme, and positioning of the resulting enol is crucial. In agreement 
with this hypothesis, TmE8 showed varying degrees of activity with different substituents at 
Cα. Notably, TmE8 catalyzed the reaction with 2-cyanoacetophenone, a substrate 
electronically similar to 2-fluoroacetophenone, with 250 TTN (Appendix B, Figure B-9). 
Intriguingly, the product of this reaction isomerizes to the corresponding enamine, which 
extends the pi conjugation from the arene to the nitrile, producing an intense absorption band 
in the visible region (Appendix B, Figure B-14). TmE8 showed no activity with 2-
phenylacetophenone, suggesting that it does not readily accommodate bulkier substituents at 
Cα; however, trace activity was observed with benzoylacetone (< 1 TTN). We also found 
that a variant stemming from Pyrococcus furiosus TrpB, PfTrpB7E6, exhibited similar activity 
with benzoylacetone (See Appendix B, Figure B-9). Thus, it appears that multiple TrpB 
scaffolds are capable of catalyzing this new reaction, broadening the sequence space 




Table 1. Ketone substrate scope of TmE8 and deuterium exchange rate constants 
(kexg).  
Entry Substrate TTN in 24 h kexg (min-1) 
1 
 
3 4.14 x 10-3 
2 
 
<1 5.86 x 10-4 
3 
 










[a] 2-cyanoacetophenone is insoluble in buffer. [b] Benzoylacetone hydrolyzes at 55 °C. 
As it stands currently, the maximum rate of product formation using TrpB is approximately 
limited by kexg, but this limitation does not preclude its potential utility. For example, 
assuming that a TrpB variant was limited exclusively by kexg, a reaction with 50 mM 2-
fluoroacetophenone would reach completion in less than 4 hours. Under the same conditions, 
a reaction with acetophenone would near completion in 12 hours. Nevertheless, emulating 
Nature’s machinery may comprise the ultimate solution. Despite the fact that the keto-enol 
equilibrium strongly favors the ketone in aqueous conditions, enolates are common 
nucleophiles in biology, and several strategies to overcome these unfavorable 
thermodynamics have evolved naturally. For example, type I aldolases form an intermediate 
Schiff base between the substrate carbonyl and an active-site lysine residue to effectively 
reduce the pKa of the Cα proton.21 Although TmE8 does not boast such sophistication, there 
are no obvious factors that would directly preclude engineering the machinery necessary to 












In conclusion, we have demonstrated that TrpB can be evolved for the asymmetric 
alkylation of ketones and have provided a glimpse into the scope of substrates that may be 
compatible with this new enzymatic transformation. Given that TrpB TmE8 does not 
influence the keto-enol tautomerization rate, yet exhibits control over the formation of 
diastereomeric products, we posit that the active site has been engineered to bind a particular 
configuration of the nucleophilic enol tautomer and direct its approach to the electrophilic 
amino acrylate. The linear products of the TrpB-catalyzed reactions presented herein 
spontaneously cyclize to form derivatives of 1-pyrroline-5-carboxylic acid,22 which could be 
further processed by a suitable imine reductase in a cascade system to furnish chirally dense 
noncanonical prolines.23 Furthermore, expanding this platform to include aldehydes as 
nucleophilic substrates and β-branched amino acids as amino-acrylate precursors would 
provide access to each carbon substituent on the nitrogen heterocycle. Finally, this study 
demonstrates that enolates can be intercepted by enzymes, raising the possibility that other 
classes of enzymes could also be leveraged for asymmetric ketone alkylation in the future. 
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SUPPLEMENTARY INFORMATION FOR CHAPTER III 
B.1 Supplementary figures 
 





Figure B-2. Racemization of enzymatic propiophenone-derived cyclic imine product 
over time.  Reactions were set up according to Section B.2.8. Reaction conditions: 50 mM 
propiophenone in DMSO (5% v/v), 50 mM serine, 100 μM purified TmE2. Reactions were 
incubated at 37 °C and quenched after 20 minutes and 24 hours. HPLC-MS chromatograms 
are cyclic imine ion mass+1 (204). Cyclic imine retention times are ~1.71 and ~1.95 min. 
 
Figure B-3. Sodium cyanoborohydride reduction of 2-fluoroacetophenone product. 





Figure B-4. Tm9D8* KIE experiment. Reactions were set up according to Section B.2.8. 
Reaction conditions were identical to those in Figure 3-3B except enzyme loading: 50 mM 
nucleophile in DMSO (5% v/v), 50 mM serine, 100 μM purified Tm9D8*, incubation at 
55 °C. 
 
Figure B-5. Substrate scope of TmE8. Boxed substrates reactions were set up according 
to Section B.3.7. Reaction conditions: 50 mM nucleophile in DMSO (5% v/v), 50 mM 
serine, 5 or 100 μM TmE8, 24 h incubation at 55 °C TTN were determined from standard 
curve. All other reactions were set up according to Section B.2.7. Reaction conditions: 10 
mM nucleophile in DMSO (5% v/v), 50 mM serine, 100 μL TmE8 lysate, 24 h incubation 





Figure B-6. HPLC-MS traces for para-chloro-2-fluoroacetophenone. Reactions were 
set up according to Section B.2.7. Reaction conditions: 10 mM para-chloro-2-
fluoroacetophenone in DMSO (5% v/v), 50 mM serine, 100 μL TmE8 lysate or pET22b(+) 
lysate control, 24 h incubation at 55 °C. 
 
Figure B-7. HPLC-MS traces for 2,2-difluoroacetophenone. Reactions were set up 
according to Section B.2.7. Reaction conditions: 10 mM 2,2-difluoroacetophenone in 
DMSO (5% v/v), 50 mM serine, 100 μL TmE8 lysate or pET22b(+) lysate control, 24 h 





Figure B-8. HPLC-MS traces for benzoylacetone. Reactions were set up according to 
Section B.2.7. Reaction conditions: 10 mM benzoylacetone in DMSO (5% v/v), 50 mM 
serine, 100 μL TmE8 lysate or pET22b(+) lysate control, 24 h incubation at 55 °C. 
  
Figure B-9. Substrate scope reactions. Reactions were set up according to Section B.2.8. 
Reaction conditions: 50 mM nucleophile in DMSO (5% v/v), 50 mM serine, purified 
protein (Acetophenone: 100 μM, max TTN 500; 2CN-acetophenone: 5 μM, max TTN 
10,000; Benzoylacetone: 100 μM, max 500 TTN) 24 h incubation at 55 °C. 
B.2 Methods 
B.2.1 General experimental methods 
Chemicals and reagents were purchased from commercial sources and used without further 
purification. NMR spectra were recorded on a Varian Unity/Inova 500 spectrometer 
operating at 500 MHz and 125 MHz for 1H and 13C, respectively, a Bruker Avance 400 
spectrometer equipped with a cryoprobe operating at 400 MHz and 101 MHz for 1H and 13C, 




1H and 19F, respectively. Chemical shifts are reported in ppm (δ) and calibrated using the 
residual solvent resonance. For 1H NMR: D2O, δ 4.79; DMSO-d6, δ 2.50; CDCl3, δ 7.26. 
For 13C NMR: DMSO-d6, δ 39.52; CDCl3, 77.16. Data are reported as follows: chemical 
shift (multiplicity [singlet (s), doublet (d), doublet of doublets (dd), doublet of doublet of 
doublets (ddd), triplet (t), triplet of doublets (td), multiplet (m)], coupling constants [Hz], 
integration).  
All cultures were grown in Terrific Broth supplemented with 100 μg/mL carbenicillin 
(TBcarb). Cultures were shaken in New Brunswick Innova 4000 (shaking diameter 19 mm) 
shakers, with the exception of 96-well plates, which were shaken in a Multitron INFORS HT 
(shaking diameter 50 mm) shaker. Lysis buffer was composed of 50 mM potassium 
phosphate, pH 8.0 (KPi buffer), supplemented with 200 μM pyridoxal 5’-phosphate (PLP), 
unless otherwise specified. Reactions were performed in 50 mM KPi, pH 8, unless otherwise 
specified. Liquid chromatography/mass spectrometry (LCMS) was performed on an Agilent 
1260 HPLC-MS equipped with an S18 silica guard column (Guard: Poroshell 120, UHPLC 
Guard, ESC18, 4.6 mm; Column: Poroshell 120 ESC18, 4.6x50 mm, 2.7 m) using 
CH3CN/H2O (0.1% acetic acid by volume): 5% to 95% CH3CN over 3 min; 1 mL/min.  
Table B-1. Chemicals, reagents, and equipment 
Chemical, reagent, or equipment Supplier Catalog # 
ArctiSeal™ 96 Well Square Silicone/PTFE Coating Arctic White LLC AWSM-1003S 
AcroPrep wwPTFE 96-well filter plates VWR 76308-642 
Biotage Sfär silica C18-D 12 gram column Biotage FSUD-0401-0012 
HPLC 2-mL Glass Vials Agilent 5183-2068 
BugBuster 10X Protein Extraction Reagent (Novagen) Millipore Sigma 70921-4 
Bradford 1X dye reagent Bio-Rad #5000205 
Clean and Concentrate -5 kit Zymo D4004 
cOmplete™ His-Tag Purification Column Sigma Aldritch 6781543001 
DpnI New England Biolabs R0176 
E. cloni® EXPRESS BL21(DE3) cells Lucigen 60300 
Gel DNA extraction kit Zymo D4008 
Glass-lined polypropylene 96-well reaction plates VWR 10036-272 
Hen egg white lysozyme Sigma Aldritch  
Isotemp™ Digital-Control Water Bath Fisherbrand™ Model 220 
Microlab NIMBUS96 liquid handler Hamilton  
Taq New England Biolabs M0273 
Phusion New England Biolabs M0530 
Pierce™ BCA Protein Assay Kit ThermoFisher 23225 
Quick Start™ Bradford 1x Dye Reagent BioRad 500-0205 




B.2.2 Cloning, expression, and purification of TrpB variants  
The gene encoding Tm9D8* was previously cloned into pET22b(+) with a C-terminal 6x 
His tag. Protein expression of the variants was carried out in Lucigen E. cloni® EXPRESS 
BL21(DE3) cells by inoculating 5 mL of TBcarb with a single colony and incubating this pre-
culture overnight at 37 °C and 230 rpm. For expression, 8 mL culture was used to inoculate 
800 mL Tbcarb (1:100 dilution) in a 1.8-L Fernbach flask and shaken at 200 rpm and 37 °C 
for 5 hours. Cultures were chilled on ice for 20–30 minutes, and protein expression was 
induced with a final concentration of 1 mM isopropyl β-D-thiogalactopyranoside (IPTG). 
Expression proceeded at 200 rpm and 20 °C for approximately 24 h. Cells were harvested by 
centrifugation at 10,000g for 20 minutes at 4 °C, and the supernatant was decanted. The pellet 
was stored at −20 °C until further use. 
For protein purification, cells were thawed and resuspended in 4 mL lysis buffer per gram of 
pellet (standard lysis buffer: 1 mg/mL lysozyme, 0.1 mg/mL bovine pancreas DNase I, 1X 
BugBuster). BugBuster was added after the pellet had been mostly resuspended to prevent 
foaming. Cells were gently agitated on a rocking platform at room temperature for 30 
minutes followed by heat-treatment in a 75 °C water bath for >1 h. The supernatant was 
collected from clarified lysate following centrifugation for 20 min at 14,000g and 4 
°C. Purification was performed with an AKTA purifier FPLC system (GE Healthcare) and a 
1-mL Ni-NTA column. Protein was eluted by applying a linear gradient of 100 mM to 500 
mM imidazole in 25 mM KPi buffer, pH 8.0 and 100 mM NaCl. Fractions containing purified 
protein were dialyzed into 50 mM KPi buffer, pH 8.0, flash frozen in liquid nitrogen, and 
stored at −80 °C. Protein concentrations were determined using the Bio-Rad Quick Start™ 
Bradford Protein Assay.  
B.2.3 Construction of site-saturation mutagenesis libraries  
Site-saturation mutagenesis libraries were generated with the Tm9D8* gene (and 
evolutionary variants) using degenerate ‘NNK’ primers. Forward and reverse primers were 




region with a Tm = 60 °C (not including the degenerate site). The entire plasmid was 
amplified in a single PCR using the Phusion polymerase. PCR fragments were treated with 
DpnI for 1 h at 37 °C, analyzed via agarose gel, purified using Zymo Gel DNA extraction 
kit, and then inserted into a pET22b(+) vector via Gibson assembly.2 The Gibson assembly 
product was purified and concentrated using the Zymo DNA Clean and Concentrate–5 kit. 
Lucigen E. cloni® EXPRESS BL21(DE3) cells were transformed with the Gibson assembly 
product. 
 
Figure B-10. Gibson assembly primers. 
Table B-2. Site saturated mutagenesis PCR mix 
Component Volume (μL) 
primer_F (10 M) 1 
primer_R (10 M) 1 
Template (~50-100 ng) 0.5 
NTP mix (10 mM) 1 
Phusion 0.5 








Table B-3. Site saturated mutagenesis PCR thermal cycler method 
Step Temp (°C) Time (min) 
1 Initial denature 98 0:30 
2 Denature 98 0:10 
3 Anneal 55 0:15 
4 Extend 72 2:20 
Repeat 2–4 X30 
5 Final extension 68 10:00 
6 Hold 10 ∞ 
B.2.4 Construction of random mutagenesis libraries  
Random mutagenesis libraries were generated with the Tm9D8* gene (and evolutionary 
variants) as template by the addition of 200–400 μM MnCl2 to a Taq PCR reaction as 
previously reported.3 PCR fragments were treated with DpnI for 1 h at 37 °C, purified by gel 
extraction, and then inserted into a pET22b(+) vector via Gibson assembly.2 The Gibson 
assembly product was purified and concentrated using Zymo DNA Clean and Concentrate–
5 kit. Lucigen E. cloni® EXPRESS BL21(DE3) cells were transformed with the Gibson 
assembly product. Libraries generated with 200, 300, and 400 μM MnCl2 were tested (one 
96-well plate each) to determine which library gave the optimal balance of high diversity and 
low rate of inactivation. The chosen library was then tested further (see below). 
Table B-4. Gibson assembly primers to insert TrpB into pET22b(+) vector 










Table B-5. Random mutagenesis PCR mix 
Component 
Volume (μL) 
200 μM MnCl2 300 μM MnCl2 400 μM MnCl2 
Template DNA (~100 ng/mL prep) 1 1 1 
10x Taq buffer 10 10 10 
dNTPs (10 mM) 4 4 4 
TrpB_F primer (10 μM) 2 2 2 
TrpB_R primer (10 μM)  2 2 2 
MnCl2 (1 mM) 20 30 40 
Taq polymerase 1.6 1.6 1.6 
Water 69.4 59.4 49.4 
 
Table B-6. Random mutagenesis PCR thermal cycler method 
Step Temp (°C) Time (min) 
1 Initial denature 95 2:00 
2 Denature 95 0:30 
3 Anneal 55 0:30 
4 Extend 68 1:25 
Repeat 2–4 X30 
5 Final extension 68 10:00 
6 Hold 10 ∞ 
B.2.5 Construction of StEP recombination libraries 
Recombination libraries were generated using the staggered extension process (StEP) PCR 
method as previously reported.4 All winning variants from rounds 1–6b were combined in a 
single template master mix such that each StEP PCR reaction received 35 ng/variant. The 
TrpB gene was amplified using the TrpB_F and TrpB_R primers from Table S5.  The 
extension temperature ranged a gradient from 44.6–61.1 °C across eight PCR samples. A 
small quantity (2.5 μL) of each PCR was ran on an analytical gel to determine the lowest 
successful extension temperature. The samples were digested with DpnI for 1 hour at 37 °B. 
The PCR with the lowest successful extension temperature(s) were used as template for a 
secondary PCR to amplify the library. The secondary PCR was analyzed via an analytical 
gel, purified using the Zymo Gel Extraction kit, and then inserted into a pET22b(+) vector 




Table B-7. StEP Primary PCR mix 
Component Volume (μL) 
Template (35 ng/variant) Variable  
10x Standard Taq buffer 2 
dNTPs (10 mM) 0.4 
TrpB_F primer (1 μM) 1 
TrpB_R primer (1 μM) 1 
Taq polymerase 0.33 
Water Q.S. 20 
Total 20 
Table B-8. StEP Primary PCR thermal cycler protocol 
Step Temp (°C) Time (min) 
1 Initial Denature 95 05:00 
2 Denature 95 00:10 
3 Anneal 55 00:05 
4 Extend Gradient* 00:05 
Repeat 2–4 X120 
5 1 10 hold 
Table B-9. StEP Secondary PCR mix 
Component Volume / reaction 
Template 5 
5x GC buffer 20 
DMSO 4 
dNTPs (10 mM) 2 
TrpB_F primer (10 μM) 2 









Table B-10. StEP Secondary PCR thermal cycler protocol 
Step Temp (°C) Time (min) 
1 Initial denature 98 0:30 
2 Denature 98 0:10 
3 Anneal 55 0:15 
4 Extend 72 0:30 
Repeat 2–4 X30 
5 Final extension 68 10:00 
6 Hold 10 ∞ 
B.2.6 Library expression and screening 
Individual colonies were grown in 300 μL TBcarb in deep-well 96-well polypropylene plates 
sealed with EasyApp Microporous Film and grown overnight at 37 °C, 250 rpm, and 80% 
humidity. The following day, 20 μL overnight culture were used to inoculate 630 μL TBcarb 
cultures in deep-well 96-well plates and grown at 37 °C and 250 rpm. After 2 h, cultures 
were chilled on ice for 20–30 minutes and protein expression was induced upon addition of 
50 μL IPTG (final conc. 1 mM) diluted in TBcarb. Cultures were shaken at 20 °C and 250 rpm 
for 20–24 h, after which they were subjected to centrifugation at 5,000g for 5–10 min. The 
cell pellets could be frozen at −20 °C until further use or used immediately.  
Pellets were resuspended in 300 μL standard lysis buffer, heat treated for >1 h in a 75 °C 
water bath, and then the heat-treated lysate clarified by centrifugation at 5,000g for 10 
minutes. To a glass-lined 96-well deep-well plate charged with 10 μL of propiophenone or 
2-fluoroacetophenone dissolved in DMSO (final conc.10 mM nucleophile, 5% v/v DMSO), 
100 μL heat-treated lysate were transferred using a Microlab NIMBUS96 liquid handler, 
followed by the addition of 90 μL serine (final conc.10 mM) in 50 mM KPi. Reactions were 
sealed with silicone ArctiSeal™ and incubated in a 55 °C water bath. After 18–24 h 
(overnight), reactions were quenched with 600 μL 2:1 acetonitrile/1M HCl and centrifuged 
at 5,000g for 10 minutes. For MISER reactions, an acetonitrile/1M HCl mixture was 
supplemented with 10 mM benzimidazole as internal standard. The supernatant was 
transferred with the liquid handling robot to a wwPTFE 96-well filter atop a polypropylene 




MS, and improved variants (‘hits’) were defined as wells that exhibited higher activity 
relative to activity exhibited by parent expressed on the same plate. 
All hits were validated using the procedure described in Section B.2.7.  
B.2.7 Small-scale reactions with heat-treated lysate 
Potential hits were streaked out on agar plates, and single colonies were picked to inoculate 
5 mL overnight cultures. The next day, the cultures were used to inoculate expression 
cultures, miniprepped for sequencing, and prepared as glycerol stocks. In 250-mL 
Erlenmeyer flasks, 50 mL culture were inoculated with 500 μL overnight culture, each, and 
grown for 2.5–5 hours at 250 rpm. The cells were placed on ice for 20–30 minutes and 
induced with a final concentration of 1 mM IPTG. Expression proceeded at 20 °C and 250 
rpm for approximately 24 h. Cells were harvested by centrifugation at 10,000g for 20 minutes 
at 4 °C, and the supernatant was decanted. The pellet was stored at −20 °C until further use 
or used immediately. The cell pellet was resuspended in 4 mL/g standard lysis buffer and 
lysed for >1 h in water bath at 75 °B. The heat-treated lysate was clarified by centrifugation 
for 20 min at 14,000g and 4 °B. Protein concentration was roughly approximated using 
Bradford assay.  
A 2-mL HPLC vial was charged with 10 μL propiophenone or 2-fluoroacetophenone 
dissolved in DMSO (final conc.10 mM), 100 μL heat-treated lysate, and 90 μL serine (final 
conc.10 mM) in 50 mM KPi. The reactions were incubated in a water bath at 55 °C. After 
18–24 h (overnight), reactions were quenched with 600 μL 2:1 acetonitrile/1M HCl. 
Reactions were transferred to 1.7-mL tube and centrifuged 14,000g for 10 minutes. The 
supernatant was analyzed by HPLC-MS. 
B.2.8 Small-scale reactions with purified protein 
All analytical reactions were performed in 2-mL glass HPLC vials charged with 10 μL 
nucleophile (final concentration variable) dissolved in DMSO (5% v/v), followed by the 
addition of serine (final concentration 50–100 mM), PLP (final concentration 200 μM), and 




mM KPi buffer to a final volume of 200 μL. Reactions were incubated at 55 °B. The 
reaction was then quenched by the addition of either 2:1 CH3CN/H2O + 8 mM caffeine or 
2:1 CH3CN/1M HCl. Reactions measuring selectivity (Figure 3-2 A-B) were quenched after 
20 minutes to prevent racemization. Reactions measuring total turnover number (TTN) were 
quenched after 24 hours. The 2F-acetophenone product was found to decompose slowly with 
the addition of acid, therefore the workup mixture was adjusted to be 1:1 acetonitrile/ddiH2O 
+ 8 mM caffeine (internal standard). This workup is not recommended for regular use as it 
is not as effective at crashing out protein and can result in aggregation of protein on the HPLC 
column. Reactions were transferred to 1.7-mL tubes and centrifuged 14,000g for 10 minutes. 
The supernatant was analyzed by HPLC-MS. 






Nucleophile [Nucleophile] (mM) 
Max 
TTN 
2A 100 50 Propiophenone 50 500 
2B 5 50 2-fluoroacetophenone 50 10,000 








1, 2.5, 5, 10, 
25, 50, 100 
Varied 
3B 10 50 2-fluoroacetophenone 50 10,000 
3D Varied 50 2-fluoroacetophenone 50 Varied 










5 2-cyanoacetophenone 10,000 
100 Benzoylacetone 500 
For Figure 3-3D experiment progress curve fitting: 
We can fit the curves to the following equation 
P(𝑡)=Δ𝐴(1-𝑒−𝑘𝑡)) 
where 𝑃 is mM product, t is time in minutes, and 𝑘 is the observed rate constant. ΔA is a 
constant that describes the change in amplitude of the exponential function, which will 
change as a function of [substrate]. To calculate the initial rate of product formation (at 50 




Table B-12. Progress curve fit parameters for Figure 3-3D 
Enzyme concentration ΔA k V0 (mM/min) 
10 µM 24.7 0.00257 0.0635 
50 µM 44.3 0.00523 0.232 
75 µM 42.6 0.00750 0.319 
100 µM 41.2 0.00969 0.400 
150 µM 41.4 0.0123 0.509 
B.2.9 Sodium cyanoborohydride reduction of 2-fluoroacetophenone product  
Two mL HPLC vials were charged with 10 μL 2-fluoroacetophenone dissolved in DMSO 
(final concentration 50 mM), followed by the addition of serine (final concentration 50 mM), 
PLP (final concentration 200 μM), and purified TmE8 (100 μΜ final concentration) diluted 
in 50 mM KPi buffer to a final volume of 200 μL. Reactions were incubated at 55 °C for 20 
minutes. To one vial, 200 μL of 1M HCl were added, followed by the addition of 10 μL 1M 
sodium cyanoborohydride in 6.25M NaOH solution. To the control vial, 210 μL of 50 mM 
KPi buffer was added. The vials were incubated at 55 °C for 2 minutes, then reactions were 
quenched with 600 μL 2:1 acetonitrile:1 M HCl. Reactions were transferred to 1.7-mL tubes 
and centrifuged 14,000g for 10 minutes. The supernatant was analyzed by HPLC-MS. 
B.2.10 Measurement of proton/deuteron exchange rates  
A 2-mL HPLC vial was charged with 10 μL ketone dissolved in DMSO (final concentration 
50 mM except 2-Phenylacetophenone, which was run at 1 mM due to solubility issues), 190 
μL either protonated or deuterated 50 mM KPi, pH 8.0. Reactions were prepared in duplicate, 
quenched by the extraction of ketone into 600 μL 1:1 hexanes/ethyl acetate, and measured 
by GSMS. The amount of isotopically labeled ketone species was estimated by the extracted 
area of the ion mass and corrected for natural isotopic abundance.  
The curves can be fit to an exponential: 
𝐶𝑖𝑠𝑜𝑡𝑜𝑝𝑒(𝑡)=Δ𝐴(𝑒−𝑘𝑡) 
where 𝐶𝑖𝑠𝑜𝑡𝑜𝑝𝑒 is the concentration of the isotopically labeled substrate (H2 for the protonated 
substrate and D2 for the deuterated subsrate), 𝑡 is time in minutes, and 𝑘 is the observed rate 




which will change as a function of [substrate]. To calculate your initial rate of exchange 
(at 50 mM [substrate]), you simply multiply k by ΔA. 
Table B-13. Rate of proton exchange 
Condition ΔA kexg (min-1) V0 (mM/min) 
Propiophenone 50.0 0.000586 0.293 
Acetophenone 49.8 0.00414 0.206 
2-Fluoroacetophenone 50.0 0.0147 0.735 
2-Phenylacetophenone n.d.[a] 0.0515 n.d.[a] 
[a] ΔA and V0 not determined because of ketone solubility issues. 
 
 
Figure B-11. Exchange curves of ketones in deuterated KPi buffer.  
 
 




B.3 Enzyme lineage 
Table B-14. Summary of directed evolution for enolate activity  















F184H TmE1 4981 
2 TmE1 Random mutagenesis I174T TmE2 4980 
3 TmE2 Random mutagenesis F41Y TmE3 4981 









85X, 86X, 87X, 
117X, 118X, 119X, 
198X, 199X, 200X, 
201X, 
2F-acetophenone 
N86G TmE5 4983 











N86S TmE6.1  
6B 
TmE5.1 Random mutagenesis 
T100P TmE6.2  
I166V TmE6.3 4984 




S228G TmE6.6 4985 
TmE5.2 Random mutagenesis - -  
TmE6.1 Random mutagenesis A169T TmE6.7  
7 TmE5.1 
StEP recombination 





8 TmE7 Alanine scanning H184A TmE8 4987 






Variants identified through screening were DNA sequenced using Sanger Sequencing 
(Laragen) to determine their identities. The DNA sequences of all TrpB genes tested in this 
paper are included here. All variants were cloned into a pET22b(+) vector as described 
above. T7 and T7-terminator primers were used to sequence all variants.  
Table B-15. Sequencing primers  
Primer Direction Sequence 
T7 Forward (5’ to 3’) taatacgactcactataggg 
T7-term Reverse (3’ to 5’) ctagttattgctcagcggtg 
Pf7E6 
Mutations: - 






































































































Mutations: K39I, E40G, P54Q, I195T 








































































































































































































Mutations: I166V S228G 








































B.4 Synthesis, isolation, and characterization of products 
B.4.1 Enzymatic synthesis, isolation, characterization, and standard curve of 
propiophenone product 
 
Scheme B-1. TrpB catalyzed propiophenone+serine reaction.  
Two 800 mL cultures of BL21 (DE3) cells expressing TmE4 were grown according to 
expression conditions described in Section B.2.2. The expression cultures were centrifuged 
for 20 min and 14,000g. The pellets (33 g) were resuspended in 120 mL lysis buffer, rocked 
on a platform gently at room temperature for 30 minutes followed by heat-treatment in a 75 
°C water bath for > 1 h. Heat-treated lysate was centrifuged for 20 min at 14,000g, and the 
lysate was decanted into a fresh container. To a 500-mL flask, serine (726 mg, 6.90 mmol, 
1.02 equiv.) and lysate (120 mL) were added, sparged with argon for 10 minutes to prevent 
oxidation of the products, followed by the addition of propiophenone (919.8 mg, 6.75 mmol, 
1.00 equiv.) and 15 mL KPi buffer to bring the reaction volume to 135 mL. The reaction was 
incubated in a water bath at 55 °C, swirled every few hours, and quenched with 100 mL 
acetonitrile after 24 hours. The reaction mixtures were centrifuged to remove precipitated 
cell mass, and the acetonitrile was removed in vacuo. The aqueous reaction mixture was then 
frozen and lyophilized to concentrate the sample for purification on a Biotage Isolera One 
purification system, using C18 silica as the stationary phase (Sfär silica C18 12-gram column), 
CH3CN (0.1% acetic acid) as the strong solvent, and H2O (0.1% acetic acid) as the weak 
solvent. The product was obtained as a white solid (9.5 mg, 0.7% yield). 1H NMR (500 MHz, 
D2O, 23 °C, δ): [mixture of diastereomers] 8.01–7.95 (m, 2 H major + minor), 7.85–7.79 (m, 
1 H major + minor), 7.69–7.63 (m, 2 H major + minor), 5.03 (t, J = 8.5 Hz, 1 H minor), 4.93 




minor). Due to the complexity of the spectrum, individual signals from the Cβ and Cγ 
protons could not be identified with certainty. 
Solutions of authentic propiophenone product standard were made in 1:1 CH3CN/1 M aq. 
HCl (total conc.1 mM). Two hundred μL of each standard were placed in a vial and diluted 
with 600 μL of 1:1 acetonitrile/H2O + 8 mM caffeine (final caffeine concentration was 6 
mM) and analyzed by HPLC. The ratios of product peaks to area of HPLC absorbance at 254 
nm were correlated to the actual ratios by a linear relationship (Figure B-13). 
 





B.4.2 Enzymatic synthesis, isolation, characterization, and standard curve of 2-
cyanoacetophenone product 
 
Scheme B-2. TrpB catalyzed 2-cyanoacetophenone+serine reaction.  
An 800 mL culture of BL21 (DE3) cells expressing TmE8 was grown according to 
expression conditions described in Section B.2.2. The expression culture was centrifuged for 
20 min at 14,000g. The pellet (15 g) was resuspended in 60 mL lysis buffer, rocked on 
platform gently at room temperature for 30 minutes, followed by heat-treatment in a 75 °C 
water bath for > 1 h. To a 250-mL flask, serine (724 mg, 6.89 mmol, 5.00 equiv.), 2-
cyanoacetophenone (200 mg, 1.38 mmol, 1.00 equiv.), 50 mL lysate, and 5 mL KPi buffer 
were added. The reaction was incubated in a water bath at 55 °C, swirled every few hours, 
and quenched with 50 mL acetonitrile after 24 hours. The reaction mixtures were centrifuged 
to remove precipitated cell mass, and acetonitrile removed in vacuo. The aqueous reaction 
mixture was then frozen and lyophilized to concentrate the sample for purification on a 
Biotage Isolera One purification system, using C18 silica as the stationary phase (Sfär silica 
C18 12-gram column), CH3CN (0.1% acetic acid) as the strong solvent, and H2O (0.1% 
acetic acid) as the weak solvent. The product was obtained as a green solid (191.17 mg, 
64.7% yield). 1H NMR (500 MHz, DMSO-d6, 23 °C, δ): 12.93 (br s, 1 H), 7.74–7.70 (m, 2 
H), 7.53–7.49 (m, 3 H), 7.34 (br s, 1 H), 4.46 (dd, J = 12.4, 6.5 Hz, 1 H), 3.20 (dd, J = 14.7, 
12.4 Hz, 1 H), 2.93 (dd, J = 14.7, 6.5 Hz, 1 H). 13C NMR (101 MHz, DMSO-d6, 23 °C, δ): 





Figure B-14. 2-cyanoacetophenone cyclized enamine product dissolved in methanol.  
Solutions of authentic 2-cyanoacetophenone product standard were made in methanol 
(Figure B-14). Two hundred μL of each standard were placed in a vial and diluted with 600 
μL of 1:1 acetonitrile/H2O + 8 mM caffeine (Final caffeine concentration 6 mM) and 
analyzed by HPLC. The ratios of product peaks to area of HPLC absorbance at 254 nm were 
correlated to the actual ratios by a linear relationship (Figure B-15). 
 




B.4.3 Enzymatic synthesis, isolation, characterization, and standard curve of 2-
fluoroacetophenone product 
 
Scheme B-3. TrpB catalyzed 2-fluoroacetophenone+serine reaction.  
A 500 mL culture of BL21 (DE3) cells expressing TmE8 was grown according to expression 
conditions described in Section B.2.2. The expression culture was centrifuged for 20 min at 
14,000g. The pellet (10 g) was resuspended in 40 mL lysis buffer rocked on platform gently 
at room temperature for 30 minutes followed by heat-treatment in a 75 °C water bath for > 1 
h. To a 250-mL flask, serine (760.76 mg, 7.24 mmol, 5.00 equiv.), 2-fluoroacetophenone 
(200 mg, 1.45 mmol, 1.00 equiv.), and 40 mL lysate were added. The reaction was incubated 
in a water bath at 55 °C, swirled every few hours, quenched with 1 M HCl after 48 hours, 
and extracted with ethyl acetate to remove any excess 2-fluoroacetophenone starting 
material. Upon addition of acid, the 2-fluoroacetophenone product slowly decomposes to 2-
phenylpyrrole (validated by authentic standard on GSMS), which is a bright pink/purple 
color (Figure B-16). However, 2-phenylpyrrole is easily removed from the aqueous layer 





Figure B-16. 2-fluoroacetophenone product decomposes to 2-phenylpyrrole upon 
addition of acid to reaction mixture.  
The aqueous layer was lyophilized to concentrate the sample for purification on a Biotage 
Isolera One purification system, using C18 silica as the stationary phase (Sfär silica C18 12-
gram column), methanol as the strong solvent, and H2O as the weak solvent. The cyclized 2-
fluoroacetophenone product was obtained as a brown solid (16 mg, 5.3% yield). 1H NMR 
(500 MHz, D2O, 23 °C, δ) [mixture of diastereomers]: 7.82–7.76 (m, 2 H major + minor), 
7.46–7.41 (m, 1 H major + minor), 7.41–7.35 (m, 2 H major + minor). 6.12 (dddd, J = 54.1, 
7.1, 2.8, 1.3 Hz, 1 H major), 6.02 (ddd, J = 53.9, 7.9, 4.2 Hz, 1 H minor), 4.75 (dddd, J = 6.8, 
5.6, 5.6, 1.2 Hz, 1 H major), 4.51 (td, J = 8.8, 5.3 Hz, 1 H minor), 2.74 (ddt, J = 22.6, 14.6, 
8.1 Hz, 1 H minor), 2.44 (dddd, J = 30.7, 15.0, 7.6, 2.7 Hz, 1 H major), 2.23 (dddd, J = 30.3, 
15.1, 7.1, 5.7 Hz, 1 H major), 2.02 (dddd, J = 31.8, 14.6, 5.4, 4.2 Hz, 1 H minor). 19F NMR 
(282 MHz, D2O, 23 °C, δ) [mixture of diastereomers]: −170.5 (dddd, J = 54.0, 31.7, 22.2, 
9.5 Hz, 1 F minor), −173.5 (dddd, J = 54.1, 30.7, 30.3, 5.6 Hz, 1 F major). 
Solutions of authentic 2-fluoroacetophenone cyclized product standard were made in 
acetonitrile. Two hundred μL of each standard were placed in a vial and diluted with 600 μL 
of 1:1 acetonitrile/H2O + 8 mM caffeine (Final caffeine concentration 6 mM) and analyzed 
by HPLC. The ratios of caffeine to product peaks at 254 nm were correlated to the actual 





Figure B-17. 2-fluoroacetophenone product standard curve. Minor isomer: y= 1.97x-
0.017, R2= 0.9998. Major isomer: y= 1.97x-0.031, R2= 0.9998. 




∗ 𝐶  
where CP is the concentration of product (mM), RF is the response factor (1.97093347), AP 
is the area of the product, AC is the area of the caffeine internal standard, and CC is the 
concentration of caffeine (6 mM). 
B.4.4 Synthesis of 2-fluoroacetophenone-2,2-d2 
2-Fluoroacetophenone-2,2-d2 was synthesized and purified according to a previously 
reported method.5 1H NMR (500 MHz, DMSO-d6, 23 °C, δ)7.89 (d, J = 8.0 Hz, 2 H), 7.68 
(t, J = 7.4 Hz, 1 H), 7.55 (t, J = 7.8 Hz, 2 H). 13C NMR (125 MHz, DMSO-d6, 23 °C, δ) 193.9 
(d, JCF = 14.1 Hz), 134.0, 133.5, 128.9, 127.6 (d, JCF = 1.6 Hz), 83.4 (dt, JCF = 173.5 Hz, 
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Enzyme orthologs sharing identical primary functions can have different promiscuous 
activities. While it is possible to mine this natural diversity to obtain useful biocatalysts, 
generating comparably rich ortholog diversity is difficult, as it is the product of deep 
evolutionary processes occurring in a multitude of separate species and populations. Here, 
we take a first step in recapitulating the depth and scale of natural ortholog evolution on 
laboratory timescales. Using a continuous directed evolution platform called OrthoRep, we 
rapidly evolved the Thermotoga maritima tryptophan synthase β-subunit (TmTrpB) through 
multi-mutation pathways in many independent replicates, selecting only on TmTrpB’s 
primary activity of synthesizing L-tryptophan from indole and L-serine. We find that the 
resulting sequence-diverse TmTrpB variants span a range of substrate profiles useful in 
industrial biocatalysis and suggest that the depth and scale of evolution that OrthoRep affords 






4.1 Introduction  
Natural enzymes typically have many orthologs. While the primary activity of orthologous 
enzymes is largely the same,1 promiscuous functions not under selective pressure can vary 
widely.2,3 Such variation may be attributed to the deep and distinct evolutionary histories 
shaping each ortholog, including long periods of neutral drift, recalibration of primary 
activity, and adaptation to new host environments such as temperature. These rich histories 
act to produce extensive genetic diversity, which underpins different promiscuity profiles.2 
Diversity in promiscuous functions across orthologs is of both fundamental and practical 
importance. An enzyme’s reserve of promiscuous activities dictates what secondary 
reactions, environmental changes, or niches the enzyme can accommodate.4,5 Diversity in 
promiscuous activities therefore contributes to the basic robustness of life and adaptation. An 
enzyme’s reserve of promiscuous activities can also be mined in the application of enzymes 
for biocatalysis.6,7 Ortholog diversity therefore expands the range of reactions at the disposal 
of enzyme engineers, supporting the growing role of “green” enzymatic processes in the 
chemical and pharmaceutical industries.8–10 
Inspired by the remarkable ability of enzyme orthologs to encompass promiscuous activities, 
we asked whether we could extend the substrate scope of useful enzymes by evolving 
multiple versions of an enzyme in the laboratory, selecting only for its primary function. 
Although this idea has been explored before using classical directed evolution approaches, 
most notably through the generation of cryptic genetic variation with neutral drift libraries,11–
14 we recognized that our recently developed continuous evolution system, OrthoRep, may 
be considerably better poised for this challenge.15,16 Classical directed evolution mimics 
evolution through an iterative procedure that involves diversifying a gene of interest (GOI) 
in vitro (e.g., through error-prone PCR), transforming the resulting GOI library into cells, 
and selecting or screening for desired activities, where each cycle of this procedure represents 
one step in an evolutionary search.17 However, since each cycle is manually staged, classical 
directed evolution does not readily admit depth and scale during exploration of functional 




searches (depth), let alone do so in many independent experiments (scale). Yet 
evolutionary depth and scale are precisely the two characteristics responsible for ortholog 
diversity in nature. Natural orthologs have diversified from their ancestral parent over great 
evolutionary timescales, allowing for the traversal of long mutational pathways shaped by 
complex selection histories (depth). Natural orthologs are also the result of numerous 
independent evolutionary lineages, since spatially separated species and populations are free 
to take divergent mutational paths and experience different environments (scale). Systems 
that better mimic the depth and scale of natural enzyme evolution, but on laboratory 
timescales, are thus needed for the effective generation of enzyme variants that begin to 
approach the genetic and promiscuity profile diversity of orthologs. 
OrthoRep is such a system. In OrthoRep, an orthogonal error-prone DNA polymerase 
durably hypermutates an orthogonal plasmid (p1) without raising the mutation rate of the 
host Saccharomyces cerevisiae genome.16 Thus, GOIs encoded on p1 rapidly evolve when 
cells are simply passaged under selection. By reducing the manual stages of classical directed 
evolution down to a continuous process where cycles of diversification and selection occur 
autonomously in vivo, OrthoRep readily accesses depth and scale in evolutionary search.16,18 
Here, we apply OrthoRep to the evolution of the Thermotoga maritima tryptophan synthase 
β-subunit (TmTrpB) in multiple independent continuous evolution experiments, each carried 
out for at least 100 generations. While we only pressured TmTrpB to improve its primary 
activity of coupling indole and serine to produce tryptophan, the large number of independent 
evolution experiments we ran (scale) and the high degree of adaptation in each experiment 
(depth) resulted in a panel of variants encompassing expanded promiscuous activity with 
indole analogs. In addition to the immediate value of these newly evolved TmTrpBs in the 
synthesis of tryptophan analogs, our study offers a new template for enzyme engineering 
where evolutionary depth and scale is leveraged on laboratory timescales to generate 




4.2 Establishing a selection system for the evolution of TmTrpB variants 
To evolve TmTrpB variants using OrthoRep, we first needed to develop a selection where 
yeast would rely on TmTrpB’s primary enzymatic activity for growth. TmTrpB catalyzes the 
PLP-dependent coupling of L-serine and indole to generate L-tryptophan (Trp) in the 
presence of the tryptophan synthase α-subunit, TmTrpA.19 In T. maritima and all other 
organisms that contain a heterodimeric tryptophan synthase complex, TrpA produces the 
indole substrate that TrpB uses and the absence of TrpA significantly attenuates the activity 
of TrpB through loss of allosteric activation.19,20 TRP5 is the S. cerevisiae homolog of this 
heterodimeric enzyme complex, carrying out both TrpA and TrpB reactions and producing 
Trp for the cell. We reasoned that by deleting the TRP5 gene and forcing S. cerevisiae to rely 
on TmTrpB instead, cells would be pressured to evolve high stand-alone TmTrpB activity in 
order to produce the essential amino acid Trp in indole-supplemented media (Figure 4-1). 
This selection pressure would also include thermoadaptation, as yeast grow at mesophilic 
temperatures in contrast to the thermophilic source of TmTrpB. Therefore, the selection on 
TmTrpB’s primary activity would be multidimensional—stand-alone function, temperature, 
and neutral drift implemented when desired—and could result in complex evolutionary 
pathways that serve our goal of maximizing functional variant diversity across replicate 
evolution experiments. In addition, the multidimensional selection also serves practical goals 
as stand-alone activity is useful in biosynthetic applications (enzyme complexes are difficult 
to express and use in vitro) and activity at mesophilic temperatures is more compatible with 
heat-labile substrates, industrial processes where heating costs can compound, or in vivo 





Figure 4-1. Pipeline for the use of OrthoRep continuous directed evolution to generate 
many diverse, functional TmTrpB sequences. TmTrpB variants are first evolved in replicate 
for Trp production in yeast. OrthoRep enables replicate evolution through error-prone 
replication of an orthogonal plasmid by an orthogonal polymerase, maintaining low error 
rates in genome replication. By encoding a TmTrpB variant on this plasmid in a tryptophan 
synthase (TRP5) deletion mutant, TmTrpB may be both continuously diversified and 
selected for through gradual reduction in Trp supplied in the growth medium. Evolved 
populations containing many diverse, functional  individuals may then be randomly 
sampled and tested for activity with indole analogs.  
To test this selection, we turned to a positive control TmTrpB variant called TmTriple. This 
variant was previously engineered to enable stand-alone activity, free from dependence on 
allosteric activation by TrpA, through a minimal set of three mutations.7 We found that 
TmTriple rescued TRP5 function in a Δtrp5 strain in an indole-dependent manner, validating 
our selection (Appendix C, Figure C-1). Notably, TmTriple, along with other TrpB variants 
tested, only supported complementation when expressed from a high-strength promoter 
(Appendix C, Figure C-1). This highlighted the opportunity for substantial adaptation and 
drift even in evolution experiments that start from already engineered TmTrpB variants. 
4.3 Continuous evolution of TmTrpB with depth and scale 
We encoded wild-type (wt) TmTrpB, TmTriple, as well as a nonsense mutant of TmTriple, 
TmTripleQ90*, onto OrthoRep’s p1 plasmid, which is replicated by a highly error-prone 
orthogonal DNA polymerase. TmTripleQ90* was included because reversion of the stop 
codon at position 90 in TmTripleQ90* would act as an early indication that adaptation was 
occurring, giving us confidence to continue passaging our evolution experiments for several 




TmTrpB sequences enabled only minimal indole-dependent complementation 
(Appendix C, Figure C-1). This was expected for wt TmTrpB, which has low stand-alone 
enzymatic activity and TmTripleQ90*, which has a premature stop codon, and was 
unsurprising for TmTriple, since TmTriple displayed indole-dependent complementation 
only when artificially overexpressed (Appendix C, Figure C-1). 
To continuously evolve TmTrpB, we passaged cells encoding wt TmTrpB, TmTriple, or 
TmTripleQ90* on OrthoRep in the presence of 100 μM indole while reducing the amount of 
Trp in the medium over time. In total, six 100-mL and twenty 3-mL cultures were passaged, 
each representing a single independent evolutionary trajectory. Passages were carried out as 
1:100 dilutions where Trp concentrations were decreased in the (N+1)th passage if cells grew 
quickly in the Nth passage, until Trp was fully omitted. All six of the 100-mL cultures, and 
four of the twenty 3-mL cultures fully adapted and were capable of robust growth in indole-
supplemented media lacking Trp after 90–130 generations (13–20 passages) (Figure 4-2; 
Appendix C, Table C-1). Populations that did not achieve growth in the absence of Trp still 
adapted, but stopped improving at ~5 µM supplemented Trp, suggesting a suboptimal local 
fitness maximum that is easier to escape through the greater sequence diversity represented 
in larger populations. This could explain the different success rates in reaching full adaptation 
between the 3-mL and 100-mL populations. Cultures that did adapt fully were passaged for 
an additional ~40 generations without increasing selection stringency to allow for 





Figure 4-2. Selection trajectories for ten replicate cultures that evolved sufficient 
TmTrpB activity to support cell growth without supplemented Trp. Each point represents 
a single 1:100 dilution (passage) into fresh indole-supplemented growth medium. Trp 
concentration of fresh media was reduced when high saturation was achieved in the 
previous passage. Plots are slightly offset from true values to allow for visibility of all 
selection trajectories. Tm3C and Tm3D are plotted as one line as their trajectories were 
identical.  
For each of the ten fully adapted populations, we PCR amplified and bulk sequenced the 
TmTrpB alleles on the p1 plasmid. Mutations relative to the parent TmTrpB variant detected 
at >50% frequency in each population were deemed consensus mutations for that population, 
with the exception of reversion of the stop codon in populations evolving TmTripleQ90*. 
This stop codon reversion occurred at 100% frequency in the relevant populations and was 
not counted in any subsequent analyses due to its triviality. An average of 5.6 (± 2.3 s.d.) and 
a range of 3–11 consensus amino-acid changes per population were observed (Figure 4-3; 
Appendix C, Table C-2). Some of these mutations occurred at residues previously identified 




observed, however, have not been previously identified in laboratory engineering 
experiments, suggesting that even the consensus of these populations explored new regions 
of TmTrpB’s fitness landscape, doing so with diversity across replicates (Figure 4-3) that 
might translate to diversity in promiscuous activities across evolved variants. 
 
Figure 4-3. TmTrpB homology model and table depicting consensus mutations of the 
ten cultures shown in Figure 4-1. Mutations are colored by their appearance in 
populations evolved from wt TmTrpB (orange), TmTriple or TmTripleQ90* (green), or 
both (purple). 
4.4 Evolved TmTrpB variants improve Trp production in vivo and contain cryptic 
genetic variation 
To ensure that evolved TmTrpB variants and not potential host genomic mutations were 
primarily responsible for each population’s adaptation, we cloned individual TmTrpBs into 
a standard low copy yeast nuclear plasmid under a promoter that approximates expression 
from p1,23,24 transformed a fresh Δtrp5 strain with the constructs, and tested for the ability of 
the variants to support indole-dependent growth in the absence of Trp (Figures 4-4; 




individual variants from each of the ten fully adapted populations. We found that 12 of 
the 16 TrpB variants complemented growth to a similar degree as TRP5 when supplemented 
with 400 μM indole, demonstrating substantial improvement over their wt TmTrpB and 
TmTriple parents (Figure 4-4a). 
Unsurprisingly, this set of clonal TmTrpBs contained more sequence diversity than the 
consensus sequences of the ten populations from which they were taken. Together, the 
variants tested comprised a total of 85 unique amino-acid substitutions, with an average of 
8.7 (± 2.1 s.d.) and a range of 5–13 non-synonymous mutations per variant (variant set 1; 
Appendix C, Tables C-2 and C-3). Since the 12 TmTrpBs from this set exhibiting 
complementation were all similarly active in their primary activity yet mutationally diverse 
(Figure 4-4b), we may conclude that our scaled evolution experiments generated substantial 
cryptic genetic variation. We note that four of 16 TmTrpB variants exhibited similar or lower 
Trp productivity compared to their parent (Appendix C, Figure C-2B). We suspect that the 
multicopy nature of p1 in the OrthoRep system allowed for deleterious mutations that 
appeared toward the end of the experiment to be maintained for a period of time without 
experiencing purifying selection if they arose in the same cell as functional variants, 
explaining the presence of these low activity TmTrpBs. Indeed, this multicopy “buffering” 
may have worked to our advantage by promoting genetic drift under selection, facilitating 
both greater adaptation and greater diversity of evolutionary pathways across replicates (see 
Section 4.8 Discussion). This may partly account for the high activity and high cryptic 





Figure 4-4. In vivo activity and diversity of individual TmTrpB variants from 
OrthoRep-evolved populations. (a) Evaluation of TRP5 complementation by evolved 
variants through a growth rate assay. Maximum growth rates over a 24-h period for Δtrp5 
yeast strains transformed with a nuclear plasmid expressing the indicated TmTrpB variant, 
grown in medium with or without 400 μM indole. Points and error bars represent mean ± 
s.d. for four biological replicates, respectively. Shaded area is the mean ± s.d. growth rate 
for the TRP5 positive control (i.e. plasmid expressing the endogenous yeast TRP5). Green 
box indicates the mean ± s.d. growth rate for all strains shown when Trp is supplemented. 
Growth rates for individual replicates in all three media conditions are shown in Appendix 
C, Figure C-12. Note that growth rates below ~0.15 per hour correspond to cultures that 
did not enter the exponential phase; in these cases, the reported growth rate is not 
meaningful and instead can be interpreted as no quantifiable growth. (b) Parent populations 
from which OrthoRep-evolved variants shown in (b) are derived and all non-synonymous 
mutations present in each. 
4.5 Evolved TmTrpBs exhibit high primary and promiscuous activity in vitro 
We further characterized the evolved TmTrpBs in vitro to approximate conditions of 
industrial application, make kinetic measurements, and test whether promiscuous activity 
could be detected. Nine TmTrpB variants were sampled from those that supported robust 




C-terminal polyhistidine tag, and overexpressed. To mimic streamlined purification 
conditions compatible with biocatalytic application of TmTrpBs, we generated heat treated 
E. coli lysates (1 hour incubation at 75 °C) and tested them for their ability to couple indole 
and serine to produce Trp at 30 °C. Three of the nine OrthoRep-evolved TrpBs, WT-003-1-
A, Q90*-003-1-A, and Tri-100-2-A, demonstrated improved activity over the benchmark 
TmTriple, as measured by total turnover number (TTN) (Appendix C, Figure C-3). 
Conveniently, each of these variants was evolved from a different starting point, meaning 
that wt TmTrpB, TmTriple, and TmTripleQ90* were all viable starting points for reaching 
high activity TmTrpBs. (See Appendix C, Table C-3 for an explanation of variant naming 
conventions where each name designates the source of the variant. For example, WT-003-1-
A designates variant A taken from the first replicate of a 3-mL evolution experiment starting 
from wt TmTrpB.) 
Since the benchmark TmTriple against which we compared the evolved TmTrpBs was 
engineered through classical directed evolution involving screening E. coli lysates, whereas 
our TmTrpB variants were evolved in yeast but expressed in E. coli for characterization, it is 
likely that the high-activity evolved TmTrpBs would compare even more favorably if 
normalized by expression. We therefore purified WT-003-1-A, Q90*-003-1-A, and Tri-100-
2-A by immobilized metal affinity chromatography (IMAC) and reevaluated their activity 
for coupling indole with serine to generate Trp. By TTN, all three variants showed a 4- to 5-
fold increase in activity over TmTriple at 30 °C (Appendix C, Figure C-4). At 75 °C, 
however, WT-003-1-A had only ~2-fold higher activity than TmTriple, while the other two 
variants were less active than TmTriple. Since the thermostability of WT-003-1-A, Q90*-
003-1-A, and Tri-100-2-A had not been reduced dramatically (T50 > 83.7 °C; Appendix C, 
Figure C-5), adaptation in these variants occurred at least partially by shifting the activity 
temperature profile. This is a practically valuable adaptation, since thermostable enzymes 
that operate at mesophilic temperatures allow for greater versatility in application without 




Further testing of WT-003-1-A, Q90*-003-1-A, and Tri-100-2-A revealed that all three 
enzymes had at least a 22-fold higher kcat/KM for indole than did TmTriple at 30 °C 
(Appendix C, Table C-4 and Figure C-6). Finally, testing for production of Trp analogs 
revealed that these variants’ improved performance with indole transferred to alternate 
substrates (Appendix C, Figure C-4), validating their utility as versatile biocatalysts and 
also the hypothesis that continuous evolution of TmTrpB variants can uncover promiscuous 
activities for which they were not selected. 
4.6 A diverse panel of evolved TmTrpB variants encompasses a variety of useful 
promiscuous activities with indole analogs 
Given the exceptional performance of WT-003-1-A, Q90*-003-1-A, and Tri-100-2-A and 
their ability to transfer primary activity to new substrates as promiscuous activity, we decided 
to further sample the variant diversity generated across the multiple TmTrpB evolution 
experiments. We cloned 60 randomly chosen TmTrpBs from the ten continuous evolution 
populations into E. coli expression vectors for in-vitro characterization. These 60 TmTrpBs 
represent extensive diversity, with an average of 9.3 (± 2.8 s.d.) non-synonymous mutations 
per variant and a total of 194 unique amino acid changes across the set; in addition, each 
sequence encoded a unique protein (variant set 2; Appendix C, Tables C-2 and C-3). Since 
each variant had multiple non-synonymous mutations (up to 16) accumulated through >100 
generations of adaptation and neutral drift, the depth of OrthoRep-based evolution was 
indeed leveraged in their evolution. We visualized these sequences, together with the 
consensus sequences of the populations from which they were derived, as nodes in a force 
directed graph related by shared mutations (Appendix C, Figure C-7). With only one 
exception, all individual sequences cluster near the consensus sequence for their population, 
meaning that interpopulation diversity exceeded intrapopulation diversity. Thus, the scale of 
OrthoRep-based evolution was also leveraged in these variants—if fewer independent 
evolution experiments had been run, the reduction in diversity would not be recoverable from 




Preparations of TmTrpBs WT-003-1-A, Q90*-003-1-A, and Tri-100-2-A, the 60 new 
variants, and four top-performing TrpB benchmark variants from past classical directed 
evolution campaigns (including TmTriple) were all tested for product formation with indole 
by UV absorption and nine indole analogs by high performance liquid chromatography-mass 
spectrometry (HPLC-MS) to detect substrate promiscuity (Figure 4-5a). The panel of 63 
OrthoRep-evolved TmTrpB variants exhibited an impressive range of activities (Figure 4-
5b). First, we observed that a number of variants had primary activities with indole that 
surpass the benchmark TmTriple in lysate, with initial velocities of Trp formation up to 3-
fold higher than WT-003-1-A (Figure 4-5b; Appendix C, Figure C-8) whose kcat/KM for 
indole is 1.37 x 105 M-1 s-1, already 28-fold higher than TmTriple’s at saturating serine 
concentrations (Appendix C, Table C-4 and Figure C-6). Second, direct comparison of 
some of the best panel variants to TmTriple revealed dramatic general activity improvements 
for multiple indole analogs (Figure 4-5b). For example, across the three most versatile 
variants (Q90*-003-1-C, Tri-003-1-D, and Q90*-003-1-D) the maximum fold-improvement 
in product yields over TmTriple were 37, 5, 19, and 50 using substrates 5-CN, 7-CN, 5-Br, 
and 6-Br, respectively (Figure 4-5c). Finally, with the exception of 6-Br and azulene, at least 
one variant from the OrthoRep-evolved panel converted the indole analog substrates as well 
as or better than benchmark TrpBs Pf2B9, TmAzul, and Tm9D8*, which had been 
deliberately engineered toward new substrate scopes, though at higher temperatures (Figure 
4-5b; Appendix C, Figure C-9).7,21,25,26 
The diverse properties represented in our 63 variants were not just limited to primary activity 
increases on indole and promiscuous activities for indole analogs. Multiple variants from the 
panel also exhibited substantial improvements in selectivity for differently substituted 
indoles, which could be useful when working with substrate mixtures that may be less 
expensive to use industrially. For example, we observed many TmTrpBs with greater 
selectivity for 7-Br over 5-Br as compared to all four of the benchmark engineered TrpBs 
(Figure 4-5d). Another variant in the panel, Tri-100-1-G, stood out for having appreciable 
activity with nearly all substrates tested, including 6-CN and 5-CF3, which are poorly utilized 




Notably, the ability to accept 5-CF3 as a substrate was unique to Tri-100-1-G: all other 
variants, as well as the benchmark TrpBs, showed no detectable product formation with this 
substrate (Figure 4-5e; Appendix C, Figure C-9). Repeating the reaction with purified 
enzyme in replicate confirmed the observed activity (Appendix C, Figure C-10). Tri-100-
1-G may therefore be a promising starting point for new engineering efforts to access exotic 
Trp analogs. In short, despite having been selected for native activity with indole, OrthoRep-
evolved TmTrpBs have extensive and diverse activities on a range of non-native substrates, 





Figure 4-5. Promiscuous activities of a panel of evolved TmTrpBs. (a) Indole substrates 
used to test the substrate scope of a panel of TmTrpB variants. 5-CN, 5-cyanoindole; 6-
CN, 6-cyanoindole; 7-CN, 7-cyanoindole; 5-Br, 5-bromoindole; 6-Br, 6-bromoindole; 7-
Br, 7-bromoindole; 5-MeO, 5-methoxyindole; 5-CF3, 5-trifluoromethylindole. (b) 
Heatmap of TrpB activities reported as yield of the Trp analog produced from indicated 
substrates where 100% yield corresponds to full conversion of the indole analog to the Trp 
analog. Reactions were carried out using heat treated (1 h at 75 °C) cell lysate, yield was 
measured by HPLC-MS, and V0 is the initial rate of Trp formation from indole at saturating 
serine concentrations. Panel TmTrpB variants are ordered first by the parental cultures from 
which they were derived, then by activity with indole. Reactions with OrthoRep-evolved 
variants other than WT-003-1-A, Q90*-003-1-A, and Tri-100-2-A were performed in one 
replicate and all other reactions performed in quadruplicate. Empty designates expression 
vector without any TrpB encoded. (c) Bar graph of selected indole analog activities from 
panel b. Points represent percentage HPLC yield for individual replicates, bars represent 
mean yield for multiple replicates or yield for a single replicate. (d) Activities of all variants 
shown in b for reactions with substrates 7-Br and 5-Br to show selectivity. Individual 
replicates are shown for empty vector and benchmark TrpBs and only mean values are 
shown for OrthoRep-evolved variants tested in replicate (i.e. WT-003-1-A, Q90*-003-1-
A, and Tri-100-2-A) for clarity. (e) Heat-treated lysate activity with 5-CF3 for indicated 




4.7 Mutations in evolved TmTrpBs may modulate conformational dynamics and 
fine tune the active site 
Of the ~200 unique mutations in the OrthoRep-evolved TmTrpBs that we characterized, there 
were some mutations whose effects could be rationalized from comparison to previous work. 
Since the TmTrpBs had to evolve stand-alone activity, it is unsurprising that many of the 
mutations we observed have been implicated in the loss of allosteric regulation by TrpA. For 
example, Buller et al. previously examined a series of engineered variants from Pyrococcus 
furiosus TrpB (PfTrpB) and found that evolution for stand-alone activity was facilitated by 
a progressive shift in the rate-limiting step from the first to the second stage of the catalytic 
cycle as well as stabilization of the ‘closed’ conformation of the enzyme.27 That work 
implicated eight residues in this mechanism, seven of which correspond to homologous sites 
where we observed mutations in the evolved TmTrpB variants (i.e., P14, M18, I69, K96, 
L274, T292, and T321). Another mutation, N167D, present in three of the ten consensus 
sequences for evolved populations (Figure 4-3), has also been implicated in stabilizing the 
closed state.21 Additional mutations observed but not studied before (e.g., S277F, S302P, and 
A321T) could also reasonably alter the allosteric network linking TmTrpB activity to its 
natural TmTrpA partner, based on existing structures and molecular dynamics simulations 
on the homologous PfTrpA/PfTrpB complex.22,27 Taken together, these mutations are likely 
implicated in converting allosteric activation by TmTrpA into constitutive activity to 
establish stand-alone function of TmTrpBs. 
During the evolution of stand-alone activity, not only must allosteric activation by TmTrpA 
be recapitulated by mutations in TmTrpB, the surface of TmTrpB that normally interacts with 
TmTrpA must adjust to a new local environment. Consistent with this adaptation, all 
consensus sequences for the ten successfully evolved populations from which our TmTrpB 
variants were sampled contain a mutation to at least one of a set of five residues located on 
the canonical TrpA interaction interface (Figure 4-3; Appendix C, Figure C-11). These 
mutations might improve solubility by increasing hydrophilicity (e.g. G3D, Y8H, and A20T) 
or form new intramolecular interactions that compensate for lost interactions with TmTrpA, 




We also detected strong convergent evolution in a region near the catalytic lysine, K83, 
which directly participates in TmTrpB’s catalytic cycle through covalent binding of PLP and 
multiple proton transfers (Appendix C, Figure C-12).19 For example, A118 was mutated in 
the consensus sequence of four of the ten fully adapted populations, while adjacent residues 
T117 or A119 were mutated in an additional three (Figure 4-3). Furthermore, the three 
populations in which these residues were not mutated contained other consensus mutations 
that are either part of the α-helix to which K83 belongs, or, like residues 117–119, within ~8 
Å of this helix (Figure 4-3; Appendix C, Figure C-12). We hypothesize that the α-helix 
harboring K83 is a focal point of evolution, whereby mutations in its vicinity may finely 
adjust the positioning of K83 and the PLP cofactor to improve catalysis, perhaps as 
compensation for structural changes induced by thermo adaptation. Some OrthoRep-evolved 
variants also contained mutations to first- and second-shell active site residues (Appendix 
C, Figure C-13), which may directly modulate the activity of TmTrpBs, although these 
mutations were rare. Taken together, we hypothesize that these mutations near the active site 
residues of TrpB were adaptive or compensatory. 
The ~20 mutations considered above are rationalized with respect to their impact on 
TmTrpB’s primary catalytic activity. While substrate promiscuity changes may be influenced 
by these explainable mutations, previous literature suggests that substrate specificity is 
globally encoded by amino acids distributed across an entire enzyme.28 Indeed, the majority 
of the ~200 mutations found in our panel of TmTrpBs were far away from TmTrpB’s active 
site and not rationalizable based on the known structural and kinetic properties of TrpBs. We 
suspect that the cryptic genetic variation this majority of mutations encompasses contributes 
to the diversity in substrate scope across our variants. 
4.8 Discussion 
In this work, we showed how the depth and scale of evolutionary search available in 
OrthoRep-driven protein evolution experiments could be applied to broaden the secondary 
promiscuous activities of TmTrpB while only selecting on its primary activity. The 




utility of the new TmTrpB variants we obtained and the second concerning how this 
evolution strategy may apply to future enzyme evolution campaigns and protein engineering 
in general. 
Practically, the new TmTrpBs should find immediate use in the synthesis of Trp analogs. Trp 
analogs are valuable chiral precursors to pharmaceuticals as well as versatile molecular 
probes, but their chemical synthesis is challenged by stereoselectivity requirements and 
functional group incompatibility. This has spurred enzyme engineers to evolve TrpB variants 
capable of producing Trp analogs,20,21,25,26 but the capabilities of available TrpBs are still 
limited. Compared to existing engineered TrpBs, our new panel of variants has substantially 
higher activity for the synthesis of Trp and Trp analogs at moderate temperatures from almost 
all indole analogs tested and also accepts indole analogs, such as 5-CF3 (Figure 4-5a), for 
which benchmark TrpBs used in this study showed no detectable activity (Figure 4-5e). In 
fact, only one TrpB variant has shown detectable activity for this substrate in previous 
classical directed evolution campaigns.21 In addition, at least one member of the panel 
accepted each of the nine indole analogs we used to profile promiscuity, suggesting that 
additional indole analogs and non-indole nucleophiles not assayed here will also be accepted 
as substrates.29,30 Finally, the evolved TmTrpBs are both thermostable and adapted for 
enzymatic activity at 30 C. This maximizes their industrial utility, as thermostability 
predicts a protein’s durability and can be exploited for simple heat-based purification 
processes, while mesophilic activity is compatible with heat-labile substrates, industrial 
processes where heating costs can compound, or in-vivo applications in model mesophilic 
hosts (e.g. S. cerevisiae or E. coli). 
Of more general significance may be the process through which the TmTrpBs in this study 
were generated. Previous directed evolution campaigns aiming to expand the substrate scope 
of TrpB screened directly for activity on indole analogs to guide the evolution process,21,26 
whereas this study only selected for TmTrpB’s primary activity on indole. Yet this study still 





A partial explanation may come from the high primary activities of OrthoRep-evolved 
TmTrpBs, as validated by kinetic measurements showing that variants tested have kcat/KM 
values for indole well in the 105 M-1 s-1 range. Since OrthoRep drove the evolution of 
TmTrpB in a continuous format for >100 generations, each resulting TmTrpB is the outcome 
of many rounds of evolutionary improvement and change (evolutionary depth). This 
contrasts with previous directed evolution campaigns using only a small number of manual 
rounds of diversification and screening. Continuous OrthoRep evolution, on the other hand, 
allowed TmTrpBs to become quite catalytically efficient with minimal researcher effort. We 
suggest that the high primary catalytic efficiencies also elevated secondary activities of 
TmTrpB, resulting in the efficient use of indole analogs. However, this explanation is not 
complete, as evolved TmTrpBs with similar primary activity on indole had differences in 
secondary activities (Figure 4-5). In other words, high primary activities did not uniformly 
raise some intrinsic set of secondary activities in TmTrpB, but rather influenced if not 
augmented the secondary activities of TmTrpB in different ways. We attribute this to the fact 
that we ran our evolution experiments in multiple independent replicates (evolutionary 
scale). Each replicate could therefore evolve the same primary activity through different 
mutational paths, the idiosyncrasies of which manifest as distinct secondary activities. A 
third explanation for the promiscuous profile diversity of these TmTrpB variants is that each 
replicate evolution experiment had, embedded within it, mechanisms to generate cryptic 
genetic variation without strong selection on primary activity. Many of the clones we 
sampled from each TmTrpB evolution experiment had novel promiscuity profiles but 
mediocre primary activity with indole (Figure 4-5). We believe this is because OrthoRep 
drove TmTrpB evolution in the context of a multicopy plasmid such that non-neutral genetic 
drift from high-activity sequences could occur within each cell at any given point. Therefore, 
TmTrpB sequences with fitness-lowering mutations could persist for short periods of time, 
potentially allowing for the crossing of fitness valleys during evolution experiments and, at 
the end of each evolution experiment, a broadening of the genetic diversity of clones even 
without explicitly imposed periods of relaxed selection. Since enzyme orthologs are capable 
of specializing toward different sets of secondary activities when pressured to do so,2,3 non-




should also access different secondary activities, further explaining the diversity of 
promiscuous activity profiles across clones selected from replicate evolution experiments. 
The combination of these mechanisms likely explains the variety of properties encompassed 
by the panel of TmTrpBs. 
Our approach to TmTrpB evolution was inspired by the idea of gene orthologs in nature. 
Orthologs typically maintain their primary function while diversifying promiscuous 
activities through long evolutionary histories in different species.2,31 We approximated this 
by evolving TmTrpB through continuous rounds of evolution, mimicking long histories, and 
in multiple replicates, mimicking the spatial separation and independence of species. Such 
depth and scale of evolutionary search is likely responsible for the substrate scope diversity 
of the TmTrpBs we report even as they were selected only on their primary activity. We 
recognize that the evolved TmTrpBs represent lower diversity than natural orthologs. For 
example, the median amino acid sequence divergence between orthologous human and 
mouse proteins is 11%,32 while the median divergence between pairs of variants from our 
experiment is 4.3% with a maximum of 8% (Appendix C, Figure C-14). Still, this level of 
divergence between functional variants is substantial for a laboratory protein evolution 
experiment and suggests that it is realistic to model future work on the processes of natural 
ortholog evolution (Figure 4-6). For example, it should be straightforward to scale our 
experiments further, to hundreds or thousands of independent populations each evolving over 
longer periods of time. This would better simulate the vastness of natural evolution. It should 
also be possible to deliberately vary selection schedules by adding competitive TmTrpB 
inhibitors (such as the very indole analogs for which they have promiscuous activity), 
changing temperatures, or cycling through periods of weak and strong selection at different 
rates. Such evolutionary courses would approximate complexity in natural evolutionary 
histories. These modifications to OrthoRep-driven TmTrpB evolution should yield greater 
cryptic genetic diversity, which may result in further broadening of promiscuous functions. 
The generation of cryptic genetic diversity at depth and scale should also be useful in efforts 
to predict protein folding and the functional effects of mutations via co-evolutionary 




such computational efforts, so our ability to mimic natural ortholog generation on 
laboratory timescales may be applicable to protein biology at large. Within the scope of 
enzyme engineering, we envision that the process of continuous replicate evolution, selecting 
only on primary activities of enzymes, will become a general strategy for expanding 
promiscuous activity ranges of enzymes as we and others extend it to new targets. 
 
Figure 4-6. Conceptual similarities between natural enzyme ortholog evolution and 
OrthoRep evolution. Splitting OrthoRep cultures into many replicates can be seen as a 
form of speciation occurring by spatial separation. Complex selection schedules may 
emulate varied selection histories of natural orthologs, generating substantial sequence 
divergence across replicates. Evolved OrthoRep cultures contain diverse populations of 
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A p p e n d i x  C  
SUPPLEMENTARY INFORMATION FOR CHAPTER IV 
C.1 Supplementary tables 
Table C-1. Summary of all cultures passaged for evolution of TmTrpB variants.  







wt TmTrpB (GR-Y053) 
3 4 1 
100 2 2 
TmTriple (GR-Y055) 
3 8 2 
100 4 4 
TmTripleQ90* (GR-Y057) 
3 8 1 
100 0 0 
 
Table C-2. Mutation summary statistics for OrthoRep-evolved TrpB populations.  















consensus 10 43 5.6 2.3 3.0 2.3 
1 16 85 8.7 2.1 6.3 4.4 
2 60 194 9.3 2.8 6.5 3.0 
 



















1 A Tm11g Tm11 13 3 TmTrpB 
1 B Tm12f Tm12 9 7 TmTrpB 
1 C Tm1Ff Tm1F 7 1 TmTrpB 
1 D Tm4Ge Tm4G 6 11 TmTripleQ90* 
1 E Tm4Gf Tm4G 11 15 TmTripleQ90* 
1 F Tm3Cc Tm3C 9 3 TmTriple 




1 H Tm3Cg Tm3C 11 4 TmTriple 
1 R Tm3Df Tm3D 9 6 TmTriple 
1 J Tm33f Tm33 10 5 TmTriple 
1 K Tm34e Tm34 9 7 TmTriple 
1 L Tm34f Tm34 8 6 TmTriple 
1 M Tm35f Tm35 5 3 TmTriple 
1 N Tm36b Tm36 7 11 TmTriple 
1 O Tm36e Tm36 10 1 TmTriple 
1 P Tm36f Tm36 6 14 TmTriple 
2 B1 Tm11-B1 Tm11 16 11 wt TmTrpB 
2 B3 Tm11-B3 Tm11 12 7 wt TmTrpB 
2 B4 Tm11-B4 Tm11 14 10 wt TmTrpB 
2 B6 Tm11-B6 Tm11 14 9 wt TmTrpB 
2 B8 Tm11-B8 Tm11 12 9 wt TmTrpB 
2 D5 Tm12-D5 Tm12 9 10 wt TmTrpB 
2 D4 Tm12-D4 Tm12 7 5 wt TmTrpB 
2 D8 Tm12-D8 Tm12 7 6 wt TmTrpB 
2 D7 Tm12-D7 Tm12 9 8 wt TmTrpB 
2 D6 Tm12-D6 Tm12 10 5 wt TmTrpB 
2 D3 Tm12-D3 Tm12 7 9 wt TmTrpB 
2 C2 Tm12-C2 Tm12 9 9 wt TmTrpB 
2 D1 Tm12-D1 Tm12 8 9 wt TmTrpB 
2 A1 Tm1F-A1 Tm1F 9 4 wt TmTrpB 
2 A7 Tm1F-A7 Tm1F 10 8 wt TmTrpB 
2 A6 Tm1F-A6 Tm1F 8 4 wt TmTrpB 
2 A5 Tm1F-A5 Tm1F 8 6 wt TmTrpB 
2 A4 Tm1F-A4 Tm1F 7 5 wt TmTrpB 
2 A3 Tm1F-A3 Tm1F 7 7 wt TmTrpB 
2 A2 Tm1F-A2 Tm1F 8 4 wt TmTrpB 
2 A8 Tm1F-A8 Tm1F 6 2 wt TmTrpB 
2 F3 Tm4G-F3 Tm4G 14 8 TmTripleQ90* 
2 F5 Tm4G-F5 Tm4G 14 8 TmTripleQ90* 
2 F6 Tm4G-F6 Tm4G 11 9 TmTripleQ90* 
2 F7 Tm4G-F7 Tm4G 9 6 TmTripleQ90* 
2 F2 Tm4G-F2 Tm4G 16 6 TmTripleQ90* 
2 F1 Tm4G-F1 Tm4G 11 9 TmTripleQ90* 
2 C8 Tm3C-C8 Tm3C 10 5 TmTriple 
2 C5 Tm3C-C5 Tm3C 15 6 TmTriple 




2 C1 Tm3C-C1 Tm3C 6 4 TmTriple 
2 C7 Tm3C-C7 Tm3C 12 3 TmTriple 
2 C3 Tm3C-C3 Tm3C 7 5 TmTriple 
2 E8 Tm3D-E8 Tm3D 8 11 TmTriple 
2 E3 Tm3D-E3 Tm3D 13 4 TmTriple 
2 E1 Tm3D-E1 Tm3D 10 3 TmTriple 
2 E2 Tm3D-E2 Tm3D 12 8 TmTriple 
2 G1 Tm33-G1 Tm33 5 5 TmTriple 
2 G2 Tm33-G2 Tm33 9 6 TmTriple 
2 G3 Tm33-G3 Tm33 6 5 TmTriple 
2 G4 Tm33-G4 Tm33 10 8 TmTriple 
2 G7 Tm33-G7 Tm33 7 2 TmTriple 
2 G5 Tm33-G5 Tm33 8 4 TmTriple 
2 G6 Tm33-G6 Tm33 6 5 TmTriple 
2 H3 Tm34-H3 Tm34 8 5 TmTriple 
2 H6 Tm34-H6 Tm34 10 15 TmTriple 
2 H4 Tm34-H4 Tm34 12 10 TmTriple 
2 H7 Tm34-H7 Tm34 10 10 TmTriple 
2 H2 Tm34-H2 Tm34 13 4 TmTriple 
2 H1 Tm34-H1 Tm34 9 15 TmTriple 
2 H5 Tm34-H5 Tm34 9 10 TmTriple 
2 C6 Tm35-C6 Tm35 6 2 TmTriple 
2 B2 Tm35-B2 Tm35 8 4 TmTriple 
2 B5 Tm35-B5 Tm35 5 2 TmTriple 
2 B7 Tm35-B7 Tm35 6 3 TmTriple 
2 C4 Tm35-C4 Tm35 7 3 TmTriple 
2 E5 Tm36-E5 Tm36 6 8 TmTriple 
2 E7 Tm36-E7 Tm36 8 7 TmTriple 
2 E4 Tm36-E4 Tm36 6 6 TmTriple 
2 F8 Tm36-F8 Tm36 7 5 TmTriple 
 
Table C-4. Kinetic parameters of selected TmTrpB variants at 30 °C.  
variant 
kcat [95% credible 
region] (s-1) 
KM [95% credible 
region] (µM) 
kcat/KM [95% credible 
region] (mM-1 s-1) 
TmTriple 0.2 [0.16, 0.31] 41.23 [14.32, 192.66] 4.89 [1.54, 12.12] 
C 0.53 [0.49, 0.58] 3.89 [1.85, 7.99] 137.22 [70.29, 276.04] 
D 0.77 [0.72, 0.83] 5.79 [3.82, 8.8] 133.38 [91.24, 193.71] 





C.2 Supplementary figures 
 
Figure C-1. Evaluation of indole-dependent TRP5 complementation of TrpB 
variants. (a)-(c) Spot plating assays for trp5 yeast strains expressing TrpB variants from 
a nuclear plasmid under two different promoter strengths (a), from a nuclear plasmid under 
a strong promoter (b), or from p1 at a high copy number (wt TP-DNAP1 expressed in trans) 





Figure C-2. In vivo Trp production by evolved TrpBs. (a) Spot plating assay for TRP5-
deleted yeast with a nuclear plasmid expressing TRP5, TmTriple, or an individual 
OrthoRep-evolved TmTrpB variant driven by a promoter (pRNR2) that approximates 
expression of TmTrpB variants from OrthoRep’s p1 plasmid, grown on indicated media. 
(b) Evaluation of TRP5 complementation by evolved variants through a growth rate assay. 
Maximum growth rates over a 24-hour period for Δtrp5 yeast strains transformed with a 
nuclear plasmid expressing the indicated TmTrpB variant, grown in medium with or 
without 100 μM indole, and with or without Trp, as indicated. Points and error bars 
represent mean ± s.d. of four technical replicates, respectively. (c) Optimization of indole 
concentration. Growth rates during exponential growth for trp5 yeast with a nuclear 
plasmid expressing randomly chosen OrthoRep-evolved TrpB variants (exact sequence not 
determined), supplemented with one of four indole concentrations, Trp, or neither of these. 





Figure C-3. In vitro Trp production by evolved TrpBs with heat-treated lysate. Trp 
production at 30 °C by indicated TmTrpB variants. Reactions with TmTriple were 
performed with both heat-treated lysate and with purified protein, while all other reactions 
were performed only with heat-treated lysate. TTN, total turnover number. Maximum TTN 
is 5,000. Points represent TTN for individual replicates, bars represent mean TTN for 





Figure C-4. In vitro Trp and Trp analog production with purified enzyme. (a)-(b) 
Production of (a) Trp at 30 °C or 75 °C with 40,000 maximum TTN or (b) indicated Trp 
analogs at 30 °C by column-purified TmTrpB variants. TTN, total turnover number with 
10,000 as maximum TTN. Points represent TTN for individual replicates, bars represent 





Figure C-5. Thermal shift assay on various TmTrpBs. Proportion of TmTrpB variants 
TmTriple (a), C (b), D (c), or K (d) that remain folded after incubation at indicated 
temperature for 1 hour, as measured by the fraction of Trp production relative to incubation 
at 25 °C. T50, temperature at which 50% of enzyme is irreversibly inactivated, as estimated 





Figure C-6. Michaelis-Menten plots for rate of Trp production at saturating serine 
for evolved TmTrpB variants. Initial rate of Trp formation (k, per second) with TrpB 
variants TmTriple (a), C (b), D (c), or K (d) at saturating serine concentration (40 mM) vs. 
indole concentration. Points, median estimates for initial rate based on absorbance change 
over time (see Methods Section B3). The median estimated Michaelis-Menten curve is 
shown as a dark green line, with the 25, 50, 75, and 95% credible regions displayed from 





Figure C-7. Relatedness of TrpB panel sequences generated by OrthoRep evolution. 
Force directed graph where each node represents an individual sequence (all variants from 
set 2, and variants C, D, and K) or consensus sequence for one of the ten evolved 
populations. Edge weights are proportional to the number of shared mutations between two 
nodes. Higher edge weight yields a stronger attractive force between two nodes and is 
visualized as a darker color and a thicker line. Nodes for individual sequences are colored 
according to initial rate of Trp formation, similar to Figure 4-5C. Dotted lines are drawn 
around consensus sequences and individual sequences that are derived from the same 





Figure C-8. TrpB panel indole activity by initial rate of Trp formation. Initial rate of 
Trp formation at saturating l-serine by UV-vis spectrophotometry. Points represent rate for 
individual replicates, bars represent mean rate for reactions with multiple replicates, or rate 
for a single replicate otherwise. OrthoRep-evolved variants are ordered first by the 
population from which they were derived, then by indole activity. Empty, expression vector 
without TrpB variant. Sterile, reaction master mix without heat-treated lysate added. 
Empty, Pf2B9, TmAzul, Tm9D8*, TmTriple, C, D, and K all performed in quadruplicate; 



































Figure C-9. TrpB panel activity with indole analogs by HPLC yield. (a)-(i) HPLC yield 
of (a) 5-cyanoTrp, (b) 6-cyanoTrp, (c) 7-cyanoTrp, (d) 5-bromoTrp, (e) 6-bromoTrp, (f) 7-
bromoTrp, (g) 5-methoxyTrp, (h) 5-trifluoromethylTrp, and (i) β-(1-azulenyl)-L-alanine 
for indicated variants supplied with L-serine and each indole substrate. Points represent % 
yield for individual replicates, bars represent mean % yield for reactions with replicates, or 
% yield for a single replicate otherwise. Replicates and variant order are as in Fig. S8, and 





Figure C-10. Substrate activity profiles for large scale purification of variants B5 and 
G6. Total turnover number (TTN) for TmTrpB variants B5 and G6 purified at large scale 
(see Section C.3 Methods) and supplied with L-serine and the indicated indole analog, 
azulene, or indole (nucleophile), with a maximum TTN of 10,000. All reactions were 
performed in duplicate. Points represent TTN for individual replicates, bars represent mean 






Figure C-11. Commonly observed mutations at the α-subunit interaction interface. 
(a) Homology-predicted TmTrpB structure (based on engineered stand-alone PfTrpB, PDB 
6AM8), with commonly mutated TmTrpB residues located near the TrpA interaction 
interface highlighted. Solvent-exposed regions of TrpA (purple) (PDB 1WDW) are shown 
as a surface. Mutations are indicated by the wt residue and position, followed by any 
residues to which this wt residue is mutated in OrthoRep-evolved TrpB sequences. (b) 
Total number of sequences in both variant sets 1 and 2 that contain the indicated number 
of mutations to any of the residues highlighted in panel (a). 
 
Figure C-12. Commonly observed mutations to residues near a catalytic α-helix. (a) 
Homology-predicted TmTrpB structure (aligned to engineered stand-alone PfTrpB, PDB 
6AM8) with wt residues on or near the α-helix housing K83, which are commonly mutated 
in OrthoRep-evolved populations (orange). PLP (green) and Trp (green) are shown as 
sticks, and the catalytic lysine K83 (teal) is shown as spheres. Mutations are indicated by 
the wt residue and position, followed by any residues to which this wt residue is mutated 
in OrthoRep-evolved TrpB sequences. Dotted lines connect the α-carbon of residues not 
located on the K83 α-helix with the α-carbon of the nearest residue on the K83 α-helix, 
with the distance noted in Ångstroms. (b) Total number of sequences in both variant sets 1 






Figure C-13. First- and second-shell active site mutations. (a)-(c), Homology model of 
TmTrpB (aligned to PfTrpB, PDB: 6AM8) highlighting residues mutated in OrthoRep-
evolved variants (orange) that may influence (a) indole charge, (b) PLP six-member ring 
binding, and (c) PLP-phosphate binding. Mutations are indicated by the wt residue and 
position, followed by any residues to which this wt residue is mutated in OrthoRep-evolved 
TrpB sequences. d) Total number of sequences in both variant sets 1 and 2 that contain the 





Figure C-14. Sequence divergence for natural and OrthoRep-evolved TrpBs. (a)-(b), 
Distributions of pairwise % amino acid sequence divergence for a diverse group of 38 
naturally occurring mesophilic TrpB variants (a) and OrthoRep-evolved variant sets 1 and 
2 (b). 
C.3 Methods 
C.3.1 DNA plasmid construction  
All plasmids that were not generated in a previous study were constructed via Gibson 
assembly1 from parts derived from the Yeast Toolkit,2 from previously described OrthoRep 
integration cassette plasmids,3 from E. coli expression vectors for previously described TrpB 
variants,4,5 from synthesized oligonucleotides, from yeast genomic DNA, or from the 
standard E. coli expression vector, pET-22b(+). All DNA cloning steps and E. coli protein 




oligonucleotides used for PCR were purchased from IDT, and all enzymes and reagents 
used for cloning were purchased from NEC. 
Parts used to generate yeast nuclear expression plasmids for testing the selection and p1 
integration plasmids were PCR amplified from DNA sources listed above, Gibson 
assembled, used to transform E. coli, and plated onto selective LB agar plates. Individual 
clones were picked, grown to saturation in selective LB liquid media, miniprepped, and 
sequence confirmed. Following evolution of TrpB, individual variants were assembled into 
new yeast or E. coli expression vectors through PCR amplification of purified DNA from 
evolved yeast cultures, bulk cloning into the appropriate expression vector, picking 
individual colonies, and confirming absence of any frameshift mutations by Sanger 
sequencing. 
C.3.2 Yeast strains and media  
All yeast strains used in this study are listed in Supplementary Table 6. Yeast were incubated 
at 30 °C, with shaking at 200 rpm for liquid cultures, and were typically grown in synthetic 
complete (SC) growth medium (20 g/L dextrose, 6.7 g/L yeast nitrogen base w/o amino acids 
(US Biological), 2 g/L SC dropout (US Biological) minus nutrients required for appropriate 
auxotrophy selection(s)), or were grown in YPD growth medium (10 g/L bacto yeast extract, 
20 g/L bacto peptone, 20 g/L dextrose) with or without antibiotics, if no auxotrophic markers 
were being selected for. Media agar plates were made by combining 2X concentrate of 
molten agar and 2X concentrate of desired media formulation. Prior to all experiments, cells 
were grown to saturation in media selecting for maintenance of any plasmids present. 
C.3.3 Yeast transformation  
All yeast transformations were performed as described in Gietz and Shiestl.6 After all 
transformations, transformed cells were streaked onto selective media agar plates, and 
resulting single colonies were picked for all further uses. Transformations for integration 
onto p1 were performed as described previously:7 2–4 µg of plasmid DNA with ScaI 
restriction sites adjacent to integration flanks was cut with ScaI-HF (NEB) and used to 




miniprepping resulting clonal strains as previously described,7 visualizing the 
recombinant p1 band of the desired size by gel electrophoresis, and PCR and Sanger 
sequencing of the gene of interest integrated onto p1. Resulting strains were then transformed 
with either of two plasmids for nuclear expression of an OrthoRep terminal protein DNA 
polymerase 1 (TP-DNAP1) variant: wt TP-DNAP1 (pAR-Ec318) for evaluating trp5 
complementation of TrpB variants without mutagenesis, or error-prone TP-DNAP1 (pAR-
Ec633) for generating strains ready for TrpB evolution. These strains were passaged for ~40 
generations in order to stabilize copy number of the recombinant p1 species, prior to any use 
in experiments. 
Genomic deletions were made through co-transformation of a CRISPR/Cas9 plasmid 
targeting the region of interest and a linear DNA fragment comprised of two concatenated 
50 bp homology flanks to the region of interest.8 Transformations were then plated on 
selective media agar, colonies were re-streaked onto nonselective media agar, and resulting 
colonies were grown to saturation in liquid media. The region of interest was PCR amplified 
and Sanger sequenced to confirm presence of desired modification. 
C.3.4 Plating assays 
Yeast strains expressing a TrpB variant either from a nuclear plasmid, or from p1, with wt 
OrthoRep polymerase (TP-DNAP1) expressed from a nuclear plasmid, were grown to 
saturation in SC –L or SC –LH, spun down, washed once with 0.9% NaCl, then spun down 
again, and the resulting pellet was resuspended in 0.9% NaCl. Washed cells were then diluted 
1:100 (or 1:10,000 where indicated) in 0.9% NaCl, and 10 µL of each diluted cell suspension 
were plated onto media agar plates in pre-marked positions. After three days of growth, cell 
spots were imaged (Bio-Rad ChemiDoc™). Resulting images were adjusted uniformly 
(‘High’ set to 40,000) to improve visibility of growth (Bio-Rad Image Lab™ Software). 
Figures utilizing these images (Supplementary Figures C-1 and C-2) were made by 
manually combining images of different plates, but all images of the same media condition 




C.3.5 TmTrpB evolution 
Yeast strains with a nuclear plasmid expressing error-prone TP-DNAP1 and with wt 
TmTrpB, TmTriple, or TmTripleQ90* encoded on p1 (GR-Y053, GR-Y055, and GR-Y057, 
Supplementary Table 6) were grown to saturation in SC –LH, prior to passaging for 
evolution. All cultures passaged for evolution of TmTrpB regardless of success are described 
in Supplementary Table 1. To provide enough indole substrate for sufficient Trp production, 
but not enough to induce toxicity, all growth media used for evolution of TrpB activity were 
supplemented with 100 μM indole, as informed by results shown in Supplementary Fig. 1. 
All passages for evolution were carried out as 1:100 dilutions. In order to induce a growth 
defect but still allow for some growth, the first passage for each evolution culture was carried 
out in SC –LH media with 37 µM Trp (7.6 mg/L). After two or three days of shaking 
incubation, if OD600 > 1.0 (Bio-Rad SmartSpec™ 3000) for 100-mL cultures, or if most wells 
in a 24-well block of 3-mL cultures were saturated to a similar degree by eye, cultures were 
passaged into fresh growth medium with a slightly reduced Trp concentration. If the level of 
growth was beneath this threshold, the culture was passaged into growth medium with the 
same Trp concentration. This process was continued until cultures were capable of growth 
in a Trp concentration of 3.7 µM (or, in the sole case of WT-100-1, 4.7 μM), at which point 
a passage into media lacking Trp was attempted, which typically resulted in successful 
growth. Resulting cultures were then passaged six additional times into growth medium 
lacking Trp. 
C.3.6 Growth rate assays 
Yeast strains containing nuclear plasmids encoding one of several OrthoRep-evolved TrpB 
variants, wt TmTrpB, TmTriple, or none of these (denoted ‘empty’) were grown to saturation 
in SC –L, washed as described above, then inoculated 1:100 into multiple media conditions 
in 96-well clear bottom plates, with four biological replicates per media/strain combination. 
Plates were then sealed with a porous membrane and allowed to incubate with shaking at 30 
°C for 24 hours, with OD600 measurements taken automatically every 30 minutes (Tecan 
Infinite M200 Pro), according to a previously described protocol.9 Multiple 24 hour periods 




well plate to ensure validity of growth in other cultures. Raw OD600 measurements were 
fed into a custom MATLAB script,10 which carries out a logarithmic transformation to 
linearize the exponential growth phase, identifies this growth phase, and uses this to calculate 
the doubling time (T). Doubling time was then converted to growth rate by the equation 
ln(2)/T. 
C.3.7 Enzyme characterization: General experimental methods 
Chemicals and reagents were purchased from commercial sources and used without further 
purification. All cultures were grown in Terrific Broth supplemented with 
100 μg/mL carbenicillin (TBcarb). Cultures were shaken in a New Brunswick Innova 4000 
shaker (shaking diameter 19 mm), with the exception of the 96-well deep-well plates (USA 
Scientific), which were shaken in a Multitron INFORS HT shaker (shaking diameter 50 
mm). Lysis buffer was composed of 50 mM potassium phosphate, pH 8.0 (KPi buffer), 
supplemented with 100 or 200 µM pyridoxal 5’-phosphate (PLP). Heat lysis was performed 
in a 75 °C water bath (Fisher) for >1 hour. Protein concentrations were determined using a 
Pierce™ BCA Protein Assay Kit (Thermo Scientific). Reactions were performed in KPi 
buffer. Liquid chromatography/mass spectrometry (LCMS) was performed on an Agilent 
1290 UPLC-LCMS equipped with a C-18 silica column (1.8 μm, 2.1 × 50 mm) using 
CH3CN/H2O (0.1% acetic acid by volume): 5% to 95% CH3CN over 2 min; 1 
mL/min. Liquid chromatography/mass spectrometry (LCMS) was also performed on an 
Agilent 1260 HPLC-MS equipped with Agilent InfinityLab Poroshell 120 EC-C18 column 
(2.7 μm, 4.6×50 mm): hold 5% CH3CN for 0.5 min, 5-95% CH3CN over 2 min; 1 mL/min. 
TrpB variants selected for further characterization were cloned into a pET-22b(+) 





C.3.8 Expression and characterization of set 1 variants  
C.3.8.1 Large scale expression and lysis 
A single colony containing the appropriate TrpB gene was used to inoculate 5 mL TBcarb and 
incubated overnight at 37 °C and 230 rpm. For expression, 0.5 mL of overnight culture were 
used to inoculate 50 mL TBcarb in a 250-mL flask and incubated at 37 °C and 250 rpm for 3 
hours to reach an OD600 of 0.6–0.8. Cultures were chilled on ice for 20 min and expression 
was induced with a final concentration of 1 mM isopropyl β-D-
thiogalactopyranoside (IPTG). Expression proceeded at 25 °C and 250 rpm for 
approximately 20 hours. Cells were harvested by centrifugation at 5,000g for 5 min at 4 °C, 
and then the supernatant was decanted. The pellet was stored at −20 °C until further use or 
used immediately for whole cell transformations. 
Pellets were lysed in 5 mL of lysis KPi buffer with 200 μM PLP, supplemented with 1 
mg/mL lysozyme (HEWL, Sigma Aldrich), 0.02 mg/mL bovine pancreas DNase I, and 0.1X 
BugBuster (Novagen) and incubated at 37 °C for 30 minutes. Lysate was clarified by 
centrifugation at 5,000g for 10 min, divided into 1-mL aliquots, and stored at −20 °C until 
further use.  
C.3.8.2 Expression and characterization of set 1 variants—lysate and whole cell small-
scale reactions 
Protein concentration in lysate was quantified by BCA. Lysate reactions were performed in 
2-mL glass HPLC vials (Agilent) charged with indole (final conc. 20 mM) dissolved in 
DMSO (5% w/v), followed by the addition of lysate (final enzyme conc. 4 μM), and 
serine (final conc. 20 mM) to achieve a final volume of 200 μL. Whole-cell reactions were 
performed in 2-mL glass HPLC vials (Agilent) charged with indole (final conc. 20 mM) 
dissolved in DMSO (5% w/v), followed by the addition of cells diluted in KPi buffer (final 
OD600=6), and serine (final conc. 20 mM) to achieve a final volume of 200 μL. Reactions 
were incubated at 30 °C for 24 hours, diluted with 800 μL 1:1 CH3CN/1 M aq. HCl, and 




C.3.8.3 Expression and characterization of set 1 variants—thermostability 
determination 
Enzyme T50 measurements (the temperature at which 50% of the enzyme is irreversibly 
inactivated after a 1-hour incubation) were used to report on the thermostability of the 
enzyme. In a total volume of 100 µL, samples were prepared in KPi buffer with 1 µM enzyme 
in PCR tubes and either set aside (25 °C) or heated in a thermal cycler on a gradient from 
79–99 °C (OrthoRep-generated variants), or 59–99 °C (TmTriple), for 1 hour, with each 
temperature performed in duplicate. Precipitated protein was pelleted via centrifugation, and 
75 µL of each sample were carefully removed and added to the wells of a 96-well UV-
transparent assay plate containing 0.5 mM indole and 0.5 mM serine. Relative product 
formation was observed by measuring the change in absorbance at 290 nm to determine the 
temperature at which the sample had 50% residual activity compared to the 25 °C samples 
(modeled as a logistic function).  
C.3.8.4 Enzyme kinetics 
Enzymatic parameters, kcat and KM, for the conversion of indole to Trp were estimated via 
Bayesian inference assuming Michaelis-Menten behavior under saturating serine (40 mM) 
in KPi buffer. Briefly, initial velocities (v) were determined by monitoring Trp formation in 
a Shimadzu UV-1800 spectrophotometer at 30 °C for 1 min over a range of indole 
concentrations at 290 nm using the reported indole-Trp difference in absorbance coefficient 




and estimates for v and Vmax were converted to k and kcat by normalizing for enzyme 
concentration. Parameter estimates are obtained as Hamiltonian Markov chain Monte Carlo 
(MCMC) posterior samples and reported as the median with their 95% credible regions (CR). 
The MCMC software used for sampling was Stan (pystan version 2.19.0.0). The sampling 
was performed with four separate chains, each starting with 2000 warm-up (disregarded) 




lognormal distributions with means log(150) and log(500), standard deviations 2.5 and 
1.5, with units of sec-1 and µM, respectively. This provided non-negative probability density 
that covered low-to-moderate values of the parameters for many known enzymes, but still 
had significant density out to very high values for each parameter. (In all cases, the data was 
shown to significantly inform the prior.) The code used to generate these estimates (along 
with example data) can be found at http://githuC.com/palmhjell/bayesian_kinetics. 
C.3.9 Expression and characterization of set 2 variants  
C.3.9.1 Small scale expression and lysis 
Variants were arrayed into a 96-well deep-well plate along with TmTriple, Tm9D8*, TmAzul, 
and Pf2B9. Individual colonies were grown in 600 μL TBcarb in 96-well polypropylene plates 
overnight at 37 °C, 250 rpm, 80% humidity. The following day, 20 μL of overnight culture 
were used to inoculate 630 μL TBcarb in deep-well 96-well plates and grown at 37 °C, 250 
rpm. After 4 hours, cultures were chilled on ice for 20–30 min and protein 
expression was induced with 50 μL IPTG (final conc. 1 mM) diluted in TBcarC. Cultures were 
shaken at 20 °C, 250 rpm for 20–24 hours, after which they were subjected to centrifugation 
at 5,000g for 10 min. The cell pellets were frozen at −20 °C until further use or used 
immediately. 
C.3.9.2 Indole rate measurements 
Pellets were lysed in either 600 μL of KPi buffer with 100 μM PLP and heat treated at 75 °C 
for 1 hour, or in 600 μL of this buffer supplemented with 1 mg/mL lysozyme, 0.02 
mg/mL bovine pancreas DNase I, and 0.1X BugBuster and incubated at 37 °C for 1 hour. 
Lysate from both conditions was clarified by centrifugation at 4,500g for 10 min and stored 
at 4 °C until further use. 
Reaction master mix composed of 625 μM indole and 25 mM serine in KPi buffer was 
prepared and, before reactions, plates and master mix were incubated in a 30 °C water 




To UV-transparent 96-well assay plates (Caplugs, catalog # 290-8120-0AF), 160 μL pre-
heated reaction master mix was added by 12-channel pipet followed by 40 μL of lysate from 
the pre-heated plate using a Microlab NIMBUS96 liquid handler (Hamilton). Plates were 
immediately transferred into the plate reader, shaken for 10 sec to mix and the absorbance of 
each well at 290 nm was recorded as rapidly as possible (~20 s between measurements) for 
120 cycles. The rate of product formation was determined by finding the rate of absorbance 
change over time and converting to units of concentration using ∆ε290 = 1.89 mM-1 cm-
1 (see above) and a determined path length of 0.56 cm. We observed no systematic difference 
in activity between the two lysate preparations (Supplementary Fig. 15), suggesting that most 
enzyme variants retained sufficient thermostability for purification via heat treatment, and 
this method was used in subsequent experiments.  
C.3.9.3 Substrate scope screen 
Pellets were lysed in 300 μL KPi buffer with 200 μM PLP and clarified by centrifugation at 
4,000g for 10 min. To a 96-well deep-well plate charged with 10 μL nucleophile dissolved 
in DMSO (final conc. denoted in the table directly below), 40 μL of the heat treated lysate 
were transferred using a Microlab NIMBUS96 liquid handler (Hamilton), followed by 
addition of 150 μL serine (final conc. 20 mM) with a 12-channel pipet. Reactions were 
sealed with 96-well ArctiSeal™ Silicone/PTFE Coating (Arctic White) and incubated in a 
30 °C water bath for ~24 hours. Reactions were diluted with 600 μL 2:1 CH3CN/1 M aq. 
HCl, subjected to centrifugation at 5,000g, and 400 μL were transferred to 2-mL glass HPLC 
vials (Agilent). Samples were analyzed by HPLC-MS. Azulene samples were further diluted 





Table C-5. Nucleophiles tested in substrate scope screen  
Nucleophile  Source  Catalog #  CAS  Final conc. 
(mM)  
5-Cyanoindole  Chem Impex  21849  15861-24-2  20  
6-Cyanoindole  Chem Impex  21181  15861-36-6  20  
7-Cyanoindole  Sigma  CDS008484   20  
5-Bromoindole  Sigma  B68607  10075-50-0  20  
     
6-Bromoindole Sigma 524344 52415-29-9 20 
7-Bromoindole Sigma 473723 51417-51-7 20 
5-Methoxyindole  Combi-Blocks  IN0049  1006-94-6  20  
5-Trifluoromethylindole  Sigma  701068  100846-24-0  10  
Azulene  Alfa Aesar  L08271  275-51-4  20  
 
All samples except those containing azulene were analyzed at 277 nm, representing the 
isosbestic point between indole and Trp and allowing estimation of yield by comparing the 
substrate and product peak areas for indole analogs.12 Azulene yield was estimated as 
described previously.13 Nucleophile retention times were determined though injection of 
authentic standards and product retention times were identified by extracting their expected 
mass from the mass spectrum. 
C.3.10 Characterization of Tri-100-3-F and Tri-100-1-G 
C.3.10.1 Large-scale expression and purification 
A single colony containing the appropriate TrpB gene was used to inoculate 5 mL TBcarb and 
incubated overnight at 37 °C and 230 rpm. For expression, 2.5 mL of overnight culture were 
used to inoculate 250 mL TBcarb in a 1-L flask and incubated at 37 °C and 250 rpm for 3 
hours to reach OD600 0.6–0.8. Cultures were chilled on ice for 20 min and expression was 
induced with a final concentration of 1 mM IPTG. Expression proceeded at 25 °C and 250 
rpm for approximately 20 hours. Cells were harvested by centrifugation at 5,000g for 5 min 
at 4 °C, and then the supernatant was decanted. The pellet was stored at −20 °C until further 
use. 
Pellets were lysed in 25 mL KPi buffer with 200 μM PLP for >1 hour at 75 °C. Lysate was 




purified over hand-packed HisPur™ Ni-NTA Resin (Thermo Scientific, catalog # 
88221), dialyzed into KPi buffer, and quantified by BCA.  
C.3.10.2 Tri-100-3-F PLP-binding assay 
Variant Tri-100-3-F did not exhibit the characteristic yellow color of PLP-
bound TrpB variants after purification, however BCA indicated protein concentrations 
comparable to the Tri-100-1-G variant. We have previously observed that 
some TrpB variants lose binding affinity for PLP resulting in non-functional apoenzyme. We 
evaluated Trp formation of Tri-100-3-F supplemented with 0, 0.1, 0.25, 0.5, 1, 2, 5, and 
100 μM PLP via UV-Vis spectrophotometry. Serine (final conc. 25 mM) + PLP master 
mixes of the eight concentrations were prepared and dispensed into a 96-well UV-transparent 
plate. Enzyme dilutions (final conc. 1 μM) with or without indole master mixes were 
prepared, and 100 µL thereof were dispensed into the 96-well plate. The plate was 
immediately transferred into plate reader, shaken for 10 s to mix, and product formation was 
measured ~20 s for 120 cycles at 290 nm. 
Only the 100 µM PLP condition restored activity, supporting our hypothesis that the purified 
enzyme was apoprotein and binds PLP poorly, requiring supplementation of PLP to re-form 
a functional holoenzyme.  Thus, we chose to supplement PLP in the subsequent purified 
protein reactions. 
C.3.10.3 Small scale analytical reactions   
Reactions were performed in 2-mL glass HPLC vials (Agilent) charged with nucleophile 
(final conc. 20 mM) dissolved in DMSO (5% w/v), followed by the addition of purified 
protein (final enzyme concentrations were either 2 μM or 40 μM), PLP (final conc. 
100 μM)  and serine (final conc. 20 mM) to achieve a final volume of 200 μL. Reactions 
were incubated at 30 °C for ~24 hours. Reactions were diluted with 600 μL 2:1 CH3CN/1 M 
aq. HCl, subjected to centrifugation at 5,000g, and 400 μL transferred to 2-mL glass HPLC 
vials (Agilent). Samples were analyzed by HPLC-MS. Azulene samples were further diluted 
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C h a p t e r  V  
 
DEEP MUTATIONAL SCAN OF THE TRYPTOPHAN SYNTHASE 
BETA SUBUNIT 
E.J.W.D. and B.J.W. conceived of the project. E.J.W.D. designed and performed all 
experimental work. E.J.W.D. adapted code from B.J.W. for analysis of next generation 






Machine learning has the potential to revolutionize how proteins are engineered, but requires 
large quantities of data to train models. In this chapter, I describe the development of a deep 
mutational scanning experiment of combinatorial site-saturation mutagenesis (SSM) 
libraries using the tryptophan synthase β-subunit (TrpB). The aim of the project is to generate 
a large dataset that maps enzyme sequence to function for the purpose of studying epistasis 
using machine learning. This project will generate triple- and quadruple-SSM libraries (8,000 
and 160,000 unique variants, respectively) and sequence the populations using Next 






The aim of this project is to collect a dataset on the combinatorial interactions of residues to 
study the nature of epistasis using machine-learning algorithms. We know that evolution 
generally works through the stepwise accumulation of single, beneficial mutations. Many 
mutations, however, are only beneficial in the context of another. This phenomenon, known 
as epistasis, has traditionally been studied by phylogenetic analysis, as so far, understanding 
general principles about epistasis has largely been constrained by a lack of data.1 Intra-
protein interactions can be explored by Combinatorial Site-Saturation Mutagenesis (CSSM), 
in which one or more positions in a protein are mutated to create a library of variants for 
screening. However, methods for collecting and parsing through the large datasets of DNA 
sequences were previously insufficient to measure combinatorial fitness landscapes. 
Breakthroughs in high-throughput sequencing technologies as well as the blossoming 
machine-learning field have poised the evolution community to begin to unfold complex 
protein phenomena.2,3  
Deep Mutational Scanning (DMS) has emerged as a method to evaluate large library 
selections. DMS utilizes Next Generation Sequencing (NGS) to characterize library 
populations before and after a selection.4 The frequencies of library variants represented in 
the sequencing before and after selection are compared to calculate a ‘functional score,’ or 
selection coefficient, corresponding to the fitness of the enzymes (Figure 5-1, right). The 
resultant calculated fitness landscape can then be analyzed via machine learning (ML) to 
uncover patterns that reveal complex interactions between the targeted protein residues 
which may be impossible to identify by human analysis alone. While many groups have used 
this technology to study epistasis in a context of binding,4 I wanted to generate a fitness 
landscape surrounding a much more difficult challenge: enzyme catalysis. 
For this project, I proposed to perform a deep mutational scan to measure combinatorial 
fitness landscapes of a tryptophan synthase -subunit (TrpB) in order to observe and predict 
evolutionary pathways to novel functions. Once collected, the data will be used to train 




believe using the combination of DMS and NGS with TrpB libraries will fulfill the need 
of the protein-engineering ML community and deliver large, quality datasets to develop 
generalized, predictive models so that we can begin to explore underlying principles that 
govern proteins.  
5.2 Original design overview 
For this DMS study, I planned to generate three- and four-site CSSM libraries of which TrpB 
with a selection on the variants’ ability to accept indole to complement a Trp autotrophic 
yeast strain (Figure 5-1, left). The libraries would be sequenced before and after selection 
via NGS, and functional scores, otherwise known as selection coefficients, were to be 
calculated from the frequency of each variant at each timepoint (Figure 5-1, right). The 
8,000-variant, three-site combinatorial library was planned to serve as the lower cost, pilot 
study to ensure our cloning, selection, and sequencing workflow are optimized for the more 
challenging, 160,000-variant, four-site library. This work is unfinished and will be continued 
by another Arnold Lab member. I developed the entire project to be performed in a yeast 
host, but technical issues associated with library cloning and DNA preparation proved to be 
extremely challenging. While the selection system will be re-developed using Escherichia 
coli to circumvent yeast-specific problems, the insights gained and the PCR methods 





Figure 5-1. Deep mutational scan overview. Left: Deep mutational scanning scheme. 
Indole is provided to a strain of yeast that is auxotrophic for Trp, with each cell expressing 
a TrpB variant. If the TrpB variant is active, it will synthesize Trp, thus complementing the 
auxotrophy and allowing the yeast to survive. The TrpB variants better at complementation 
should grow faster and therefore be better represented in the population after the selection. 
Right: How functional scores are calculated. The frequency of each variant is measured 
before and after the selection. The functional score (Sx) is calculated by dividing the 
frequency of variant X after the selection, (Fx, after) by the frequency of variant X before the 
selection (Fx, before)  
There are several key factors that are important to consider for collecting quality deep 
mutational scanning data. 
1) To ensure adequate sampling of the library, at least ten times as many transformants 
as library members should be obtained.5 
a. Although there is a possibility of 8,000 different unique amino-acid 
combinations for a three-site library, using NNK degenerate codons to 
construct the library will result in more codon combinations than variants, 
with some amino acid combinations occurring more than others. We can 
calculate the least frequently occurring variant for the three-site library as 




will be approximately 3x104 variants. We can therefore estimate that if 
we need ten times the least frequently occurring variant, we will need 3✕105 
transformants.  
b. For a four-site library, the least frequently occurring variant is 1/324, so the 
library size is estimated to be 1✕106, and the library transformation efficiency 
must be 1✕107. 
2) Each variant should be covered by at least 100 sequencing reads in the initial library.5 
a. We must consider the quantity of DNA that we are able to extract from 
samples as well as the quantity necessary for preparation of the library for 
NGS. The DNA extraction efficiency will influence the size of the culture 
necessary for the selection. These values must be determined empirically. 
3) Deep mutational scanning data can be noisy, so at least one biological replicate 
should be obtained.5 
4) Extending experiment time and sampling more timepoints results in higher precision 
for measuring selection coefficients.6 
5.3 Establishing the yeast selection 
I began by obtaining the Trp autotrophic yeast strain (Saccharomyces cerevisiae BY4742 
ΔTrp5) from the Chang Liu lab at UC Irvine. Yeast offers several advantages over our typical 
E. coli expression host. First, the Liu lab has already demonstrated TrpB’s ability to 
complement the yeast autotrophic strain BY4742 ΔTrp5 and standard protocols have been 




avoid false positives that could arise from library-cloning errors. By integrating TrpB 
into the genome of yeast via homologous recombination using constructs from the MoClo 
Yeast Tool kit,8 uniform gene copy number is ensured and any risk associated with multiple 
transformants in a single cell is removed. The TrpB genes were cloned into the pYTK096 
integration plasmid that has homology to the Ura3 region of the genome. I cloned the I-SceI 
“landing pad” into BY4742 ΔTrp5, which is recognized by the I-SceI restriction enzyme. 
Yeast cells can be co-transformed with a plasmid encoding I-SceI and the linearized 
pYTK096 plasmid, and the restriction enzyme is expressed in vivo to introduce a double 
stranded break at the recognition site, encouraging higher rates of recombination (Figure 5-
2). The I-SceI step is optional and can be avoided if the cells are transformed with a larger 
quantity of library DNA. 
 
Figure 5-2. Genomic integration by homologous recombination.  
To test the selection, I cloned five different TmTrpB variants that were known to have a range 
of activity on indole into the auxotrophic yeast strain. TmTriple was selected because it was 
a starting point for the previous OrthoRep evolution project7 and possesses the fewest 
mutations required to create a stand-alone TrpB,9 Tm9D8* was selected because of its known 
activity at 37 °C compared to other TrpB variants that function best at temperatures ranging 
from 55–75 °C,10 Tm9D8* E105G was selected because it is known that the E105G mutation 
dramatically decreases Trp activity11 and could be compared to Tm9D8*; and finally, Tm1Ff 
and Tm4Ge were chosen because they were evolved in the BY4742 ΔTrp5 strain for 




In a qualitative test, I grew the five different variants with and without the addition of 
400 μM indole and monitored their growth over the course of several days (Figure 5-3). The 
concentration of 400 μM was determined previously by Gordon Rix to be the maximum 
concentration tolerable without causing indole toxicity and stunting yeast growth.7 The 
variants behaved exactly as expected during the selection, with the Orthorep evolved variants 
growing fastest and the Tm9D8* E105G variant growing the slowest. 
 
Figure 5-3. Pilot selection with TrpB variants integrated into yeast genome. 1:100 
dilution from overnight culture, 48 h growth, Synthetic Defined (SD) Trp dropout minimal 
medium, 30 °C, 250 rpm (Innova 42). Five TrpB variants cloned into the yeast genome 
were grown in the absence (Left box) and presence (Right box) of 400 μM indole. The cells 
should not grow without indole (negative control) and should grow at varying rates that 
correspond to TrpB activity when in the presence of indole. The turbidity of the culture 
represents how well the culture grew. Variants better at Trp complementation (Tm1Ff, 
Tm4Ge, and Tm9D8*) are very opaque, while variants that are not (TmTriple and Tm9D8* 
E105G) remain transparent.  
It is important that the cultures be maintained in the exponential regime of the growth curve 
during the selection so that the selection conditions are consistent throughout the entire 
experiment.6 The size of the culture and the frequency of the timepoints were yet to be 
determined because I needed to measure the quantity of DNA that could be extracted per 
optical density at 600 nm (OD600) and volume of cells. Regardless, it was necessary to 




could be appropriately passaged to maintain growth in the exponential phase. An 
overnight Tm9D8* culture in YPD media was diluted 1:20 and the growth curves measured 
over the course of 25 hours in 5-mL and 50-mL cultures. From the assay, the cultures reached 
stationary phase at approximately OD600 of 7–8, so they should be passaged in an OD600 
range of 4–6 to maintain logarithmic growth (Figure 5-4).  
 
Figure 5-4. Growth curve assay of BY4742 ΔTrp5 expressing Tm9D8* in minimal 
media. 1:20 dilution from overnight culture, 25 h growth, Synthetic Defined (SD) Trp 
dropout minimal medium supplemented with 400 μM indole, 30 °C, 250 rpm (Innova 42). 
Shaded regions in 5-mL assay represent +/- 2 standard deviations from the mean.  
During a trial selection, I observed that the growth curve did not follow the typical behavior 
of a homogeneous population, most likely caused by the heterogeneity of TrpB variant 
activity. The initial density of cells is comprised of a range of slow to fast growing cells, and 
as the faster growing cells overtake the slow ones, the apparent doubling time of the entire 
culture accelerates. Since it was impossible to predict the time that the cells reached 
exponential phase, continuously monitoring the culture would prevent a situation where the 




Quantifier technology from Aquila Biolabs, which reports cell density in real time using 
a detector that is placed underneath the shake flask during growth. 
5.4 Cloning combinatorial libraries 
Because the aim of the project is to study epistasis, it is paramount to make libraries with 
residues that are likely to interact epistatically. Residues that are spatially adjacent to one 
another are more likely to be epistatic than residues that are not.12 Therefore, I chose to 
construct ten different libraries that contained spatially adjacent residues based on the 
Pyrococcus furiosus TrpB crystal structure (PDB: 6AMH),13 focusing primarily on active-
site residues and ones that had been previously shown to influence activity (Table 5-1 and 
Figure 5-5). 
Table 5-1. Sites selected for triple-site combinatorial libraries (Thermotoga maritima 
scaffold numbering).  
Library Site 1 Site 2 Site 3 
A 104 105 106 
B 105 106 107 
C 106 107 108 
D 117 118 119 
E 184 185 186 
F 162 166 301 
G 227 228 301 
H 228 230 231 





Figure 5-5. Site-saturation mutagenesis libraries highlighted in Pyrococcus furiosus 
scaffold (PDB: 6AMH). Green sticks: PLP with amino-acrylate bound. Purple sphere: 




I initially designed standard site-saturation mutagenesis Gibson primers to clone the 
libraries and used Sanger sequencing to verify that there was good representation of each 
base at the randomized positions (Figure 5-6A). Unfortunately, when the libraries were later 
sequenced by MiSeq NGS, I discovered that they were strongly biased for the parent 
sequence. This was likely because the primer that contained the parent sequence would be 
thermodynamically favored during the library generation PCR since it possesses more base 
pairs matched to the template sequence than any other library primer. To circumnavigate this 
issue, I devised a two-step PCR scheme with the help of Bruce Wittmann that eliminated the 
possibility for bias (Figure 5-6B and 5-7). The first PCR amplified the entire plasmid except 
the region where the mutations are being introduced (called the ‘gap PCR’), and then the 
reaction was DpnI digested to remove all template DNA. Afterwards, this new template was 
used with the library primers that introduce the genetic diversity at the gap region and the 
resultant linear PCR product was assembled via Gibson assembly as normally. Using the 
two-step gap PCR technique, most of the libraries were successfully constructed, and their 





Figure 5-6. Combinatorial library primer design. A) Standard Gibson assembly primer 
design. The traces to the right represent the Sanger Sequencing results of a library. B) Two-
step gap PCR technique. The first PCR amplifies everything except region of mutagenesis. 
The second PCR introduces genetic variation at region of mutagenesis without parent 
sequence present to bias binding.  
 




Although I had previous experience at transforming yeast with the pYTK096 plasmid for 
genomic integration at high efficiencies in the Ellington Lab at the University of Texas at 
Austin, I encountered difficulty transforming them in the Arnold Lab. I tried numerous 
different transformation protocols,14,15 different libraries that I had constructed, and different 
DNA concentration techniques, and I was only able to successfully transform one library. 
After exhausting all of my own abilities, I recruited the help of Sabine Brinkmann-Chen, 
who also had prior experience with yeast transformations. Together, we still could not 
transform the libraries with multiple attempts, and even the positive control plasmids failed. 
An industry expert on yeast transformations suggested that quality of the agar plates can have 
a dramatic effect on whether colonies grow, so it was possible that the issue was with the 
growth conditions after the transformation. The recommended plate brand was ordered, but 
shipping was heavily delayed due to COVID.  
5.5 Preparing library amplicons for NGS 
Next generation sequencing is the key technology that enables the execution of deep 
mutational scans. Without the ability to sequence reads in parallel, it would be impractical to 
embark on projects that require sequencing thousands of variants. Since deep mutational 
scanning studies rely heavily on quality NGS data to accurately report variant frequencies, it 
is important to minimize the amount of error that is introduced in the sequencing runs. The 
error rate of NGS can be up to 1%, which can result in fictitious mutations that do not 
accurately reflect the library.5 This issue can be ameliorated by using paired-end reads, which 
generate double coverage of the sequence of interest, thus reducing the error rate and 
allowing the researcher to throw out any sequences whose forward and reverse sequences do 
not match at the positions of interest.  
The low sequence diversity in a deep mutational scanning library presents two major 
challenges. First, during library preparation, incomplete PCR products can act as mega-
primers for other templates, which causes a scrambling of variant identities (Figure 5-8A). 
This is not a large concern for libraries where the codons are immediately adjacent to one 




one another. Some of the libraries I designed did not have three consecutive sites mutated, 
and I wanted the method I developed to be as generalizable as possible, so it was prudent to 
treat all libraries as if this recombination were to occur. To minimize this effect, researchers 
try to keep the number of PCR cycles during library preparation as low as possible, reducing 
the number of chances that a recombination event could occur. While an effective solution, 
I imagined that this issue could be completely avoided by implementing an emulsion-based 
water-in-oil droplet PCR (emPCR) method that spatially separates the templates, thus 
eliminating any chance of different templates coming into contact with one another (Figure 
5-8B). Emulsion PCRs have been used for NGS library preparation in similar ways before,16 
and I had personally worked to optimize an emulsion technique for amplification of DNA in 
whole yeast,17 so I believed that this approach would be feasible. 
 
Figure 5-8. Template recombination and yeast emulsion scheme. (a) Recombination of 
templates results in false mutation combinations. (b) Abstraction of emulsion bubbles. 
Yeast are spheroplasted to make the membrane permeable to PCR reagents in buffer. 
Primers are designed to amplify the TrpB gene integrated into the genome. (c) 40X image 
of emulsion bubbles with diameters measured to estimate the number of bubbles in each 




The libraries are to be sequenced using Illumina NGS Mi-Seq and Hi-seq technology. 
Briefly summarized, Illumina NGS technology works by attaching DNA to a flow cell with 
adaptors that have homology to oligos affixed to the surface of the flow cell, then amplifying 
each gene to generate small clusters of DNA, and flowing dNTPs that have fluorescent labels 
with color associated for each base attached to them. For each position that is sequenced, the 
fluorescent labels are excited, recorded, and then removed so that the next round of dNTPs 
can be attached to the following base (Figure 5-9).  
 
Figure 5-9. General overview of Illumina sequencing. The method of adaptor attachment 
can vary; here is shown how a targeted gene would be prepared for sequencing.  
During sequencing, the second issue of low sequence diversity arises: the sequencing 
software uses the first 25 bases sequenced to differentiate between the clusters of DNA and 
will struggle to identify clusters that have the same exact beginning sequence.18 This is a 
problem because the cluster boundaries inferred are used to assign bases, otherwise known 




quality of the calls. It is common to spike sequencing runs with sheared genomic DNA 
from the virus phiX174 to artificially introduce diversity and improve sequencing quality.19 
However, there are other methods that have been developed to introduce more sequence 
diversity. For example, the ‘phasing amplicon sequencing approach’ (PAS) shifts sequencing 
frames among different samples by introducing varying numbers of bases (0–7) as 
‘spacers.’20 The issue can also be addressed by introducing random 10mer barcodes at the 
beginning of each sequencing read, which artificially introduces diversity that can be used 
for calling bases.21 The random 10mer was appealing due to its relative simplicity to the PAS 
approach, so it was integrated into my primer design. I also planned other strategies for 
introducing sequence diversity; multiple libraries could be pooled into one sample (Figure 
5-10A), or different timepoints could have alternating directionality so that there would be 
at least two populations of different sequences in each run (Figure 5-10B). There was not an 
opportunity to test these ideas in the laboratory, so their effectiveness has yet to be 
demonstrated.  
The library preparation was designed to be nested PCR, with both the external and internal 
primers combined in one emPCR reaction. (Figure 5-10C). The internal primer begins with 
a ‘seed region’ that has homology to the gene of interest, then a 3mer barcode that represents 
the timepoint, followed by a random 10mer region for diversity, and then homology to the 
i5/i7 adaptor region so that the external adaptor primers can be attached. The external primer 





Figure 5-10. Library diversity strategies and amplicon primer design. (a) Including 
multiple libraries in one Illumina run can increase sequence diversity. (b) Alternating the 
directionality of the amplicons could also increase sequence diversity. (c) Final primer 
design.  
Both emPCRs and nested PCRs can be finnicky methods, and I experienced difficulty getting 
the nested PCR to work in emulsion conditions. In the interest of time, I decided to forego 
the emPCR and optimized the internal primer PCR for the minimal number of cycles on 
extracted DNA, as is the current standard method for minimizing recombination during deep 




5.6 Proposed E. coli DMS redesign 
The benefits supposedly conferred by using yeast for this selection were nullified by the 
difficulties that were encountered transforming the yeast with the libraries and preparing the 
NGS amplicons. Instead, I propose that the project be continued in an auxotrophic E. coli 
strain with library variants constitutively expressed on a plasmid. The Arnold lab has 
experience achieving high transformation efficiencies with E. coli, and E. coli systems are 
generally easier to transform and work with than yeast genomic integration. Furthermore, the 
yeast genomic extraction kit I used resulted in low DNA yields, so it would have required 
that very large selection cultures be grown in order to have enough cells to passage and 
extract for NGS amplicon preparation. In contrast, it is very easy to extract large quantities 
of plasmid DNA from E. coli, so smaller cultures can be used.22 Finally, the protocol for E. 
coli emPCR is simpler and more robust than the one for S. cerevisiae because E. coli are 
easier to lyse than yeast, so it may be easier to implement the proposed emPCR method.23  
The ‘gap PCR’ library cloning technique and NGS amplicon protocols that I have developed 
are directly transferrable to the E. coli system, so only the selection will need to be re-
established to complete the project. 
5.7 Analysis of NGS data 
When working with large datasets, it is important to establish an organized and automated 
workflow for data analysis (Figure 5-11). Next Generation Sequencing data is formatted as 
a .fastq file, which is a list of “information blocks” that consist of four lines: sequence 
identifier, sequence, quality score identifier line (consisting only of a ‘+’), and the quality 
scores (Figure 5-11, pink block). Bruce Wittmann had previously written a package to parse 
NGS data for another project and shared this package with me. I modified the package to suit 
the needs of this project. The inputs are the forward and reverse .fastq files and the reference 
sequence in string format with the mutated codons represented as ‘nnn.’ The package parses 
through all of the information blocks in the forward and reverse .fastq files and pairs together 
reads sharing the same sequence identifier. Orphan sequences that do not have a pair, 
sequences whose average quality scores over all bases are >30, and sequence pairs whose 




discarded. After sequences are parsed and paired, the now ‘wrangled’ sequence pairs are 
aligned to the reference sequence and the codons at mutated positions are translated and 
recorded. The number of each unique amino acid combination is counted, and a dictionary 
containing the amino-acid sequence and counts is returned for each different timepoint. 
These counts can be then used to calculate the frequencies and functional scores. 
Figure 5-11. Pseudocode of the data analysis package.  
The software also creates histograms of the average Q-scores for each read, which can be 





Figure 5-12. Example of poor and good quality forward and reverse read data. Poor 
quality read data has few overall reads compared to what is expected or can have the 
majority of reads with mean score below 30. Good quality data has few reads with mean 
score below 30 and thousands of high-quality reads. The expected quantity of reads will 
vary depending on type of sequencing performed.   
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A p p e n d i x  D  
SUPPLEMENTARY INFORMATION FOR CHAPTER V 
D.1 Materials 
Oligonucleotide primers were obtained from Integrated DNA Technologies (IDT DNA). 
PCRs were run with the Phusion® High-Fidelity PCR Kit (New England Biolabs). Gibson 
assembly mix is prepared with isothermal master mix in-house, and enzymes T5 
exonuclease, Phusion® DNA polymerase, and Taq DNA ligase purchased from New 
England Biolabs. Gel extractions were performed with ZymoClean gel recovery kit. 
D.2 Construction of triple-site saturation mutagenesis libraries  
Libraries were constructed according to the cloning scheme described in Section 5.4 and 
depicted in Figure D-1. The ‘gap’ PCR was set up using F Gap primer and R primer in Table 
D-1, PCR mix in Table D-2, and thermal cycler protocol in Table D-3. The PCR was then 
DpnI digested and analyzed by gel electrophoresis. The properly sized fragment was gel 
extracted and eluted in 30–50 μL ddiH2O. The library PCR was set up using the F library 
primer and R primer in Table S-2, PCR mix in Table D-2, and thermal cycler protocol in 





Table D-1. Gap/3X SSM Library PCR primers 
Lib. Primer EJW Primer name Sequence 
A 
F Gap EJW_pr205_9D8st_106_gap_F GGTGCTGGTCAGCACG 







F Gap EJW_pr218_9D8st_107_gap_F GCTGGTCAGCACGGC 







F Gap EJW_pr219_9D8st_108_gap_F GGTCAGCACGGCGTAG 







F Gap EJW_pr220_9D8st_119_gap_F GCGCTGTTCGGTATGGAAT 
F Library EJW_pr178_DMS_117-118-119_F 
ACGGCGTAGCAACTGCTNNKNNKNNKGCGCTGTTCGGTAT
GGAATGTGTAATC 
R EJW_pr179_DMS_117_R AGCAGTTGCTACGCCGTGCTGACCAGCACCCGTTTCAG 
E 
F Gap EJW_pr221_9D8st_186_gap_F GTGGTTGGTCCGCATCC 







F Gap EJW_pr222_9D8st_166_gap_F GACGAAGCTCTGCGTGAC 







F Gap EJW_pr223_9D8st_228_gap_F GGTGGTTCTAACGCTGCC 







F Gap EJW_pr224_9D8st_231_gap_F AACGCTGCCGGTATCTTCTAT 







F Gap EJW_pr225_9D8st_184_gap_F GGCTCTGTGGTTGGTCC 












Table D-2. Gap/3X SSM PCR master mix 
Component Volume (μL) 
primer_for (10 μM) 1 
primer_rev (10 μM) 1 
template 0.5 
NTP mix (10 mM) 1 
Phusion 0.5 





Table D-3. Gap/3X SSM PCR thermal cycler protocol 
Temperature (C) Time (S) Cycles 
98 30 1 
98 10 
30 55 15 
72 200 
72 600 1 
10 Infinite 1 
 
D.3 NGS amplicon preparation 
To prepare NGS amplicons, extract DNA from host and quantify amount by NanoDrop. It is 
good to know roughly how many copies of DNA are being sampled to ensure adequate 
representation of all library variants. Perform the internal primer PCR using primers from 
Table D-4, PCR mix from Table D-5, and thermal cycler protocol from Table D-6. The 
internal primer PCR amplifies the region of DNA of interest (Figure 5-6B and Figure 5-7) 
and attaches the random 10mer and timepoint barcode to each amplicon. DpnI digest the 
PCR, run on analytical gel, and gel extract. Elute in 20 μL. This can be directly sent to 
Laragen or can be used as template for external primer PCR to attach the Illumina Nexterra 
adaptors (Primers: Table D-7, PCR mix: Table D-8, thermal cycler protocol: Table D-9). 
The external primer PCR is not necessary as Laragen will attach its own adaptors but can be 




Table D-4. Internal NGS amplicon PCR primers 





Sequence 5’  3’ 









































































































































Table D-5. Internal NGS amplicon PCR master mix 
Component Conc.  Volume (L) 
internal primer_for 10 M 1 
internal primer_rev 10 M  1 
Template ~2400 ng  
NTP mix 10 mM 1 
Phusion  0.5 
HF buffer (5x)  10 
DMSO  0.5 
water  Q.S. 50 
Total:  50 
 
Table D-6. Internal NGS amplicon PCR thermal cycler protocol 
Step Temperature (C) Time (S)  Cycles 
Initial denature  98 30 1 
Denature 98 20 
15 Anneal 55 15 
Extend (30 sec/kb) 72 Variable 
Hold 10 infinite 1 
 
 
Table D-7. Nexterra adaptor (‘external’) primers 
EJW Primer name P5/P7 
Nexterra 
index 
Sequence 5’  3’ 
EJW_pr151_DMS_N501_i5_adaptor P5 N501 
AATGATACGGCGACCACCGAGATCTACACTAGATCG
CTCGTCGGCAGCGTCAGAT 
EJW_pr152_DMS_N701_i7_adaptor P7 N701 
CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCT
CGTGGGCTCGGAGATG 
EJW_pr155_DMS_N502_i5_adaptor P5 N502 
AATGATACGGCGACCACCGAGATCTACACCTCTCTA
TTCGTCGGCAGCGTCAGAT 
EJW_pr156_DMS_N702_i7_adaptor P7 N702 
CAAGCAGAAGACGGCATACGAGATCTAGTACGGTCT
CGTGGGCTCGGAGATG 
EJW_pr157_DMS_N503_i5_adaptor P5 N503 
AATGATACGGCGACCACCGAGATCTACACTATCCTC
TTCGTCGGCAGCGTCAGAT 







Table D-8. External NGS amplicon PCR 
Component Conc.  Volume (L) 
external primer_for 10 M 1 
external primer_rev 10 M 1 
Template (PCR product from step 1) 20 
NTP mix 10 mM 1 
Phusion  0.5 
HF buffer (5x)  10 
DMSO  0.5 
water  16 
Total:  50 
 
Table D-9. External NGS amplicon PCR thermal cycler protocol 
Step Temperature (C) Time (S) Cycles 
Initial denature 98 30 1 
Denature 98 20 
5 Anneal 55 15 
Extend (30 sec/kb) 72 Variable 
 
Table D-10. Sequencing primer combinations 
Library Site 1 Site 2 Site 3 F Seed R Seed Seq length (bp) 
A 104 105 106 226-285 415-394 150 
B 105 106 107 226-285 415-394 150 
C 106 107 108 226-285 415-394 150 
D 117 118 119 226-285 415-394 150 
E 184 185 186 448-473 589-565 142 
F 162 166 301 448-473 929-911 482 
G 227 228 301 659-678 929-911 271 
H 228 230 231 659-678 929-911 271 






Figure D-1. Snapshot of TrpB gene with annotations of seed regions of internal primers 
and the amplicons that would be generated 
 
